Huntington’s disease : hypothalamic, endocrine and metabolic aspects by Aziz, Nasir Ahmad
 i
Huntington’s Disease
Hypothalamic, endocrine and metabolic aspects
N. Ahmad Aziz
 ii
ISBN: 978-94-6108023-3
Design & layout: N. Ahmad Aziz
Cover design: Jorien M.M. van der Burg
Printed by: GildePrint, Enschede
© 2010 N.A. Aziz
Copyright of each chapter is with the publisher of the journal in which the work has appeared. No part of this 
book may be reproduced or distributed in any form, by print, photoprint, microfilm, digital file, or any other 
means without prior written permission from the copyright holder. 
The studies described in this thesis were partly supported by the Netherlands Organization for Scientific 
Research (grant number 017.003.098 to N.A.Aziz).
 iii
Huntington’s Disease
Hypothalamic, endocrine and metabolic aspects
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden
volgens besluit van het College der Promoties
te verdedigen op woensdag 31 maart 2010
klokke 16:15 uur
door
Nasir Ahmad Aziz
geboren te Kandahar (Afghanistan) 
in 1981
 iv
Promotiecommissie
Promotores:
Prof. dr. R.A.C. Roos
Prof. dr. H. Pijl
Overige leden:
Prof. dr. H.P.H. Kremer (Rijksuniversiteit Groningen)
Prof. dr. J.A. Romijn
Prof. dr. D.F. Swaab (Universiteit van Amsterdam, Nederlands Instituut voor Neurowetenschappen)
 v
 
                                                       ,PvD× Ölµ D× íÊkßvC éÆ ÙìVß×
 .ÙëoClÛ ÖCoC éÆ ÙìÛCpF ælÛq D×
       
                             (íwØz 1256-1317) ÍDGÂC lØe×
We are a wave, our calm is our naught,
    We have no rest, lest we will be not.
Muhammad  Iqbal (1877-1938 CE)
 vi
 vii
 
 To my father, 
  who taught me reason and perseverance
 To my mother,
  who bestowed me with love and inspiration
 To Jorien,
  for sharing the joys and sorrows of life with me
 viii
 ix
Contents
Chapter 1 GENERAL INTRODUCTION & AIMS OF THE THESIS       1
  Rev Neurosci (2007); 18: 223-251
PART I SECONDARY SIGNS OF HUNTINGTON’S DISEASE     43
Chapter 2 Weight loss in Huntington’s disease increases with higher CAG repeat number   45
  Neurology (2008); 71(19): 1506-1513
Chapter 3 Normal and mutant HTT interact to affect clinical severity and progression in 
Huntington’s disease          57
Neurology (2009); 73(16):1280-1285
Chapter 4 Sleep and circadian rhythm alterations correlate with depression and cognitive 
impairment in Huntington’s disease        73
  Parkinsonism Rel Disorders (in press)
Chapter 5 Autonomic symptoms in patients and premanifest mutation carriers of  Huntington’s 
disease                            87 
Eur J Neurol (in press)
PART II  HYPOTHALAMIC PATHOLOGY IN HUNTINGTON’S DISEASE                  99
Chapter 6  Hypocretin and melanin-concentrating hormone in patients with Huntington’s disease      101
  Brain Pathol (2008); 18(4): 474-483
PART III  ENDOCRINE STUDIES IN HUNTINGTON’S DISEASE                   119
Chapter 7 Increased hypothalamic-pituitary-adrenal axis activity in Huntington’s disease             121
  J Clinical Endocrinol Metab (2009); 94(4):1223-8
Chapter 8 Growth hormone and ghrelin secretion are associated with clinical severity in 
Huntington’s disease                           135
ontents
xEur J Neurol (in press)
Chapter 9 Altered thyrotropic and lactotropic axes regulation in Huntington’s disease                149
  Clinical Endocrinol (Oxf.) (in revision)
Chapter 10 Leptin secretion rate increases with higher CAG repeat number in Huntington’s 
disease patients                        161
Clinical Endocrinol (Oxf.) (in press)
Chapter 11 Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease              173
  J Neurol (2009) 256:1961–1965
PART IV  METABOLIC STUDIES IN HUNTINGTON’S DISEASE               183
Chapter 12 Systemic energy homeostasis in Huntington’s disease patients                185
  J Neurol Neurosurg Psychiatry (in press)
Chapter 13 SYNOPSIS, CONCLUSIONS & FUTURE PERSPECTIVES               197
APPENDICES                       205
A  Summary and conclusions in Dutch                  207
B  Excerpt in Persian                                215
C  Acknowledgments                    217
D  Curriculum vitae                    219
E  List of publications                    221
GENERAL INTRODUCTION & AIMS OF THE THESIS 
1
Chapter 1
GENERAL INTRODUCTION
& 
AIMS OF THE THESIS
Partly based on:
Aziz NA, Swaab DF, Pijl H, Roos RA. (2007). Hypothalamic dysfunction and neuroendocrine and 
metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. 
Rev Neurosci. 18(3-4): 223-251.
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“…The hereditary chorea, as I shall call it, is confined to certain and fortunately 
a few families, and has been transmitted to them, an heirloom from generations 
away back in the dim past. It is spoken of by those in whose veins the seeds 
of the disease are known to exist, with a kind of horror, and not at all alluded 
to except through dire necessity, when it is mentioned as ‘that disorder’. It is 
attended generally by all the symptoms of common chorea, only in aggravated 
degree hardly ever manifesting itself until adult or middle life, and then coming 
on gradually but surely, increasing by degrees, and often occupying years in its 
development, until the hapless sufferer is but a quivering wreck of his former 
self… I know nothing of its pathology. I have drawn your attention to this form of 
chorea gentlemen, not that I consider it of any great practical importance to you, 
but merely as a medical curiosity, and as such it may have some interest.”
George Huntington On chorea. Medical and Surgical Reporter. 1872; Vol. 
XXVI., pp. 317-21.
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1. INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant progressive, neurodegenerative disorder caused by an expanded trinucleotide (CAG) repeat in the HD (HTT) gene, located on the short arm of chromosome 
4.  Unwanted choreiform movements, psychiatric and behavioural problems and cognitive impairment 
characterize the disease.74 Other less well-known, but debilitating manifestations of HD include weight loss, 
sleep disturbances and autonomic nervous system (ANS) dysfunction. Only little is known about the exact 
pathophysiological mechanisms underlying these symptoms. In recent years, novel insights have emerged from 
both animal and human studies indicating the existence of substantial hypothalamic pathology and dysfunction 
in HD, even in an early phase of the disease.94 Considering the pivotal role of the hypothalamus in the regulation 
of systemic energy homeostasis, sleep-wake states and ANS functions,92,207,208,232,236 hypothalamic dysfunction 
per se as well as secondary (neuro)endocrine and metabolic alterations could partly explain the pathogenesis 
of emaciation, sleep disturbances and autonomic failure in patients with HD; nonetheless, the anatomical and 
functional abnormalities of the hypothalamus in HD have not been systematically studied in conjunction with 
these and other clinical parameters. Therefore, after summarizing the precise characteristics of weight loss, 
sleep and ANS problems in HD, this review aims to: 1) describe the precise nature of hypothalamic dysfunction 
and neuroendocrine and metabolic alterations in HD, and 2) link these abnormalities to the aforementioned 
clinical manifestations, thereby providing rationale for future animal and clinical studies on the relation 
between hypothalamic dysfunction and symptomatology in HD. Assuming that hypothalamic dysfunction and 
consequent neuroendocrine and metabolic abnormalities could contribute to the weight loss and disturbances 
of sleep and autonomic functions in HD, some therapeutic strategies will be discussed as well. 
2. CHARACTERISTICS OF WEIGHT LOSS, SLEEP DISTURBANCES AND AUTONOMIC 
DYSFUNCTION IN HD
2.1. Weight loss
Weight loss frequently complicates HD and is particularly marked in the later stages of the disease.112,140. 
Several studies, including clinical follow-up187 and cross-sectional prevalence studies52,181,215, anthropometric 
measurements with dietary evaluations62,63,216 as well as one post-mortem study of 217 cases,149 have all shown 
that many HD patients are either underweight or tend to lose weight in the course of their illness and eventually 
become cachectic. An exception is the recent study by Hamilton et al.73 that assessed weight changes in 927 
adults with HD who were followed prospectively for about 3 years. The authors found that most HD patients 
maintained their weight and that, on the whole, the patient group gained approximately 0.11 kg per year. 
However, on average their entire group of HD patients gained less weight than the United States national 
average, as per the third National Health and Nutrition Examination Survey,73 and weighed almost 10 kg less 
than a community sample of comparably aged adults.73 It is very likely that clinical information not available 
for that study—for example, the introduction of nutritional supplements, institutional placement, and types 
of drugs used (notably neuroleptics and antidepressants)—could account for the surprising pattern of weight 
change found by Hamilton et al. 
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In contrast to the weight loss associated with most other diseases, the emaciation in HD is not accompanied 
by anorexia but usually by an increased appetite.62,63,146,187,216 An increased caloric intake could possibly also 
underlie the peculiar observation of an inverse relation between the age-at-onset of the disease and the daily 
milk consumption in Dutch HD patients32 since the onset of HD could be marked by an increased demand 
for calories. Furthermore, in a longitudinal, prospective study of 30 patients with HD, Trejo et al.215 found 
that although nutritional supplementation (i.e. 473 kcal added to the regular diet) over a 90-day-period could 
stabilize or slightly improve body weight, it could not induce a significant change in body mass index in 87% 
of the patients. These findings support the notion that HD patients have an increased energy requirement.146 
Little is known about the pathophysiological mechanisms underlying weight loss in HD. Although dysphagia 
can complicate food intake.91,124,216 and there are indications of a higher sedentary energy expenditure due 
to increased spontaneous physical activity (unwanted movements),68,172,203 these findings do not explain the 
lower body mass index (BMI) found in certain groups of asymptomatic subjects at-risk for HD62,63 nor do they 
account for the lower body weight of those HD patients who are at an early stage of the disease when both 
dysphagia and unwanted movements are still absent.52 Moreover, it appears that HD patients tend to lose most 
weight in the final hypokinetic stages of the disease,187 although weight gain may occur in some advanced-
stage patients.146 Weight loss frequently leads to progressive general weakening, resulting in an increasingly 
higher risk of developing co-morbidity, which causes a further decline in the patient’s quality of life.146 A 
survey of patients in Venezuela demonstrated that a substantial number of them were malnourished,140 and 
in the United States nutritional deficiencies cause or contribute to death more frequently in HD patients than 
in controls.118,119 Moreover, one study has demonstrated that a higher body weight in the early stages of the 
disease is associated with slower disease progression.145 Therefore, the mechanisms which cause weight loss 
in HD may also underlie and/or aggravate the neurodegenerative process per se. In this regard dysfunction 
and pathology of various hypothalamic structures, notably the nucleus tuberalis lateralis (NTL) and the lateral 
hypothalamus, are likely to be involved (refer to the section ‘Hypothalamic pathology in HD’). 
2.2. Sleep disturbances
From a postal self- or carer-completion questionnaire community survey Taylor et al.212 estimated the prevalence 
of sleep problems to be almost 90 percent in HD patients. Nearly two-thirds of the respondents rated the sleep 
problems as either ‘very’ or ‘moderately’ important contributing factors to overall problems. Moreover, the 
majority of the principal carers also reported significant sleep disruption, primarily attributable to the patients’ 
sleep problems, which adversely affected their relationship with the patient.212 Polysomnography in patients 
with HD showed sleep fragmentation in moderately to severely affected cases, with progressive deterioration 
as the disease progresses.231 Sleep efficiency (i.e. the ratio between time spent asleep and total amount of time 
spent in bed) has been reported as varying from 48% to 80%, with frequent nocturnal awakenings, an increase 
of stage I non-rapid eye movement (NREM) sleep and a reduced amount of slow wave sleep.39,164,199,231 Also a 
shortening of rapid eye movement (REM) sleep latency, which is a cardinal characteristic of the sleeping pattern 
in narcolepsy patients, has been documented86 as well as a significant increase in sleep spindle density during 
phase II NREM sleep.58,199 Two recent studies applying wrist actigraphy demonstrated dysregulation of the 
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sleep-wake cycle and circadian timing in HD patients.84,141 During sleep, patients not only showed significantly 
more activity and spent more time making high acceleration movements, but they also made significantly more 
movements than control subjects.84 Although the presence of dyskinesia 66, medication effects and depression 
may contribute to sleep disturbances observed in HD,39 the precise pathogenetic mechanisms responsible for 
sleep disturbances in HD patients remain largely unexplored. Particularly disease-specific neurodegenerative 
changes affecting (hypothalamic) structures regulating sleep-wakefulness have not been systematically 
investigated. However, changes in the suprachiasmatic nucleus (SCN) and (functional) alterations in the 
hypothalamic histaminergic and orexinergic systems in HD are probably among the mechanisms involved 
(for further details refer to the sections ‘Hypothalamic pathology in HD’ and ‘Aminergic and neuropeptidergic 
alterations in HD brains suggestive of hypothalamic dysfunction’). Given the high prevalence of sleep disorders 
in HD and their devastating impact on the quality of life of both patients and carers,212 it is of the utmost 
importance to elucidate the underlying pathogenic pathways in order to devise effective therapeutic strategies. 
2.3. Autonomic nervous system dysfunction
Vegetative symptoms indicative of autonomic nervous system (ANS) dysfunction have repeatedly been reported 
in patients with HD and include defects in postural vasoregulatory mechanisms,2,3 hyperhydrosis of hands and 
feet, and disturbances of micturition,28 and swallowing difficulties.91,124 Although vegetative symptoms are 
most prominent in the advanced stages of the disease,99,146 autonomic complaints such as dizziness following 
standing up, excessive perspiration and tachycardia can occur even in mildly disabled HD patients (i.e. 
Shoulson and Fahn stages I and II196) and even in otherwise asymptomatic gene carriers.100
Several studies have investigated ANS function in HD patients by means of a series of standardized tests, such 
as the blood pressure response to sustained handgrip,50,100 the pupillary light reflex latency,50 orthostatic blood 
pressure test,6,50,100,192 heart rate variability at rest and during the Valsalva maneuver, and the sympathetic skin 
response.6,50,192 Compared to controls, the blood pressure response to sustained handgrip, a test of sympathetic 
function, was diminished in the patient group with a relatively long duration of disease.50,100 In contrast, the 
blood pressure response to sustained handgrip in a group of mildly disabled HD patients was elevated.100 The 
pupillary light reflex latency50 as well as the sympathetic skin response (SSR) latencies6,192 were prolonged in 
HD patients, suggesting parasympathetic and sympathetic dysfunction, respectively. The SSR amplitudes were 
also diminished in the patient group.6,192 Overall, patients showed lower heart rate variability (HRV) indices 
than controls.6,192 Spectral analysis of HRV, which yields several frequency bands of interest, demonstrated 
sympathetic hyperactivity in the asymptomatic gene carriers by a higher power of low frequency band (LFB; 
0.04-0.15 Hz).100 Similarly, a higher power of LFB and an increase in the ratio between LFB to high frequency 
band (HFB; 0.15-0.40 Hz) was demonstrated in mildly disabled HD patients.100 LFB in the supine position 
reflects both the sympathetic and parasympathetic activities and HFB reflects mainly vagal activity. A higher 
LFB/HFB ratio, which can be considered as a marker of sympathovagal balance, indicates a relatively higher 
cardiac sympathetic activity in the group of mildly affected HD patients.100 However, ANS hypofunction, 
predominantly parasympathetic dysfunction, was found in more advanced HD patients,100 although an earlier 
study of parasympathetic function in HD had not found any abnormalities.34 Moreover, the prolonged SSR 
latencies, smaller amplitudes, and lower HRV detected in HD patients by some investigators seemed to closely 
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correlate with various components of the Unified Huntington Disease Rating Scale (UHDRS) scores.6,192 The 
exact origin of impaired ANS function in individuals with HD remains to be elucidated. 
3. HYPOTHALAMIC DYSFUNCTION IN HD
Emaciation, sleep disturbances and autonomic dysfunction are on the one hand important indicators of the 
rate of disease progression and on the other hand these symptoms can considerably diminish the quality 
of a patient’s life. Therefore, it is important to elucidate the pathophysiology of these symptoms in order 
to strike novel and more effective therapeutic targets. As mentioned before, the precise aetiology of these 
symptoms in HD is largely unknown. Nevertheless, several lines of evidence derived from studies in both 
patients with HD and HD animal models indicate that HD is accompanied by considerable hypothalamic 
dysfunction, even in the very early stages of the disease. Since the hypothalamus is the main control centre 
in the brain involved in the regulation of body energy homeostasis, sleep-wake cycles and the coordination 
of autonomic functions,89,92,207,208,232,236 we propose that hypothalamic dysfunction per se as well as subsequent 
(neuro)endocrine and metabolic abnormalities in patients with HD may be the primary underlying cause of 
the aforementioned symptoms or substantially contribute to their pathogenesis. In order to substantiate this 
hypothesis, we will give an overview of all the findings suggestive of hypothalamic dysfunction in HD and 
attempt to link them to the HD symptomatology with a special focus on weight loss, sleep and autonomic 
disturbances.
3.1. Hypothalamic pathology in HD 
A comprehensive summary of hypothalamic changes in HD patients, found in post-mortem brain preparations, 
has been given by Swaab.208 In short, qualitative changes are presumed in the supraoptic nucleus (SON) and 
the paraventricular nucleus (PVN), 188,227 the ventromedial nucleus (VMN) and the lateral hypothalamus.29 
Normally, the neurons of the PVN project not only to the neurohypophysis and the median eminence, but 
also to various brainstem nuclei as well as to the intermediolateral columns of the spinal cord, and in this way 
modulate and coordinate various autonomic functions,92 including autonomic innervation and control of adipose 
tissue.67,109,110 Moreover, the PVN, VMN and the lateral hypothalamus are tightly involved in the physiological 
regulation of body energy homeostasis. So, pathology of these structures in HD could cause symptoms such 
as weight loss and autonomic failure. However, the cited papers about hypothalamic changes in HD generally 
describe a single188 or a few  cases,29,227 while systematic morphological studies, such as performed for the NTL 
(see further), have not been reported for the PVN, VMN or the lateral hypothalamus (H.P. Kremer, thesis). 
Quantitatively, no significant neuronal loss was found in the nucleus basalis of Meynert.41 Kremer et al.111,113,114 
elaborated on the previous reports of a striking cell loss in the NTL of HD patients228,229 and found that the 
NTL is indeed consistently affected in this disorder: up to 90% of  the neurons in the NTL were lost in HD 
brains, while the remaining neurons showed features of degeneration.113,114 Moreover, they found astrocytosis 
with an unchanged number of astrocytes, whereas the number of oligodendrocytes was reduced by 40%. The 
neurons of the tubero-mammillary nucleus (TMN) seemed to be largely well preserved.113 The log-transformed 
neuronal counts in the NTL of HD patients correlated closely with age at death (n =16; r = 0.66; p < 0.01) and 
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age of onset (n = 16; r = 0.78; p < 0.001), but neither with the duration of the disease, nor with the severity of 
the neostriatal changes.114 Patients who had died young or who first displayed motor disturbances at an early 
age had considerably fewer neurons left than HD patients who had died in old age.114 The authors hypothesized 
that the NTL is entwined in a network of structures involved in the regulation of feeding and weight and that 
weight loss in the course of HD is the expression of NTL pathology112 since the loss of NTL neurons is less 
marked in patients with an older age at onset of the disease and the fact that late-onset patients tend to have a 
higher BMI at initial examination which is associated with a slower rate of disease progression.145 Recently, 
the neuropathological data obtained from the aforementioned studies were extended by an in vivo study which 
demonstrated, by using magnetic resonance imaging and the technique of voxel based morphometry, that even 
in the early stages of the disease considerable hypothalamic neuronal atrophy is present in HD patients,94 which 
is in line with the view that hypothalamic changes are both consistent and early features of HD. 
In HD mouse models considerable anatomical and/or functional hypothalamic alterations have also been 
identified recently [107,127,141,156,162]. For example, Morton et al. 141 found a profound disintegration of 
circadian behaviour in the R6/2 mouse strain which was accompanied by marked disruption of expression 
of the circadian clock genes mPer2 and mBmal1 in the suprachiasmatic nuclei and associated with reduced 
SCN expression of prokineticin 2, a transcriptional target of mBmal1 encoding a neuropeptide that normally 
suppresses daytime activity in nocturnal mammals 141. These animal data are thus also in favour of the notion 
that pronounced hypothalamic changes may be a consistent feature of HD.
Exactly why the hypothalamus is involved in HD is not known. However, one intriguing possibility could 
be the abnormal interaction of mutant huntingtin with huntingtin-associated protein 1 (Hap1) which is more 
abundantly expressed in the hypothalamus than in other brain regions.194 Inhibition of Hap1 expression in 
vitro decreases epidermal growth factor receptor signalling and cell viability whereas overexpression of Hap1 
enhances this signalling activity and inhibits mutant huntingtin-mediated cytotoxicity.127 Moreover, deletion of 
Hap1 causes the selective degeneration of hypothalamic neurons.127 Interestingly, recently it was demonstrated 
that Hap1 is involved in intracellular trafficking of the GABAA receptor, and that insulin exerts its feeding-
inhibitory actions by downregulating Hap1 expression. Decreasing the expression of mouse hypothalamic 
Hap1 caused a decrease in food intake and body weight.194 A link between mutant huntingtin expression, 
hypothalamic degeneration and weight loss may therefore be provided by Hap1.161
It is noteworthy that as yet intraneuronal aggregates of mutant huntingtin, the neuropathological hallmark of the 
disease, have not been studied systematically in the hypothalamus of patients with HD. Systematic assessments 
of polyglutamine aggregates in HD hypothalami could provide valuable insights into which hypothalamic loci 
are predominantly involved in HD, thereby providing precedent for more targeted evaluations of specific 
hypothalamic nuclei. Although it should be emphasized that the exact role of polyglutamine aggregates in cell 
death and dysfunction in HD is still much debated.9,22,201 In the following section a recapitulation will be given 
of the aminergic and neuropeptidergic (post-mortem) findings in the brains of HD patients which appear to be 
of relevance for understanding the pathophysiology of, among other things, weight loss, sleep problems and 
vegetative symptoms in HD.
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3.2. Aminergic and neuropeptidergic alterations in HD brains suggestive of hypothalamic dysfunction
3.2.1. Histamine
The distribution of histamine H2- and H3-receptors have been assessed in both control cases and patients with 
HD by means of autoradiographic techniques.72,133 In healthy subjects, the highest levels of histamine H2-
binding sites were found in the caudate, putamen, and accumbens nuclei,133 and the highest levels of histamine 
H3-binding sites were detected within the external and internal segments of the globus pallidus, substantia nigra 
and the striatum (within the striatum, H3-binding was noticeably higher in both the nucleus accumbens and the 
acetylcholinesterase-deficient striosomes).72 In HD patients the levels of histamine H2-receptor binding sites 
were found to be markedly decreased in virtually all brain regions investigated, particularly in the putamen and 
globus pallidus lateralis. Furthermore, the loss of H2-binding sites was found to be related to the grade of the 
disease.133 Comparably, values for H3-binding were also significantly lower in the caudate nucleus, putamen 
and both the external and internal globus pallidus, although not the insular cortex, in HD cases.72 Since the TMN, 
the only site in the brain where histamine-releasing neurons are located,25 does not show a clear cell loss in this 
disorder,113 a functional change of the histaminergic system may be expected in HD.208 As the histaminergic 
system plays a major role in the maintenance of wakefulness,25,198 its dysfunction could underlie some features 
of sleep complaints in HD patients such as, and in particular, daytime sleepiness.212 Histaminergic neural 
circuits are also involved in the control of energy balance.134,214 However, activation of H2 receptors inhibits 
food intake, and H3 receptor knock out mice are obese and insulin resistant,130,214 suggesting that the diminution 
of these receptors in HD is a compensatory consequence rather than a cause of weight loss. It should be noted 
though that perturbations have also been described in other, extra-hypothalamic, aminergic systems which too 
are involved in the coordination of sleep-wake cycles and food intake,198 such as the noradrenergic14,38,235 and 
the serotoninergic pathways135, which could likewise contribute to the pathogenesis of sleep disruptions and 
weight loss in HD subjects. 
3.2.2. Somatostatin and neuropeptide Y
Somatostatin (SST) 1-12 immunoreactivity is normally abundantly present in the neurites and perikarya of 
the NTL, while SST immunoreactivity is greatly reduced in the NTL of HD patients.213 In general, higher 
staining intensity is present in HD patients who have more NTL neurons left than in those who have fewer NTL 
neurons left. The data obtained so far suggest that NTL neurons cease to express SST-like peptides quite some 
time before their actual disappearance.208,213 Since the SST neurons in the periventricular nucleus are thought 
to be primarily involved in the neurohumoral regulation of growth hormone (GH) secretion,71 it is unclear to 
what extent elevated plasma GH levels observed in HD patients (see ‘Endocrine abnormalities in HD’) can 
be attributed to diminished SST availability in the NTL of HD subjects. In contrast to the diminished levels 
of NTL SST, the concentrations of both SST and neuropeptide Y (NPY) are markedly increased in the basal 
ganglia of patients with HD7,11-13,48,136 which is consistent with selective preservation of a population of aspiny 
neurons in which both SST and NPY are colocalized48. Beal et al.13 examined both SST-like immunoreactivity 
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and NPY-like immunoreactivity in 24 pathologically graded HD cases and 12 controls. Both SST and NPY 
immunoreactivity were significantly increased (about threefold) in the caudate, putamen, and the nucleus 
accumbens. Increases of SST and NPY immunoreactivity in mild and severe grades were similar indicating 
a relative but not absolute sparing of striatal aspiny neurons in which SST and NPY are colocalized.13 
Moreover, because neuropeptide changes were seen in the nucleus accumbens in early grade cases, when 
there is relatively little tissue atrophy, it is probable that not atrophy alone but also some other process, such 
as increased terminal sprouting, could contribute to the increased levels seen in these cases.13 Among the other 
subcortical regions examined, SST immunoreactivity was significantly increased in the external pallidum, red 
nucleus, and locus ceruleus, whereas significant increases of NPY immunoreactivity were found in the external 
pallidum, subthalamic nucleus, substantia nigra compacta, claustrum, anterior and dorsomedial thalamus, bed 
nucleus of stria terminalis and locus ceruleus.13 Interestingly, the locus ceruleus is known to contain NPY 
neurons, indicating that this nucleus could provide increased NPY innervation to other regions.13 Except for 
the subthalamic nucleus, the NPY concentrations have not yet been determined in other structures of the 
hypothalamus of HD patients. NPY is a naturally occurring appetite transducer, and under normal conditions 
NPY-ergic transmissions represent an essential component of the common final pathway in the hypothalamic 
integration of energy homeostasis.92 Although NPY-producing neurons are normally located in several sites 
in the brain, two subpopulations, one representing the extra-hypothalamic cluster in the brainstem including 
the locus ceruleus, and the other located in the hypothalamus along the length of the infundibular (or arcuate) 
nucleus and in the dorsomedial nucleus, apparently participate in a disparate manner in the daily management 
of food intake 92. Regarding the disturbed systemic energy balance in HD, it would be very interesting to know 
whether perturbations also exist in the hypothalamic NPY-ergic system of these patients, especially the NPY 
neurons located in the infundibular nucleus, since animal studies suggest that huntingtin, the protein product 
of the HTT  gene, may fulfil a physiological role in the homologue of this structure (i.e. the arcuate nucleus) 
in rodents.77
 
3.2.3. Neurotensin and thyrotropin-releasing hormone 
Nemeroff et al.147 measured the concentrations of neurotensin (NT) and thyrotropin-releasing hormone (TRH) 
by means of radioimmunoassay in post-mortem brain samples from patients with HD. Compared to patients 
without psychiatric or neurological disease, the patients with HD showed significantly elevated concentrations 
of these two neuropeptides in the nucleus caudatus, while in the amygdala only TRH levels were elevated.147 
However, it is unclear to what extent the elevated NT and TRH levels might reflect increased hypothalamic 
production of these neuropeptides. Apart from its many other physiological functions, hypothalamic NT seems 
to be implicated in the regulation of energy homeostasis, particularly in the anorexigenic networks of the 
hypothalamus.92 Moreover, recently Cui et al.44 demonstrated that all the anorexigenic hormones leptin, insulin, 
and α-melanocyte-stimulating hormone directly induce NT gene expression in immortalized hypothalamic cell 
lines, which is in support of the notion that NT may have a direct role in the neuroendocrine control of feeding 
and energy homeostasis.44 Increased hypothalamic NT levels may thus underlie the disturbed energy regulation 
in HD subjects as well as some endocrine (particularly hypercortisolism) and metabolic derangements in these 
patients (for further details refer to the sections ‘Endocrine abnormalities in HD’ and ‘Metabolic abnormalities 
in HD’) as NT dose-dependently increases adrenocorticotropic hormone (ACTH) secretion and causes an 
increase in blood corticosterone and glucose concentration.217 In addition, NT exerts other potent central nervous 
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system effects including hypothermia, antinociception, and modulation of dopamine neurotransmission. 
Peripherally, it acts as a paracrine and endocrine peptide of both the digestive and cardiovascular systems.217 
TRH is a tripeptide hormone which induces the secretion of thyroid-stimulating hormone (TSH) from the 
anterior pituitary and, at least in humans, can also act as a prolactin-releasing factor.148 Thus elevated levels of 
TRH in the caudate nucleus of HD patients could possibly be secondary to increased hypothalamic production 
of this peptide, which in turn may partly explain the deviant response to the TRH-stimulation test and the 
elevated basal plasma prolactin levels in HD subjects found by some investigators.75 In addition, TRH is 
directly involved in the complex hypothalamic networks that establish energy balance by modulation of food 
intake, satiety, thermogenesis, and other autonomic responses.1,93 Elevated hypothalamic levels of both NT 
and TRH could therefore partly account for the negative energy balance observed in HD52,172 as well as some 
of the autonomic dysfunctions, especially disturbed vasomotion and thermoregulation, which can give rise to 
symptoms such as orthostatic hypotension and dyshydrosis in some of these patients.3,6,28
3.2.4. Gonadorelin
Gonadorelin or Gonadotropin-Releasing Hormone (GnRH) is a decapeptide hormone released by the 
hypothalamus that stimulates the synthesis and secretion of both luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) from the adenohypophysis. GnRH concentrations have been reported to be 
increased fourfold in the median eminence of female choreic patients as compared with controls.18 However, 
there was no difference in the median eminence levels of GnRH of the male choreic patients when compared 
with controls. Although the authors and others,178 including George Huntington himself in his seminal paper, 
present some anecdotal descriptions of increased libido among HD patients,18,83 a retarded menarche151 but 
increased fertility among the female choreic as compared to her nonchoreic sibling,178 later studies mainly 
suggest a high incidence of hypoactive sexual disorder in HD, notwithstanding the fact that certain HD patients 
may exhibit increased sexual interest and paraphilias.64 It is questionable, though, whether the behavioural 
alterations have anything to do with changes in GnRH levels in HD, as they could also be accounted for by 
other mechanisms such as pathology of the prefrontal cortex in this disorder.191
Lavin et al.120 performed a GnRH stimulation test in 8 HD patients and 10 controls, but found no clear differences 
or obvious abnormalities indicating intact pituitary responsiveness and gonadotropin release, although because 
of small subgroups (i.e. males, premenopausal and postmenopausal females) the data from the GnRH test were 
difficult to analyze. The findings of Bird et al.18 seem to be at odds with those of others who found normal 
24-hour curves of LH-secretion54 and those of Markianos et al.132 who found normal plasma levels of FSH but 
decreased plasma levels of both LH and testosterone in male HD patients. However, sex differences cannot 
be ruled out as the findings of Bird et al.18 pertained only to the female patients. Moreover, the testosterone 
plasma concentrations correlated negatively with the severity of the disease and low testosterone levels were 
associated with dementia but not with depression or psychotic features.132 The expected positive correlations 
of LH and FSH to age and the negative correlation of testosterone to age were, however, present in the patient 
samples studies by Markianos et al.132 and the authors proposed that, in addition to blunted LH secretion, the 
direct neural hypothalamic–testicular pathway that interferes with synthesis and secretion of testosterone in the 
Leydig cells, independent of the pituitary, could be involved, especially for explaining the great reductions in 
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testosterone in patients with severe symptomatology in whom LH levels were found to be normal. A possible 
explanation for the increased immunoreactive GnRH concentrations in HD hypothalami18 could thus be a 
decreased release of this neuropeptide from the hypothalamus. Nonetheless, recently a progressive reduction 
in the numbers of GnRH-immunoreactive neurons in the medial septum, diagonal band of Broca and medial 
preoptic area of the hypothalamus of the R6⁄2 mouse model of HD has been found starting at 5 weeks of age, 
prior to the onset of overt motor symptoms at 7-8 weeks of age, and becoming statistically significant with 
only 10% of the neurons remaining by 9 weeks of age.156 Therefore, both the neuropathological data and the 
clinical findings concerning the hypothalamo-gonadal axis function in HD patients need further clarification.
3.2.5. Hypocretin (orexin)
Recently it was demonstrated that there is a significant loss and atrophy of hypocretin-immunostained neurons 
in the lateral hypothalamus of post-mortem HD brain preparations,162 extending an earlier report of qualitative 
changes in this hypothalamic structure.29 Hypocretin, a novel neuropeptide discovered in 1998, can be 
synthesized in the brain exclusively by neurons in the lateral hypothalamus.186 This neuropeptide appears to 
play a crucial role in the regulation of sleep-wake cycles, body energy metabolism and autonomic functions,92,232 
partly by modification of the endocrine system including influences on the corticotropic, somatotropic and 
thyrotropic axes.103,104,155 Hypocretin loss might therefore partly account for sleep, ANS and body weight 
abnormalities in patients with HD. However, four recent papers reported normal hypocretin-1 concentrations 
in the cerebrospinal fluid (CSF) of HD patients.10,21,69,137 The apparent discrepancy between these latter findings 
and those of Petersen et al.162, who found a 27 % loss of hypocretin neurons in HD brains, could be accounted 
for by the fact that in human brain tissue the reduction in hypocretin-positive cell number was not as striking 
as in the concurrently studied R6/2 mouse model (27% vs. 72%).162 This comparatively modest reduction in 
cell number appears not to be reflected in the CSF of HD patients, possibly due to compensatory mechanisms 
whereby the remaining hypocretin neurons in HD are still able to release a sufficient amount of hypocretin to 
prevent narcoleptic-like symptoms,10,69,137 which is in accordance with rat studies indicating a need for a 73% 
decline in neuronal number to decrease CSF hypocretin levels by half.70 Nevertheless, apart from one study in 
seven HD patients that found normal CSF hypocretin-1 levels independent of the presence of sleep disorders 
and nutritional status,10 CSF hypocretin levels have not yet been investigated more accurately in conjunction 
with neuroendocrine and clinical parameters, particularly those concerned with sleep, ANS function and body 
weight and its composition. Thus, at present, any (sub)clinical consequences of a relative hypocretin deficiency 
in HD cannot be excluded with certainty. It would be interesting to assess another neuronal population in 
HD brains that is localized in the lateral hypothalamus, namely the melanin-concentrating hormone (MCH)- 
producing neurons. Like hypocretin, MCH plays a pivotal role in the orchestration of hypothalamic functions, 
in particular systemic energy homeostasis195,220 and, therefore, MCH neuronal loss or dysfunction might also 
partly explain the relentless weight loss in HD patients.
3.2.6. Corticotropin-releasing hormone
Kurlan et al. found elevated corticotropin-releasing hormone (CRH) concentrations in the CSF of 56 (30 male 
and 26 female) nonmedicated patients with early (stages I and II) HD in comparison with a control group of 
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21 subjects without neurological illness.116 Patients with HD who had depressive disorders (major depression 
or dysthymia) did not differ from those without depression with respect to CRH concentration. However, a 
positive correlation was observed between the severity of major depression (but not dysthymia) and CRH 
concentrations in HD patients. Even though it is assumed that CSF concentrations of CRH generally originate 
from extra-hypothalamic sources rather than the PVN207, three observations nonetheless suggest a hypothalamic 
origin of the elevated CRH found in the CSF of HD patients.116 First, the CSF concentration of CRH was 
positively correlated with the severity of major depression, which could indicate the PVN as the origin of 
the CRH, since an increase of CRH neuron number, CRH-mRNA, and vasopressin colocalization in CRH 
neurons in the PVN of depressed patients have been demonstrated.176,177 Second, various studies have found 
increased plasma levels of both ACTH and cortisol, indicating HPA axis hyperactivity in HD (see below under 
‘Endocrine abnormalities in HD‘). And third, De Souza et al.49 measured CRH-like immunoreactivity in control 
and HD brain tissues obtained post-mortem and found that the concentration of CRH-like immunoreactivity 
was markedly decreased in the caudate/putamen, while no significant differences were observed in the 
concentrations of CRH-like immunoreactivity between controls and HD patients in frontal, parietal, temporal, 
occipital and cingulate cortex and in globus pallidus, which also argues against an extra-hypothalamic source 
of the increased CRH concentration in the CSF of HD subjects 116; although it should be noted that there are 
also other sources of extra-hypothalamic CRH such as the thalamus.8 Assuming a hypothalamic origin of the 
elevated liquor CRH in HD, two questions remain to be sorted out: first, what is the cause of this elevation, 
and second, what are exactly the functional consequences of increased CRH production in the hypothalami of 
HD patients? Regarding the first question, Heuser et al.79 suggested that the endogenous CRH overdrive in HD 
subjects might be due to a loss of GABA-containing medium-spiny neurons in the striatum of patients with HD. 
Interestingly, experimental data in the rat shows that loss of GABA-ergic innervation per se can independently 
add to the the anorexigenic actions of excess CRH as discussed below.92 However, administration of muscimol, 
a potent GABA-agonist, seemed to have no effects on plasma cortisol levels in 4 HD patients,209 rendering the 
explanation offered by Heuser et al.79 somewhat questionable. With regard to the second question, CRH is the 
primary hypothalamic hormone stimulating the release of pituitary ACTH, which stimulates cortisol secretion 
from the adrenal glands. CRH-producing cells involved in regulation of the pituitary-adrenal axis are localized 
mainly in the parvocellular subdivision of the PVN.92 Central injection of CRH produces behavioral effects 
suggestive of major depression as well as anorexia, as evidenced by attenuation of nocturnal and fasting-
induced feeding, and diminishes feeding in a number of pharmacological and behavioral paradigms designed 
to evaluate ingestive behavior in rodents.92,208 Microinjection studies imply that the site of anorectic action of 
CRH lies within the PVN, and that CRH, if released locally in the PVN, may tonically restrain the action of 
endogenous orexigenic signals such as NPY.92 Heinrichs et al.78 reported that increased availability of CRH/
urocortin in the hypothalamus by the chronic central infusion of rat/human CRH(6 –33), a high affinity CRH 
binding protein inhibitor, significantly decreased body weight in Zucker obese rats that normally have reduced 
CRH stores in the hypothalamus. However,  hyperphagia was unabated in these animals, and the investigators 
suggested that the loss in body weight was due to CRH/urocortin-induced increase in energy expenditure 
and sympathetic tone produced by thermogenesis and lipolysis78,92 since CRH neurons from the PVN project 
extensively to several autonomic centres in the brain stem. Thus likewise, a chronic CRH overdrive in the 
PVN of HD subjects may substantially contribute to the emaciation seen in these patients, who nevertheless, 
frequently report an insatiable appetite. Although it should be noted that, apart from the physiological stimulus 
caused by a protracted state of negative energy balance, increased appetite in HD patients may, at the very 
least, also originate from direct pathology and/or dysfunction of the nucleus accumbens11,24,65,182 and alterations 
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of its enkephalinergic input from the more dorsal domains of the striatum.193 This is because the hedonic 
experience of the feeding consummatory act, particularly with regard to palatable foods, is largely mediated by 
opioid transmission throughout both the ventral (i.e. nucleus accumbens) and dorsal striatum96 and the opioid-
peptide containing medium-sized spiny neurons of the (particularly dorsal) striatum are among the neuronal 
groups preferentially affected in HD.138,193 Altered dopaminergic transmission through the nucleus accumbens 
could also play a role.96
3.2.7. α-Melanocyte-stimulating hormone
Konagaya and Konagaya105 measured α-melanocyte-stimulating hormone (α-MSH)-like-immunoreactivity in 
the CSF of, among others, 2 patients with HD. As compared to the values measured in control subjects, the 
α-MSH immunoreactivity in HD patients was not deviant. α-MSH is, along with ACTH, a peptide cleavage 
product of the proopiomelanocortin (POMC) molecule and the main endogenous ligand of the melanocortin-3 
and melanocortin-4 receptors which when stimulated suppress food intake. Levels of POMC mRNA are 
normally markedly reduced in fasted animals and increased by exogenous administration of leptin.236 Leptin 
increases melanocortin signalling, both by increasing α-MSH release from POMC neurons and by decreasing 
production of the melanocortin receptor antagonist agouti-related protein (AGRP).233 As HD patients are often 
underweight52 and as plasma leptin concentrations appear to be decreased in HD patients,171 α-MSH values 
within the control range105 seem to be paradoxically normal in this group. In addition, melanocortin signalling 
in the hypothalamus appears to be involved in the pathogenesis of the anorexia and weight loss associated 
with inflammatory and neoplastic disease processes.234 Although the precise mechanism whereby peripheral 
inflammatory/neoplastic factors activate the melanocortin system remains unknown, the proinflammatory 
cytokines (interleukin-1, interleukin-6, and tumour necrosis factor-alpha) that are produced in the hypothalamus 
during both inflammatory and neoplastic disease processes are likely to play a role.233 Interestingly, activation 
of various immune system compartments in HD have been reported as well.123 Thus, alterations in the 
hypothalamic melanocortin system may also bear a part in the pathogenesis of wasting in HD.
4. ENDOCRINE ABNORMALITIES IN HD
For a discussion of alterations in hypothalamic-releasing/-inhibiting factors in HD patients please refer to the 
previous section. In the following section the functional integrity of the hypothalamo-pituitary-target organ 
axes will be dealt with.  
4.1. Hypothalamo-neurohypophysial system
In order to assess the functionality of the hypothalamo-neurohypophysial system Lavin et al.120 performed 
a water deprivation test in a group of eight HD patients: the patients seemed to have retained their ability to 
concentrate urine which suggests intact osmoreceptor function and sufficient vasopressin release from the 
posterior lobe of the pituitary in HD. However, hypothalamic/neurohypophysial vasopressin and oxytocin 
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contents have never been evaluated in HD brains. Apart from their neuroendocrine functions, both vasopressin 
and oxytocin appear to have central neuromodulatory roles as well, with effects on, among others, blood 
pressure, thermoregulation, food intake, cognition, mood and hypothalamo-pituitary-adrenal axis,207 all 
of which are domains that may be affected to some degree in patients with HD. Post-mortem amounts of 
vasopressin immunoreactivity in the locus ceruleus and substantia nigra of 10 cases of HD were comparable to 
those of normal controls.183 As in the human brain the vasopressin immunoreactivity in these areas is confined 
to fibers originating in the hypothalamus, in all probability the PVN,219,225 the latter findings would argue for an 
intact hypothalamic vasopressinergic innervation. It is not known, however, to what extent disturbed central 
vasopressin synthesis and/or release could account for orthostatic hypotension in some HD patients. No data 
are available with respect to oxytocin in HD patients. Although parturition and lactation difficulties are not 
noticeably common in the past history of female HD subjects, this does not exclude abnormalities in oxytocin 
production and/or release during the illness since the disease often commences after the usual age of childbirth. 
As described before, cell degeneration and gliosis have been reported in HD subjects in both the SON and 
PVN,188,227 which are the production sites of pituitary vasopressin and oxytocin, and in a recent study in a 
mouse model of HD the hypothalamic expression of the mRNAs of both vasopressin and oxytocin were shown 
to be significantly down-regulated.107 This creates precedent for further exploration of this area in HD patients. 
4.2. Hypothalamo-pituitary-adrenal (HPA) axis
Originally, Bruyn et al. 31 reported decreased plasma levels of cortisol in some patients with HD, but later 
studies by others consistently indicate hyperfunction, instead of hypofunction, of the HPA axis in HD. CSF 
levels of CRH in HD individuals have been reported to be increased (see above under the subheading ‘CRH’ 
for a discussion of this finding). Basal levels of both ACTH79 and cortisol79,122 seem to be increased as well. 
However, after an intravenous CRH challenge test, ACTH responses tended to be blunted in concert with 
normal cortisol levels, indicating  that the negative feedback regulation of glucocorticoid secretion is probably 
intact at the pituitary-adrenal level.79 Following an overnight dexamethason suppression test, the mean cortisol 
levels did not differ significantly between the HD and the control group, whereas mean plasma dexamethason 
concentration was 57 % lower in patients than in controls,79 although the precise cause and significance of 
this latter finding remains unclear. Moreover, the cortisol (and GH) rise during hypoglycaemia, induced by 
intravenous insulin administration, occured earlier in HD patients, though peak responses were the same in 
each group.120 Durso et al.56 found no significant differences in mean plasma cortisol concentrations between 
their patient and control samples, though it should be noted that their samples consisted exclusively of female 
subjects and that three of the nine participating HD patients had the rigid-akinetic variant of the disease whose 
response may be diametrically opposed to that of choreic patients.75 On the other hand, Leblhuber et al. found 
significantly higher basal plasma levels of cortisol in 11 drug-free male HD patients compared with age- and sex-
matched normals.122 In addition, in a recent study Björkqvist et al. reported progressive alterations in the HPA 
axis in the R6/2 mouse reminiscent of a Cushing-like syndrome.20 The R6/2 mice showed enlargement of the 
intermediate lobe of the pituitary, hypertrophy of the adrenal cortex, increased ACTH plasma concentrations as 
well as a progressive increase in serum and urine corticosterone levels. However, the hypothalamic CRH levels 
were reduced by 62 % in the R6/2 mice suggesting that CRH released from the hypothalamus is not driving 
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the pituitary ACTH production in these mice, which appears to be at odds with the available data on CRH in 
humans with HD.116 Normally dopamine represses ACTH expression, but in the R6/2 mice the expression of 
pituitary dopamine D2 receptors was reduced by half which therefore could explain the increase in ACTH 
levels in these mice.20 Björkqvist et al. corroborated some of their findings in the human disease by measuring 
cortisol contents in urinary samples from 82 HD patients and 68 controls: the cortisol levels were significantly 
elevated in moderate (stage III) and moderate-advanced stage (stage IV) patients, whereas pre-symptomatic 
and early disease stage (stage I/II) patients exhibited levels that were not significantly different from age- and 
sex-matched controls. It is important to note that the R6/2 mice also exhibited muscular atrophy, reduced 
bone mineral density, abdominal fat accumulation and insulin resistance, all of which could be consequences 
of increased glucocorticoid levels. Therefore, elevated levels of cortisol may also contribute to the clinical 
symptoms like muscular wasting, mood changes and some of the cognitive deficits that occur in patients with 
HD 20.
Although Bruyn et al.30 could not detect any changes in serum levels of dehydroepiandrosterone sulphate 
(DHEAS), the major androgen secreted by the adrenals, Leblhuber et al.122 found, apart from higher basal 
levels of cortisol, significantly lower serum levels of DHEAS; consequently, there was also a significant 
difference between the DHEAS/cortisol ratio in their index and reference group which is in line with some 
previous findings.150 Because DHEAS is known to reduce the levels of glucocorticoids as well as antagonize 
their functions, DHEAS suppletion could be a strategy to counteract the noxious effects of prolonged 
hypercortisolaemia on e.g. cognition, mood and metabolism in HD subjects.121,122,150    
4.3. Somatotropic axis
Alterations in GH secretion in HD have frequently been reported and often entail an increase in mean 
basal plasma GH levels and exaggerated or paradoxical responses of GH secretion during stimulatory and/
or inhibitory functional tests.98 In contrast, most authors have found non-deviant GH concentrations during 
single baseline measurements.17 However, exaggerated GH responses followed administration of L-dopa167, 
apomorphine55, bromocriptine35, arginine125,168, insulin97,120,165 and muscimol55. Paradoxical GH responses have 
been observed to occur after administration of glucose51,115,166,167, L-dopa51 or bromocriptine.36,51 It should be 
noted though that exaggerated and paradoxical GH responses were not always uniformly present, i.e. while 
some HD patients exhibited an exaggerated response during a particular functional test, others exhibited a 
normal or even paradoxical response,51 and not all authors have been able to detect significant abnormalities 
in GH secretion,47,115,190 either suggesting the existence of considerable heterogeneity among individual HD 
patients in this respect and/or reflecting different methods in performing and interpreting the endocrine tests 
or, alternatively, differences in the severity of the disease.115 Interestingly, Hayden et al. found that a dose of 
25 mg of chlorpromazine suppressed GH release in adults with HD, but not in controls, perhaps indicating 
dopamine receptor hypersensitivity in the HD group.75 Although Durso et al.56 and Murri et al.144 have 
evaluated, respectively, basal 24-hour and nocturnal plasma levels of GH in HD, their long blood sampling 
interval (i.e. 30-minutes or more) does not allow for definite judgments regarding the precise secretory pattern 
of GH release in HD, and any possible alteration therein, because of the fairly short half-life of this hormone 
in plasma.226 Kremer et al.115 measured plasma levels of insulin-like growth factror-1 (IGF-1), an important 
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peripheral mediator of GH activity with a comparatively long half-life, in 10 HD patients at baseline and in 
8 of them also after a 2.5-year follow-up, but found no significant differences, either between the two intra-
individual measurement points or in comparison to values in matched controls; yet the authors stated that the 
assay applied probably has not been sufficiently accurate in detecting small differences.115 Non-deviant basal 
IGF-1 levels were also reported by other authors.171 Since the nature of impaired GH regulation in (some) 
patients with HD does not imply hypophysiotropic pathology, deviant GH release in HD might be attributed 
to impaired input from structures elsewhere (H.P. Kremer, thesis). GH has long been known to have profound 
effects on systemic substrate metabolism. Prolonged elevated levels of GH can induce glucose-intolerance and 
insulin-insensitivity as is the case in acromegalics. On the other hand GH is a potent physiological stimulator 
of lipolysis and e.g. GH suppletion can result in considerable loss of body fat and weight in (adult) patients 
with Prader-Willi, the most common syndromal cause of morbid obesity.81 Therefore, the abnormalities in 
carbohydrate metabolism in HD (see below under the section ‘Metabolic abnormalities in HD’) and wasting in 
this disorder could both be attributed, at least in part, to hypersomatotropism in some of these patients. 
4.4. Lactotropic axis
Many studies have targeted lactotropic axis function in HD patients. In general, prolactin dynamics are 
considered to be normal or slightly increased.98 Most studies report normal plasma prolactin concentrations 
during single daytime35,36,120,126,142, nocturnal144 or 24-hour determinations.56 Although a few authors have 
described lower76,158 or increased basal levels33,35, in these studies an insufficient wash-out period of previous 
neuroleptic medication may have confounded the results.98 Normal suppression of plasma prolactin followed 
dopaminergic stimulation35,36,55,126,143 and the prolactin response to muscimol (a GABA-agonist) as well as 
arecoline (a muscarinic agonist) were found to be similar in the HD and the control group.55 Initially, blunted 
prolactin responses were reported after chlorpromazine or TRH stimulation,33,76 but subsequent studies 
could not confirm these findings.35,120,126 Considering the methodological shortcomings or strengths of the 
various studies, the evidence from these early findings favours a slight increase in plasma prolactin levels.98 
Interestingly, Kremer et al.115 reported a decrease in the mean basal prolactin levels over 2.5 years of follow-
up in 7 patients with HD (though it should be noted that at baseline the prolactin levels of their patients and 
controls did not differ and that the control subjects could not be reinvestigated after the follow-up period), 
which clearly contradicts earlier findings.98 It remains to be sorted out to what extent this should be attributed 
to seasonal fluctuations,115 a statistical type I error115 or be considered as evidence for a ‘hyperdopaminergic 
state’ in HD as proposed in the earliest report by Hayden et al.76 Interestingly, more recent experimentation 
indeed hints at an important role for altered dopaminergic signaling in the striatal vulnerability associated 
with HD,37,87 although the implications for the hypothalamic tubero-infundibular dopaminergic system and its 
regulation of prolactin release are still obscure.
4.4. Hypothalamo-pituitary-thyroid (HPT) axis
Relatively few studies in HD patients have evaluated HPT axis activity. Basal levels of total thyroxine, 
triiodothyronine, triiodothyronine resin uptake and TSH have been reported to be comparable to values in 
normal controls.76,120 Lavin et al.120 found that the TRH test revealed no differences in basal levels of TSH, 
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or in peak response to TRH or in the increment at 20 minutes, although one of the 8 patients, but none of the 
10 controls, had a delayed response typical of a hypothalamic disorder.120 However, Hayden et al.75 reported 
impaired TSH response to TRH stimulation in 7 adults with HD as compared to 11 normal controls. Since 
depression is very common in HD and TRH stimulation test reveals a lower or blunted TSH response to TRH 
in a substantial proportion of depressed patients as well,59 it remains unclear to what extent the findings by 
Hayden et al.75 in fact might have reflected a concomitant depressive disorder in the patient group. Importantly, 
neither Lavin et al.120 nor Hayden et al.75,76 reported the mean body weight and the overall nutritional status of 
their subjects. Since it is well known that levels of thyroid hormones drop during fasting or negative energy 
balance90 and as many HD patients are underweight, values of T3, T4, fT4 and TSH within the ‘normal’ range 
in this group could, nonetheless, be indicative of HPT axis dysfunction. It is in this regard of interest to note that 
in a retrospective chart review study of 97 HD patients residing in long-term care facilities, the most commonly 
prescribed drug (6%) for problems ‘unrelated’ to HD was found to be levothyroxine.146 Moreover, both leptin 
and glucocorticoids appear to exert substantial modulatory effects on the thyroid axis90,170 and as there are 
indications that both hypoleptinaemia and hypercortisolaemia may be features of at least some patients with 
HD (see above under the headings ‘Ghrelin and leptin’ and ‘Hypothalamo-pituitary-adrenal (HPA) axis’ ), it 
can be argued that closer examination of the HPT axis function in this disorder may demonstrate abnormalities, 
which would be of particular relevance for elucidating the pathogenesis of wasting and mood changes in this 
disease. 
4.6. Hypothalamo-pituitary-gonadal (HPG) axis
For a review of HPG axis function in HD refer to the subheading ‘Gonadorelin’ in the section ‘Hypothalamic 
dysfunction in HD’.
4.7. Ghrelin and leptin
Ghrelin, an orexigenic factor of gastric origin, and leptin, a peptide hormone secreted by adipose tissue, are 
two peripherally produced hormones that exert opposite effects on the neuronal populations within the arcuate 
nucleus, VMN and lateral hypothalamus that play a key role in the regulation of body energy homeostasis.236 
Popovic et al.171 measured both circulating and CSF levels of ghrelin and leptin in 15 patients with HD and 20 
normal-weight subjects undergoing orthopaedic surgery. Blood samples were obtained by venipuncture and 
in-parallel CSF samples for ghrelin and leptin determination were obtained by lumbar puncture. Patients with 
HD had increased concentrations of ghrelin in plasma compared with healthy subjects (4523.7 ± 563.9 vs. 
2781.1 ± 306.2 pg/ml, P<0.01). On the other hand, patients with HD had decreased concentrations of leptin in 
plasma compared with healthy subjects (4.8 ± 1.6 vs. 10.9 ± 2.4 ng/ml, P<0.01). Comparably, in the CSF, the 
concentrations of ghrelin tended to be higher and the levels of leptin tended to be lower, but these differences 
failed to reach statistical significance, possibly due to the relatively small sample size.171 It should be noted 
though that the index and the reference group were not matched for BMI (20.2 ± 0.6 vs. 24.8 ± 0.8 respectively, 
p = 0.001) and that the total fat mass was not calculated and as a result the circulating leptin levels were not 
corrected for total fat mass. Nevertheless, only in the control group did plasma leptin concentration correlate 
with BMI. Two other studies reported equivalent plasma leptin levels in HD patients and controls matched for 
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BMI, fat mass and fat-free mass.68,172 However, the patients in these studies were, by selection, asymptomatic 
or were at a mild to moderate stage of the disease (stages I and II). Other confounders which could account for 
the discrepancy between the findings in these studies are: a) the circadian rhythm of plasma leptin levels, which 
are (like ghrelin levels) high in the morning and low at night;236 b) plasma levels of cortisol and insulin,45 both 
of which could be deranged in HD patients (refer to the subheadings ‘Hypothalamo-pituitary-adrenal (HPA) 
axis’ and ‘Carbohydrate metabolism’ for further details) and c) differences in sympathetic tone,102 which as 
mentioned before, may vary in the course of HD. Furthermore, it is not known to what extent increased levels 
of circulating ghrelin, which is the native substrate for the GH-releasing peptide (GHRP) receptor, could 
underlie the hypersomatotropism in some HD patients (see under the subheading ‘Somatotropic axis’ below), 
as high GH responses are induced by ghrelin infusions which act synergistically to growth-hormone releasing 
hormone (GHRH) stimuli.101,163  
5. SYSTEMIC METABOLIC ABNORMALITIES IN HD
In the following section we will give an overview of alterations in carbohydrate, lipid and protein metabolism 
in HD as well as their relation to the afore discussed hypothalamic and endocrine alterations and clinical 
symptomatology.
5.1. Carbohydrate metabolism
The studies on carbohydrate metabolism in HD subjects have yielded quite ambiguous and conflicting results.115 
Considerably large groups of HD patients have been identified with impaired glucose tolerance on oral glucose 
loading,51,168,169,190 although none of the participants displayed clinical signs or symptoms of diabetes mellitus. 
These studies compared the findings in individual patients with a pre-chosen standard, which was lower than 
currently used168,169 or ill-defined.51 Remarkably, other investigators identified appreciably fewer HD patients 
with impaired glucose tolerance.47,115 Though it should be emphasized that generally, in the earlier studies, 
information about the precise clinical condition (especially body weight and composition, stage of the disease, 
medication and immobility status) of the participants is lacking and the results of individual patients are not 
shown and therefore cannot be reinterpreted according to the current WHO-criteria.115 Several authors have 
also performed an analysis of their pooled data on the oral glucose tolerance tests by comparing the mean 
values of HD patients with those of control subjects: only Podolsky et al.168,169 were able to detect significant 
differences, while others could not replicate their findings.47,97,115,166 In addition, Kremer et al. reported 
glycosylated haemoglobin (HbA1c) levels in their HD patients to be comparable to those of controls, excluding 
marked blood glucose fluctuations over the preceding three to four weeks in their sample.115 Elevated levels 
of circulating insulin were noted in all patients with impaired glucose tolerance,168,169 whereas other studies 
reported mean insulin levels during glucose tolerance testing to be normal and fasting glucose,68,172,216 insulin 
and C-peptide levels to be unchanged.47,97,115,115 Despite the increased insulin levels found by some authors, 
insulin tolerance tests in HD patients did not demonstrate any abnormalities.97,120,166 Of note is that during the 
insulin tolerance tests all patients, although awake, lost their involuntary movements;97,120 in Lavin’s group the 
disappearance of the movements coincided with the onset of hypoglycaemia: a possible explanation could be 
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that the basal ganglia in HD are especially susceptible to neuroglycopenia.120 Only one follow-up study has 
been performed in which glucose tolerance, HbA1c and insulin values were assessed in HD patients; none 
of the investigated parameters showed any significant change after 2.5 years, although the drop-out rate was 
substantial (4 of the original 10 HD patients could not be reinvestigated for the evaluation of glucose tolerance 
and in 2 of them HbA1c and insulin could not be assessed either).115
In a retrospective study by Farrer et al.61 information about the incidence and control of diabetes mellitus in 
620 probands (278 living, 332 deceased) with HD and in their first and second degree relatives was obtained 
by a questionnaire method. Among the probands, 65 individuals (10.5%) were identified by the informant or 
verified by examination of the family records as diabetic. The age adjusted prevalence rate for the year 1975 
of diabetes in HD was calculated to be 4 times as high as in the general population. Incidence rates were not 
calculated because of ascertainment and other biases in their data. Interestingly, results from the analysis of 
family data indicated that HD affected relatives of an HD proband with diabetes were 7 times as likely to have 
diabetes over the proband’s non-HD relatives, while a non-diabetic HD proband was equally likely to have an 
HD or non-HD relative with diabetes, suggesting genetic clustering of diabetes and HD. It should be noted that 
unambiguous interpretation of Farrer’s findings is hampered by incomplete data on their criteria for diabetes, 
body composition, the use of drugs, intercurrent illness, and the level of activities, as well as by the intrinsic 
difficulties associated with a retrospective survey.115 
More recently, Underwood et al.218 applied metabolic profiling to serum samples from HD patients (10 
asymptomatic gene carriers and 20 patients in the early to moderate stages of their disease) in a non-hypothesis 
driven systems biology search for disease biomarkers and found, among others, significant changes in various 
monosaccharide levels (including glucose) between asymptomatic gene carriers/patients on the one hand and 
20 controls of similar age and sex distribution on the other hand. However, the authors did not indicate the 
direction of the changes and whether the blood samples were taken in a fasting state.
In sum, due to principal and/or methodological inadequacies of most of the studies on carbohydrate metabolism 
in HD patients and the very small sample sizes often examined, which in all probability both could account for the 
contradictory results, it still remains to be ascertained whether impaired carbohydrate metabolism is an inherent 
feature of HD and whether it has any special clinical relevance in this disorder (especially with regard to weight 
loss). If this is the case, the precise underlying mechanisms (i.e. pancreatic ß-cell dysfunction,4,19,82,85 possibly 
due to transcriptional dysregulation,4 and/or peripheral insulin insensitivity20 secondary to neuroendocrine 
and ANS dysbalance due to hypothalamic dysfunction (see previous sections)) should be elucidated in order 
to devise effective therapeutic strategies. As recent experimentations in animal models of HD demonstrate 
that the prevalence of impaired glucose tolerance is consistently higher in the affected animals compared to 
controls4,19,20,82,85,88,129,218 and that dietary manipulations that affect glucose metabolism may lead to amelioration 
of symptoms and/or increase overall life-span in these animals53 combined with strong indications that lately 
have emerged for a saccharide-polyglutamine interaction both in vitro and in vivo,95,210,211 corroboration of 
these data in humans, in both principally and methodologically sound and rigorous experimental settings, 
seems to be necessary. 
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5.2. Lipid metabolism
Notwithstanding the progressive weight loss in HD patients, which is accompanied by substantial loss of 
body fat stores, as indicated by decreased abdominal circumference and subscapular skinfold (both measures 
of central/visceral adiposity) as well as triceps skinfold thickness (a measure of peripheral adiposity),62,63,216 
systemic lipid metabolism has hardly received any direct study in individuals with this disorder. Schubotz et 
al.190 measured serum lipids and the plasma fatty acid composition of the cholesterylesters, triglycerides and 
phospholipids in 25 subjects with or at risk for HD (9 at-risk asymptomatics, 5 with light and 11 with severe 
symptoms) and found minor deviations in the fatty acid patterns in various lipid classes. Other authors have 
reported high fasting concentrations of non-esterified fatty acids (NEFAs) in choreic patients when compared 
with control subjects.166 This difference was maintained under hypoglycaemic conditions, while during 
hyperglycaemia the differences in NEFAs concentrations between the groups was abolished.166 In addition, 
plasma and CSF leptin concentrations have been measured (refer to the subheading ‘Ghrelin and leptin’ in 
the section ‘Endocrine abnormalities in HD’ for a discussion of these measurements). Recently, Underwood 
et al.218 applied metabolic profiling to serum samples from HD patients (10 asymptomatic gene carriers and 
20 patients in the early to moderate stages of the disease) in a non-hypothesis driven systems biology search 
for disease biomarkers. Among other things, they found significant changes in various markers of fatty acid 
breakdown (including glycerol and malonate) between asymptomatic gene carriers/patients and controls of 
similar age and sex. This could indicate a pro-catabolic phenotype early on in the disease progression,218 
although the precise significance of these and previous findings still remains to be clarified. In addition, the 
possible contribution of hypothalamic dysfunction in HD, and subsequent endocrine abnormalities (especially 
GH and cortisol) and autonomic dysregulations (in particular a possible dysbalance between sympathetic and 
parasympathetic innervation of adipose tissue,108,109 to the genesis of systemic alterations of fat metabolism in 
HD is far from clear and needs further exploration. 
Circumstantial evidence initially obtained from a small series of publications in the 1970s that all claimed to 
have discovered membrane abnormalities in cells of peripheral tissues (especially fibroblasts and erythrocytes) 
from HD patients, led to the belief that a ‘generalised cell membrane defect’ may be involved in HD.15 This 
prompted intensive efforts by many investigators over a considerable time span to reproduce these initial 
findings, but most of the later studies failed to substantiate the existence of a ‘generalised membrane defect’ in 
HD.15,131,189 In particular, since biochemical findings regarding phospholipid concentration, fatty acid analysis, 
lipid-bound sialic acid, neutral glycolipids, and total cholesterol were reported to be normal in erythrocyte 
lipid fractions from HD patients23,80,230 and as membrane fluidity of HD fibroblast, erythrocyte and lymphocyte 
membranes did not appear to be significantly different from that of controls,16,117,205,206 Beverstock15 concluded 
that in any event lipid fractions of peripheral cell membranes and blood plasma are not involved in HD. 
However, in a recent study, Valenza et al.222 extracted RNA from primary fibroblasts taken from control and 
HD patients and analyzed the expression of three key genes of the cholesterol biosynthetic pathway, viz. 
HMG-CoA reductase, cytochrome P450 lanosterol 14 α-demethylase and 7-dehydroxy-cholesterol reductase, 
and found that HD fibroblasts show a 35-40% decrease in the mRNA levels of these three genes. Although they 
observed no differences in cholesterol biosynthesis between normal cultured fibroblasts and HD fibroblasts 
in standard medium, exposure of the cells to lipoprotein-deficient serum (LPDS) demonstrated that HD 
fibroblasts were less capable of upregulating the mevalonate pathway, and thus de novo cholesterol synthesis, 
in response to low levels of cholesterol;222 this latter finding is in line with that of Menkes et al. who showed 
that control fibroblasts were not affected unduly by LPDS over a four day period, whereas three-quarters of the 
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HD lines failed to grow in LPDS.139 The discrepancy between the recent findings of Valenza et al.222 and the 
conclusion drawn by Beverstock,15 which was based on a review of earlier studies on lipid metabolism in HD, 
could be accounted for by the possibility that some degree of stressing of cells might be necessary to unveil 
a phenotypic difference in HD cells. However, in a later study Sakai et al.185 did find that the mean level of 
docosahexanoic acid in the erythrocyte membrane in six HD patients was significantly lower than in that of 14 
matched controls. Therefore, considerable controversy remains about any putative defects of peripheral tissue 
lipid metabolism in HD.  
Contrary to peripheral lipid metabolism, the indications of a defect in neuronal lipid metabolism in HD are 
more consistent. Ellison et al.57 reported the concentrations of phosphoethanolamine and ethanolamine to be 
significantly reduced in the caudate, putamen and nucleus accumbens of brain samples from HD subjects. More 
recently, by applying the niacin skin flush response (i.e. measuring the cutaneous erythematous vasodilatation 
response to a topical aqueous methyl nicotinate solution) Puri173 demonstrated that the response in 6 patients 
with advanced HD (stage III) was significantly lower than the mean response in a group of 14 age- and sex-
matched controls, suggesting an abnormality of neuronal membrane fatty acid metabolism, particularly an 
impaired phospholipid-related signal transduction, in advanced HD.173 Still more recently it was shown that 
the transcription of key genes of the cholesterol biosynthesis pathway is severely affected in both human post-
mortem HD striatal and cortical tissue 222 as well as in HD animal derived brain tissues.200,222   
Based on the hypothesis that a membrane defect might be fundamental in HD pathogenesis and that this might 
be partly corrected by the provision of essential fatty acids,46 a few open label studies with γ-linolenic acid and 
eicosapentaenoic acid (EPA) were conducted in patients with HD that showed significant clinical improvement 
in both motor and cognitive performances.221 Subsequent small-scale studies showed that treatment with ethyl-
EPA in HD is associated with decreased abnormal movements and changes on brain magnetic resonance 
imaging when compared to a placebo-treated group.174,221 In a recent large-scale (n = 135) clinical trial on the 
efficacy of 2 g/d ethyl-EPA versus placebo for the treatment of HD patients,175 intention-to-treat analysis after 
12 months of treatment did not reveal a significant difference between ethyl-EPA and placebo on the primary 
end point of the study, viz. Total Motor Score 4 subscale (TMS-4) of the UHDRS. However, restriction of the 
analysis to those patients who had completed the study without protocol violations (n = 83), did indicate ethyl-
EPA to be better than placebo as judged by the TMS-4 scores. It should be noted though that intention-to-treat 
analysis showed a significant worsening of the behavioural score in the EPA-treated group compared with the 
placebo-treated group. 
In conclusion, the studies on lipid metabolism in HD patients hitherto have yielded equivocal results and 
clearly do not suffice to pass a well-considered judgment on any possible systemic defects in lipid metabolism 
in these subjects. As recent findings in animal models of HD5,42,60,223,224 do support the notion of systemic 
anomalies of lipid metabolism in HD and as supplementation of certain lipid groups could be efficacious in 
patients with HD,175,221 further systematic exploration of this field, e.g. by measuring lipid synthesis and/or 
lipolyis in vivo, could yield interesting results.  
5.3. Protein metabolism
Using the anthropometric data on upper arm and calf circumferences and triceps and calf skinfold thicknesses 
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from the studies by Farrer et al.62,63 in combination with the following formulae: upper arm muscle circumference 
= upper arm circumference – π . (triceps skinfold thickness) and calf muscle circumference = calf circumference 
– π . (calf skinfold thickness), it can be calculated that individuals affected with HD have a significantly smaller 
upper arm as well as calf muscle circumferences compared to controls, despite a comparable protein and 
fat intake and even a higher carbohydrate intake and less strenuous physical activity.62 These findings were 
recently confirmed in a study by Trejo et al. in 25 HD patients and an equally large group of age- and sex-
matched controls.216 Thus apart from fat loss, muscle wasting probably also contributes to the emaciation in 
HD. In fact, three more recent studies have indeed found abnormal in vivo skeletal muscle energy generation 
in both symptomatic HD subjects and presymptomatic mutation carriers.106,128,184 These findings indicate that 
systemic mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD184 
and it is therefore likely that impaired mitochondrial function will partly underlie muscle wasting in subjects 
with HD. In addition, microarray profiling of gene expression in skeletal muscle biopsies from HD patients 
and controls demonstrated distinct expression profiles;204 none of the biopsy donors had frank diabetes or was 
emaciated, so it is unlikely that HD muscle gene expression changes would be caused by diabetes or weight 
loss. Corroboration of these data in a HD mouse model indicated that although both the diabetic phenotype 
and weight loss in these mice partly contributed to the observed changes in muscle gene expression, neither 
could explain the complete set of alterations.204 These data suggest a primary, local biochemical defect in HD 
muscles (see also180), although other factors, such as endocrine abnormalities and aberrant signalling from the 
central nervous system, are likely to be involved as well.   
While the earliest studies of amino acid metabolism in subjects with HD could not detect any appreciable 
abnormalities,27,43,152 subsequent investigations have found significant differences in plasma concentrations of 
certain amino acids.153,154,159,160,166,179,218,237 The most consistent finding appears to be a decrease in the plasma 
concentrations of neutral amino acids (especially alanine, valine, leucine and isoleucine) compared to healthy 
controls. Interestingly, in a recent non-hypothesis driven experimental approach, Underwood et al.218 found 
decreased levels of valine in asymptomatic HD-gene carriers as well as symptomatic patients, while the levels 
of alanine and leucine were elevated in the group of asymptomatic gene-carriers and tended to be lower in more 
symptomatic patients, suggesting a negative correlation between these metabolites and disease progression.218 
Also considerable systemic alterations in the kinetics of the kynurenine pathway (a major route accounting 
for the metabolism of over 90% of the non-protein tryptophan in most tissues) have been reported in patients 
with advanced HD,202 extending the earlier findings of abnormal tryptophan metabolism in the central nervous 
system of HD subjects (see202 and the references therein). However, baseline blood levels of melatonin, also 
a product of tryptophan metabolism, as well as the rise in melatonin levels after tryptophan loading were 
recently reported not to be different between HD patients and healthy controls.40 Notably, a case report has 
described the stabilization of a HD patient by a low tryptophan diet.157
Concluding, as yet it is poorly understood to what extent the aforecited alterations in protein metabolism are 
due to local changes (especially peripheral mitochondrial dysfunction (see below under ‘Basal metabolism and 
energy expenditure’)), and to what extent endocrine alterations (including impaired insulin secretion) or ANS 
dysregulation could account for these abnormalities.
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5.4. Basal metabolism and energy expenditure
The first study on basal metabolic rate (BMR) in HD subjects found that the BMR was markedly increased in a 
number of patients.17 However, a subsequent study reported that the BMR, as measured by oxygen consumption 
in a resting state, was not greater in HD subjects (n = 41; stages I and II) compared with the spouses (n = 22) who 
did not differ from the patients in regard to age, height or lean body mass (LBM); although unexplained weight 
loss exceeding 3 kg in the past years was reported by 43% of the HD patients but only by 9% of the spouses.197 
More recently, the BMR and energy expenditure have been investigated more thoroughly in HD patients.68,172 
Prately et al. measured sleeping metabolic rate (SMR) and 24-hour sedentary energy expenditure (24-h EE) 
in a human respiratory chamber in 17 patients with mild to moderate HD (3 of whom were asymptomatic) 
and 17 control subjects matched for age, sex, BMI and fat mass.172 They did not find any differences in SMR 
between the two groups, but the 24-h EE was approximately 14% higher in patients than in controls and the 
patients seemed to be in a state of negative energy balance. The increase in 24-h EE appeared to be the result 
of increased spontaneous physical activity (as measured by radar in the chamber and as reflected in the ratio 
of 24-h EE to SMR) that was proportional to the severity of the patients’ chorea score. However, the increase 
in 24-h EE did not translate into an increase in total energy expenditure (TEE) measured during 7 days in free-
living conditions by using the doubly labelled water technique, apparently because patients with HD engage 
in less voluntary physical activity.172 Unfortunately, because not all food records were completed, the authors 
could not assess dietary intake in most of the subjects during free-living conditions, and therefore, energy 
balance during this period cannot be judged. Gaba et al. assessed SMR, waking metabolic rate (WMR) and 
24-h EE (via indirect calorimetry in a human respiratory chamber) in 13 subjects with HD (stages I and II) 
and 9 controls matched for age, sex, BMI and body fat percentage.68 They found a tendency for higher SMR 
and 24-h EE in HD patients compared to controls, although the differences nearly failed to reach statistical 
significance, probably owing to the small group sizes. The WMR was, nevertheless, significantly higher in 
patients and was related to a significantly greater displacement of the centre of mass by HD subjects on a force 
platform (a measure of physical activity), in all probability as a result of the involuntary movements in the 
choreic subjects.68
Although the findings of a similar resting metabolic rate and SMR in patients and matched controls172,197 argue 
against an intrinsic metabolic defect in whole body energy metabolism in subjects with HD, other reports of 
significant and nearly significant increases in BMR17,17,68 in HD are more consistent with the possibility of an 
overall defect in mitochondrial oxidative phosphorilation, as suggested by studies in which the phosphocreatine 
to inorganic phosphate ratios were measured and shown to be decreased in both presymptomatic and 
symptomatic subjects with HD.106,128,184 An extensive review of the evidence in favour of peripheral defects in 
mitochondrial energy generation in both animals and humans with HD is given by Browne and Beal.26 While 
the findings of significantly elevated 24-h EE and WMR in HD subjects, which both correlated with the chorea 
score, do indicate that involuntary movements can contribute to a considerable extent to the energy loss in 
these patients,68,172 the fact that the total free-living energy expenditure is the same for patients and matched 
controls, as a consequence of less voluntary physical activity by the patients,172 does not explain the lower body 
weight of HD patients despite their normal or even increased appetites. Moreover, the greatest rate of body 
weight loss appears to be in the final hypokinetic stages of the disease when involuntary movements are far less 
prominent.187 However, as pointed out by Gaba et al., it might be that the variability in food intake increases 
as the total functional capacity (TFC) decreases and as a consequence the higher intakes reported on some 
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days may not be enough to offset the lower energy intakes reported on other days.68 All together, the precise 
contribution of altered BMR and TEE to weight loss in patients with HD still remains elusive. In addition, 
endocrine parameters and ANS function have not yet been assessed in conjunction with measures of energy 
intake and/or expenditure in individuals with HD and consequently their precise roles in the emaciation in this 
group of patients also await further elucidation.       
6. CONCLUSIONS
Since the hypothalamus is a major control centre in the brain for the regulation of body energy homeostasis, sleep-
wake cycles and the coordination of autonomic functions [89,92,232,236], we postulated that hypothalamic 
dysfunction per se as well as subsequent (neuro)endocrine and metabolic abnormalities in patients with HD 
may substantially contribute to the pathogenesis of weight loss, sleep disturbances and ANS dysfunction in 
HD. Moreover, some mood and cognitive disturbances associated with HD may also partially originate from 
hypothalamic involvement in this disorder. As reviewed, many studies in both animal models and human 
patients with HD indeed strongly indicate that hypothalamic dysfunction, (neuro)endocrine and metabolic 
abnormalities may be consistent as well as important features of HD, which could at least partly account for the 
pathogenesis of the aforementioned signs and symptoms. However, as noted before, the dyskinesia per se as 
well as peripheral tissue anomalies are in all likelihood also implicated in the pathogenesis of symptoms such 
as unintended loss of body weight in this disorder. 
Emaciation, sleep disturbances and autonomic dysfunction are important indicators of the rate of disease 
progression and can considerably impair the already diminished quality of a patient’s life. It is therefore of 
crucial and practical importance to elucidate the pathophysiology of these signs and symptoms in order to find 
novel and more effective therapeutic targets. On the basis of this review, it can be inferred that therapies aimed 
at affecting hypothalamic, (neuro)endocrine and metabolic parameters may indeed be promising potential 
candidate treatments for the control of these signs and symptoms that should be put to the test in future animal 
studies and subsequently in human clinical trials as well. 
7. AIMS OF THE THESIS
Part I: Secondary signs in Huntington’s disease
In the first part of the thesis, we aim to delineate of the characteristics of the less well-known symptoms and 
signs of HD,  and assess their association with other aspects of the disease, including mutation size and motor, 
cognitive and behavioural indices.  The course of weight loss and its determinants is assessed in Chapter 2. 
Guided by findings from the previous chapter,  in Chapter 3 the effects the interaction between mutant and 
normal HTT on clinical phenotype, including body weight, are described. Subsequently, the prevalence, nature 
and correlates of sleep disturbances (Chapter 4) and autonomic complaints (Chapter 5) in HD patients are 
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presented.  
Part II: Hypothalamic pathology in Huntington’s disease
The subject of this part of the thesis (Chapter 6) is the neuropathological evaluation of hypocretin-1 (also 
known as orexin-A) and melanin-concentrating hormone neurotransmission in HD patients, as well as the 
assessment of various hypothalamic regions for the presence of neuronal intranuclear and cytoplasmic 
inclusions of mutant huntingtin.
Part III: Endocrine studies in Huntington’s disease
This part of the thesis contains a compilation of a number of endocrine studies in early stage HD patients.  The 
objective is to investigate whether the corticotropic (Chapter 7), somatotropic (Chapter 8), thyrotropic and 
lactotropic axes (Chapter 9) function, and adipokine (Chapter 10) and melatonin (Chapter 11) secretion are 
altered in HD patients compared with matched control subjects.  
Part IV: Metabolic studies in Huntington’s disease
The studies detailed in this section (Chapter 12) are aimed at the evaluation of the systemic metabolism in a 
group of early stage HD patients, focusing on basal energy expenditure, and glucose and fat metabolism.
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PART I
SECONDARY SIGNS 
OF 
 HUNTINGTON’S DISEASE
44
 
“Symptoms then, are in reality nothing but the cry from suffering organs.” 
Jean-Martin Charcot Leçons cliniques sur les maladies des vieillards et les 
maladies chroniques. Paris, 1868.
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ABSTRACT
Objective: Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an expanded 
number of CAG repeats in the huntingtin gene. A hallmark of HD is unintended weight loss, the cause of 
which is unknown. In order to elucidate the underlying mechanisms of weight loss in HD, we studied its 
relation to other disease characteristics including motor, cognitive and behavioral disturbances and CAG 
repeat number. Methods:  In 517 early-stage HD patients, we applied mixed-effects model analyses to correlate 
weight changes over three years to CAG repeat number and various components of the Unified Huntington’s 
Disease Rating Scale (UHDRS). We also assessed the relation between CAG repeat number and body weight 
and caloric intake in the R6/2 mouse model of HD. Results: In HD patients mean body mass index decreased 
with -0.15 units per year (p<0.001). However, no single UHDRS component, including motor, cognitive and 
behavioral scores, was independently associated with the rate of weight loss. HD patients with a higher CAG 
repeat number had a faster rate of weight loss. Similarly, R6/2 mice with a larger CAG repeat length had a 
lower body weight, whereas caloric intake increased with larger CAG repeat length. Conclusions: Weight 
loss in HD is directly linked to CAG repeat length and is likely to result from a hypermetabolic state. Other 
signs and symptoms of HD are unlikely to contribute to weight loss in early disease stages. Elucidation of the 
responsible mechanisms could lead to effective energy-based therapeutics. 
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Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by an expanded number of CAG repeats in the huntingtin gene.1 It is characterized by motor disturbances, 
cognitive decline and behavioral problems.2 Unintended weight loss is also a hallmark of the disease, both in 
HD patients3-6 and several transgenic mouse models of HD7. Weight loss frequently leads to general weakening 
and a decline in the quality of life of HD patients.8 On the other hand, a higher Body Mass Index (BMI) has 
been associated with a slower rate of disease progression.9
The cause of weight loss in HD is unknown. It might result from decreased caloric intake, increased motor 
activity or a higher metabolic rate.10 Previous studies in both HD patients and transgenic mouse models of 
HD have shown that loss of weight occurs despite adequate or even increased caloric intake.11-13 Weight loss 
is already manifest in presymptomatic HD gene carriers14 and is particularly marked in the final hypokinetic 
stages of the disease5. These observations and recent findings in HD transgenic mice suggest that weight loss 
might be due to an increased metabolic rate.13,15,16 Other reports suggest, however, that loss of body weight 
is secondary to a higher sedentary energy expenditure due to unwanted movements.17-20 Thus, studies on the 
mechanisms underlying weight loss in HD patients have yielded conflicting results and are inconclusive.10 The 
different outcomes of these studies are likely to be due to small group sizes and their cross-sectional nature. 
Interestingly, the direct relation between the number of CAG repeats in the mutant huntingtin gene and weight 
loss has not been assessed before. Mutant huntingtin could interfere with mitochondrial function in peripheral 
tissues in a CAG repeat length-dependent manner.21,22 Consequently, CAG repeat length may predict the extent 
of systemic energy defects in HD patients. 
In this study we therefore aimed to 1) specify the course of weight loss in a large, homogenous group of 
clinically well-characterized HD patients during a long-term follow-up, 2) determine which factors (including 
motor, cognitive and behavioral) are associated with weight loss, 3) assess whether CAG repeat length is 
directly related to the rate of weight loss, and 4) determine whether CAG repeat length is also associated with 
body weight and caloric intake in the most widely used transgenic mouse (R6/2) model of HD.
METHODS
HD patients. Participants were from the European Huntington’s Disease Initiative (EHDI) study, a randomized 
placebo-controlled trial over three years to study the effects of riluzole on the progression of HD.23 For 
inclusion, participants were required to be between 25 and 65 years of age, to carry a CAG-repeat expansion 
in the HD gene of ≥ 36, to manifest clinical signs of HD, and yet to be in an early stage of the disease 
(defined on the Unified Huntington’s Disease Rating Scale (UHDRS) as a motor score ≥ 5 and Total Functional 
Capacity (TFC)-score ≥ 8). Patients on anti-choreatic (neuroleptic) treatment were not included and start 
of such medication was a predefined end point. In total, 537 HD patients were randomized of whom 379 
completed three years of follow-up. One-hundred-fifty-eight (158) HD patients (29.4%) dropped out due to 
different reasons, e.g. adverse events, suicide and suicide attempts, start of anti-choreatic medication. Here, 
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we excluded 20 participants (3.7%) from our analyses due to erroneous data on body weight (n=6) or missing 
data on height (n=14).
Clinical evaluations. Demographic data included age, gender and age of onset. Height, weight and the clinical 
scores on the UHDRS were recorded at baseline. Weight and UHDRS scores were also measured at subsequent 
visits at 2, 6, 12, 18, 24, 30, 36 and 37 months after the start of the study. Missing values at baseline observations 
were replaced by the corresponding value obtained at the screening visit wherever available.23 The UHDRS is 
divided into four components assessing motor performance, cognition, behavior and functional capacity.3,24,25 
In addition, symptoms of depression were also assessed with the Beck Depression Inventory (BDI).  
R6/2 transgenic mice. We used eight transgenic HD mice of the R6/2 line and eight wild-type littermates 
(Jackson Laboratories, Bar Harbor, ME, USA).13 They were obtained by crossing heterozygous males with 
females of their background strain (C57BL/6). CAG repeat lengths were assessed using a polymerase chain 
reaction assay (Mangiarini et al., 1996). The mice were singly housed from five weeks of age and had ad 
libitum access to water and food under standard conditions (12 h light/dark cycle, 22 °C). They were fed a 
standard diet (15% fat on a caloric basis). As R6/2 mice develop progressive locomotor problems, food was 
placed in dishes on the bottom of the cage. We monitored food intake four times per week over 24 h by pre-
weighing a portion of food and weighing it 24 h later. From week six to week 12, we measured body weight 
twice per week. At 12 weeks of age, mice were euthanized for ethical reasons. The experimental procedures 
were approved by the Regional Ethical Committee of Lund University, Sweden.
Statistical analyses. HD patients: We used linear mixed-effects models26 to examine changes in BMI during 
the follow-up period. To account for the correlation between the repeated measurements on each individual, we 
used a model with both fixed and random terms for time passed since the start of the trial. Disease duration at 
the start of the trial was considered as a fixed covariate. We also added the quadratic term for time to investigate 
potential non-linear relations between BMI and time. However, this term was not significant and was therefore 
left out. The associations between BMI changes and other demographic and clinical variables such as gender, 
various UHDRS subscores and CAG repeat length were studied by adding these variables one by one as 
explanatory variables into the model. To assess whether a variable was significantly associated with the rate 
of BMI change, also the interaction of this variable with the time variable was added and tested. A significant 
interaction entails that the variable of concern influences the rate of BMI change. To identify which predictor 
variables from Table 2 were independently associated with the rate of BMI change, we also used a stepwise 
regression procedure based on forward selection (an independent predictor of BMI change is a variable 
that remains significantly associated with the rate of BMI change after adjustment for the effects of other 
significant predictor variables.) Models were validated both graphically and analytically.26 The linear mixed-
effects models procedure applied here is valid under the Missing at Random assumption. Under the Missing 
at Random assumption drop out of subjects is allowed to depend on both previous outcome measurements 
as well as predictor variables.26 In addition, we also verified that drop out of subjects did not depend on any 
baseline characteristic using a Cox proportional-hazards regression model. Differences between the baseline 
characteristics of the placebo and the riluzole group were statistically evaluated by the unpaired Student’s t-test 
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or the χ2-test where appropriate. R6/2 mice: As R6/2 mice first display reduced growth and later (from nine 
weeks of age and onwards) lose weight, for each mouse we calculated the total area under the curve for both 
body weight and caloric intake (kCal per gram of body weight). Pearson’s correlation coefficients were then 
computed to assess correlations. 
All data are presented as means ± SEM. All tests were two-tailed and values of p < 0.05 were considered to 
be significant. Programming was performed in SPSS version 14.0 for Windows (SPSS Inc, Chicago, Ill, USA) 
and SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
RESULTS
HD patients
Baseline characteristics 
All baseline characteristics of the HD patients who were 
included are summarized in Table 1. Except for small 
differences in age at the start of the trial, age of onset and 
the number of CAG repeats, there were no significant 
differences between the baseline characteristics of 
patients on either placebo or riluzole. 
BMI and rate of BMI change 
The rate of BMI change seemed to differ significantly 
between the placebo and the riluzole group (Table 2). 
However, since the two groups differed on a number of 
basal characteristics (Table 1), we corrected for these 
differences by including age, age of onset, CAG repeat 
number and baseline BMI and their interactions with 
time in the model. After correction for these confounders 
the two treatment groups ceased to differ significantly 
in their rate of BMI change (p-value of group × time 
interaction = 0.126). Moreover, stepwise regression 
did not identify treatment group as an independent  
predictor of BMI change (Table 2). Therefore, we based 
all our subsequent analyses on the pooled data. 
At baseline the average BMI of the total study 
population (n = 517) was 23.29 (SEM = 0.16). The 
mean BMI decreased with -0.15 units per year (SEM = 0.038; 95% CI: -0.23 to -0.08; p < 0.001). A higher 
BMI at baseline was associated with a faster rate of body weight decline (adjusted p for baseline BMI × time 
interaction = 0.001; Table 2). On average women weighed significantly less than men by about -0.88 BMI units 
Table 1. Baseline characteristics of 
Huntington’s patients that participated in 
the study 
Total cohort
(n=517)
Group (n)
   Placebo
   Riluzole
173 (33.5%)
344 (66.5%)
Men (%) 260 (50.3%)
Age (yrs) † 45.65 (0.43)
Age of onset (yrs) † 43.52 (0.44)
Disease duration (yrs) 2.13 (0.09)
BMI (kg/m2) 23.29 (0.16)
Years of education 11.33 (0.17)
CAG repeat number † 45.44 (0.19)
UHDRS motor score 28.21 (0.66)
UHDRS TFC score 10.88 (0.07)
UHDRS FAS score 22.07 (0.13)
UHDRS cognitive score 175.99 (2.79)
UHDRS behavioral 
score 11.85 (0.43)
BDI score 10.10 (0.39)
Data are presented as means (± SEM). 
Abbreviations: BMI = Body Mass Index; 
UHDRS = Unified Huntington’s Disease 
Rating Scale; TFC = Total Functional 
Capacity; FAS = Functional Assessment; BDI 
= Beck Depression Inventory; † The placebo 
and the riluzole group differed significantly 
on these baseline characteristics (p < 0.05).
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(SEM = 0.322; 95% CI: -1.51 to -0.25; p = 0.007). The significant interaction between gender and time (p = 
0.037; Table 2) disappeared when corrected for BMI at baseline (p = 0.078) indicating that men and woman 
do not differ in their rate of weight loss. Age of disease onset was not associated with BMI or the rate of BMI 
change (both p ≥ 0.061; Table 2). 
Table 2. Correlates of BMI and the rate of BMI change in patients with Huntington’s disease
Predictor variable Effect on average 
BMI a  (p-value)
Effect on rate of BMI 
change b (p-value)
Stepwise forward 
selection c (p-value)
General 
variables
Age of onset 0.031 (0.061) 0.001 (0.805) -
Baseline BMI, kg/m2 0.997 (<0.001) ** -0.030 (0.005) * -0.034 (0.001) **
Genderd -0.879 (0.007) ** 0.158 (0.037) * -
CAG repeat number -0.136 (<0.001) ** -0.022 (0.017) * -0.027 (0.006) **
Group (riluzole/
placebo)e
0.568 (0.098) -0.202 (0.011)* -
Combined score -0.005 (0.262) -0.001 (0.698) -
UHDRS TFC score 0.012 (0.580) 0.003 (0.827) -
UHDRS FAS score 0.012 (0.425) -0.001 (0.949) -
Motor 
variables
UHDRS total motor 
score
-0.005 (0.172) -0.002 (0.367) -
Chorea -0.011 (0.242) -0.005 (0.418) -
Dystonia -0.021 (0.109) 0.005 (0.599) -
Rigidity 0.005 (0.853) -0.030 (0.151) -
Bradykinesia -0.075 (0.059) -0.061 (0.038)* -
Behavioral 
variables
UHDRS total 
behavioral score
-0.004 (0.292) -0.002 (0.515) -
Total behavioral score 
frequency
-0.006 (0.330) -0.004 (0.444) -
Total behavioral score 
severity
-0.009 (0.244) -0.003 (0.638) -
Depression score -0.020 (0.170) -0.003 (0.638) -
Apathy score 0.003 (0.832) -0.020 (0.079) -
BDI score -0.008 (0.063) -0.003 (0.365) -
Cognitive 
variables
UHDRS total cognitive 
score
0.001 (0.291) <0.001 (0.652) -
Verbal Fluency 0.007 (0.089) 0.008 (0.148) -
Symbol Digit Test 0.011 (0.028) * <0.001 (0.956) -
Color naming 0.003 (0.430)  0.001 (0.569) -
Word reading -0.001 (0.754) 0.002 (0.136) -
Interference -0.004 (0.355) -0.001 (0.577) -
a) This column indicates the increase or decrease in average BMI (calculated over the whole study period) per 
unit increase of the predictor variable. b) This column indicates the increase or decrease in the rate of BMI 
change [BMI units/year] per unit increase of the predictor variable. c) This column indicates the increase or 
decrease in the rate of BMI change [BMI units/year] per unit increase of those predictor variables that were 
selected by stepwise forward selection; these predictor variables are independently associated with the rate of 
BMI change. d) Gender was coded as: male = 0, female = 1. e) Group was coded as: placebo = 0, riluzole = 1. 
Abbreviations: BMI = Body Mass Index; UHDRS = Unified Huntington’s Disease Rating Scale; TFC = Total 
Functional Capacity; FAS = Functional Assessment; BDI = Beck Depression Inventory; * p < 0.05; ** p < 0.01.
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Effects of motor scores on the rate of weight loss 
Of all the motor signs of HD only bradykinesia was significantly associated with the rate of BMI change (Table 
2). Patients who became more bradykinetic during their illness had a significantly accelerated rate of body 
weight loss compared to others (p = 0.038). However, stepwise regression did not identify bradykinesia as an 
independent predictor of BMI change (Table 2). As the average bradykinesia score increased with 0.023 units 
for each unit increase in CAG repeat length (p = 0.003), CAG repeat length is likely to have confounded the 
relation between bradykinesia and weight loss.
No effect of cognitive and behavioral scores on weight change 
Except for the Symbol Digit Modalities test score, which very weakly correlated with BMI, other cognitive 
and behavioral variables did not correlate with BMI. Moreover, no single cognitive or behavioral variable was 
associated with the rate of BMI change in the HD cohort (Table 2).  
Lower mean BMI and faster rate of BMI decline 
with larger CAG repeat number
Interestingly, the BMI averaged over the follow-up 
period decreased with 0.136 units for every CAG 
codon increase in the mutant huntingtin gene (p < 
0.001). Moreover, the number of CAG repeats in the 
mutant huntingtin gene significantly interacted with 
the time variable (p = 0.017), indicating that the rate 
of body weight decline also increases for each unit 
increase in CAG repeat length (Table 2 and Figure 
1). Stepwise regression identified CAG repeat 
length also as an independent predictor of weight 
loss (adjusted p for CAG × time interaction = 0.006).
R6/2 transgenic mice
Similar to their wild-type littermates, R6/2 mice 
gained weight from the start of the study at six 
weeks of age until week nine.13 However, from nine 
weeks of age and onwards, they progressively lost weight. The length of the CAG repeat in the transgene in our 
cohort of R6/2 mice varied between 163 and 175. The area under the body weight curve decreased with larger 
CAG repeat length (r = -0.742; p = 0.035), indicating that mice with a higher number of CAG repeats have 
a lower body weight. Conversely, the area under the caloric intake curve increased with larger CAG repeat 
length (r = 0.763; p = 0.028); i.e. R6/2 mice with higher repeat lengths consume more energy per gram of body 
weight. 
Figure 1. Huntington’s disease patients with larger 
CAG repeat lengths have a faster rate of weight 
loss. The straight line represents the regression line, 
while the outer lines delineate the 95% confidence 
intervals.
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DISCUSSION
We conducted a long-term follow-up study of body weight changes in a large group of HD patients who were at 
an early stage of the disease and not on neuroleptic treatment. We found a significant decrease in body weight; 
however, no single motor, cognitive or behavioral score was independently associated with weight loss. As 
weight loss in R6/2 mice is also not related to motor activity13, our findings suggest that loss of body weight 
in HD is not secondary to hyperactivity or other symptoms, but rather results from a hypermetabolic state. As 
both HD patients and transgenic mice showed a higher rate of weight loss with greater CAG repeat number, 
this hypermetabolic state is likely to stem directly from interference of the mutant protein with cellular energy 
homeostasis. Weight loss could therefore reflect fundamental pathological mechanisms underlying HD and 
may serve as a biomarker to monitor disease progression. Moreover, patients with a higher number of CAG 
repeats are at increased risk of unintended weight loss. Therefore, their body weight should be monitored more 
closely. 
Our findings indicate that weight loss is an inherent feature of HD and are in agreement with many other 
observations.3,4,6,14 Indices of increased motor activity, such as chorea and dystonia, did not correlate with the 
rate of weight loss, neither did the total motor score of the UHDRS. Weight loss is therefore unlikely to result 
from hyperactivity. Although weight loss correlated with bradykinesia, this relation is likely confounded by 
CAG repeat number as bradykinesia increased with higher CAG repeat number and did not correlate with 
weight loss when adjusted for baseline BMI and CAG repeat number. Furthermore, cognitive impairment, 
as measured by the Symbol Digit Modalities test, weakly correlated with mean body weight. Cognitive 
impairment might cause more disability.20 However, total functional capacity and ratings on the independence 
scale, both measures of disability, were not associated with weight loss. Therefore, it seems unlikely that there 
is a causative link between specifically bradykinesia or cognitive impairment and body weight loss. Although 
Figure 2. In R6/2 mice, a greater number of CAG repeats correlates with lower body weight (r = -0.742; p = 
0.035) (A), and higher caloric intake (r = 0.763; p = 0.028) (B). AUC = area under the curve.
Weight loss in Huntington’s disease increases with higher CAG repeat number 
53
we did not collect data regarding caloric intake, a decrease in energy intake is also unlikely to account for the 
weight loss. This is because all patients were at an early stage of the disease which is generally associated with 
increased rather than decreased caloric intake.6,11,14 Similarly, R6/2 mice also do not exhibit decreased caloric 
intake until two weeks after the commencement of weight loss, indicating that decreased caloric intake is not 
the cause of weight loss.13 
Here we demonstrate that CAG repeat number in mutant huntingtin is directly related to both the average body 
weight during follow-up and the rate of weight decline in HD patients. This extends upon earlier studies that 
have found associations between CAG repeat length and several other clinical features of HD, particularly 
age of disease onset.27 Moreover, CAG repeat length has also been shown  to correlate with the rate of disease 
progression as assessed by the extent of post mortem28,29 or in vivo30-32 striatal pathology. Interestingly, R6/2 
mice with larger CAG repeat lengths had also lower body weights, despite relatively small differences in CAG 
repeat number between individual mice. When comparing different HD transgenic mouse models, CAG repeat 
length correlates with a number of biochemical abnormalities, such as decreases in brain N-acetyl aspartate 
levels.33 However, the effect of small variations in CAG repeat number within the same mouse model is not 
known. Our findings suggest that even relatively small differences (up to 12) in the number of CAG repeats 
within the same transgenic strain may lead to phenotypic dissimilarities in, e.g., body weight. 
Several mechanisms could account for the negative association between CAG repeat length and body weight. 
Mitochondrial dysfunction has long been implicated in HD pathogenesis as markers of energy metabolism 
are altered in HD brain, muscle34,35 and lymphoblastoid cells21. The extent of mitochondrial dysfunction 
may critically depend on the length of the polyglutamine tract, as CAG repeat size has been shown to affect 
both mitochondrial depolarization and ATP/ADP ratio in lymphoblastoid cells.21,22 Consequently, longer 
CAG expansions may cause both more central and peripheral pathology. Larger CAG repeat size has indeed 
been associated with more severe pathology in the striatum and cortex28,29,36 and might also be related to 
more pathology in other brain structures, such as the hypothalamus, which are directly involved in energy 
homeostasis.10,37 Interestingly, hypothalamic pathology occurs in both HD patients and transgenic mice.10,13,38 
Longer CAG repeats may cause more extensive changes in peripheral tissues as well. A recent study found 
reduced levels of branched chain amino acids in HD patients the levels of which were lower with increasing 
CAG repeat number.14 Importantly, the levels of these amino acids were also associated with weight loss.14 
Similarly, we found that R6/2 mice with longer CAG repeats had lower body weights, whereas caloric intake 
was higher in mice with longer repeat lengths. Finally, mutant huntingtin with longer polyglutamine stretches 
might interfere more strongly with the function of the wild-type protein39, which has been shown to influence 
body weight in some transgenic HD mice.40
Only two prior studies have investigated body weight changes in large groups of HD patients. 19,20 As weight 
loss is commonly considered a feature of HD10, it is surprising that weight loss was not observed in these 
cohorts. In all likelihood, the heterogeneity of these cohorts combined with lack of clinical information on 
e.g. the use of nutritional supplements and drugs (notably neuroleptics) could account for the unexpected 
findings.19,20 Moreover, CAG repeat length data were not available for these studies. In contrast, our cohort 
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of HD patients was very homogenous, consisting of patients at an early stage of the disease. Importantly, 
participants were also required not to be on neuroleptic treatment during the trial. Since neuroleptics are 
applied frequently in HD and often substantially influence systemic energy homeostasis, the EHDI cohort is 
the first large group of HD patients in which body weight changes could be investigated without confounding 
neuroleptic medication. Although our data were derived from a clinical trial with riluzole, riluzole treatment 
was reported not to affect any clinical outcome measure in this cohort23. We confirmed this and also showed 
that riluzole was not an independent predictor of weight change. Therefore, it is highly unlikely that riluzole 
treatment might have influenced our findings.
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ABSTRACT
Objective: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG 
repeat expansion in the HD gene (HTT). We aimed to assess whether interaction between CAG repeat sizes in 
the mutant and normal allele could affect disease severity and progression. Methods: Using linear regression 
and mixed-effects models, the influence of mutant and normal CAG repeat sizes interaction was assessed on: 
(1) age of onset in 921 HD patients, (2) clinical severity and progression in 512 of these patients with follow-
up data available, and (3) basal ganglia volume on magnetic resonance images in 16 premanifest HD mutation 
carriers. Results: Normal and mutant CAG repeat sizes interacted to influence:  (1) age of onset (p=0.001), 
(2) severity or progression of motor, cognitive and functional, but not behavioral, symptoms in HD patients 
(all p<0.05), and (3) in premanifest subjects, basal ganglia volumes (p<0.05). In subjects with mutant CAG 
expansions in the low range, increasing size of the normal repeat correlated with more severe symptoms and 
pathology, whereas for those subjects with expansions in the high range, increasing size of the normal repeat 
correlated with less severe symptoms and pathology. Conclusions: Increasing CAG repeat size in normal HTT 
diminishes the association between mutant CAG repeat size and disease severity and progression in HD.  The 
underlying mechanism may involve interaction of the polyglutamine domains of normal and mutant huntingtin 
(fragments) and needs further elucidation. These findings may have predictive value and are essential for the 
design and interpretation of future therapeutic trials. 
Normal and mutant HTT interact to affect clinical severity in Huntington’s disease 
59
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HTT gene, resulting in a long polyglutamine tract in the N-terminus of the 
encoded protein huntingtin.1 The disease is characterized by motor impairment, cognitive deterioration and 
behavioral disturbances.2 The size of the CAG repeat sequence in the mutant allele is inversely related to age 
of onset, accounting for up to 73% of the variance.3 Moreover, larger mutant CAG repeat sizes correlate with 
an increased rate of deterioration on motor, cognitive and functional domains as well as weight loss, whereas 
behavioral symptoms appear not to be related to repeat size.4-6
It has been suggested that the polyglutamine stretch in normal huntingtin could bind to the expanded 
polyglutamine stretch, and thereby modulate the effects of mutant  huntingtin or result in loss of function of 
the normal protein.7-9 Indeed, interaction between CAG repeat sizes in the mutant and normal allele is reported 
to influence age of onset, with larger sizes of the normal repeat being associated with a delayed age of onset 
in persons having large mutant CAG repeat sizes.10-13 However, it is not known whether interaction between 
mutant and normal huntingtin could also influence clinical signs and progression of the disease in HD patients, 
or affect indices of immanent phenoconversion in premanifest HD mutation carriers.
Therefore, this study was undertaken to test the hypothesis that CAG repeat sizes in the mutant and normal 
allele interact to influence not only age of onset, but also clinical severity and progression in HD patients, as 
well as brain pathology in premanifest HD mutation carriers.
METHODS
HD patients 
We used monitored data from the European Huntington Disease Network (EHDN) Registry study collected 
prior to December 31st 2007. Registry − a multi-centre, prospective, observational study −  is EHDN’s core 
study. It was established in 2004 to collect phenotypical data and biomaterials from a large group of HD 
patients. The study aims to enlist one third of the European HD population by 2010. More information about 
the Registry cohort can be found at ‘http://www.euro-hd.net/html/registry’. In order to assess interactive effects 
of mutant and normal CAG repeat sizes on age of onset, we included all Registry participants with a clinical 
diagnosis of HD whose ages of onset and CAG repeat numbers in both alleles (mutant allele ≥ 36 repeats) were 
available (n=921). To assess the effects on clinical severity and disease progression, only those patients with 
two or more measurement occasions were included (n=512). The clinical characteristics of all HD patients are 
summarized in Table 1.
Clinical evaluations 
Demographic data included age, gender and age of onset. Age of onset was defined as the age at which, 
according to the rater, the first motor, cognitive or behavioral signs of HD appeared.  Visit data were collected 
annually (+/- 3 months). Clinical severity was assessed using the Unified Huntington Disease Rating Scale 
(UHDRS), and was recorded at all visits.14-16 In addition, body weight was recorded at every visit.
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Premanifest HD mutation carriers
Sixteen premanifest subjects were included whose characteristics are summarized in Table 
1. Premanifest status was defined as the absence of unequivocal HD signs by a neurologist 
specialized in movement disorders (R.A.C.R.).17 In all premanifest subjects, magnetic resonance 
imaging (MRI) was performed to assess caudate, putamen and globus pallidus volumes, using 
a 3.0 Tesla scanner (Philips Medical Systems, Best, The Netherlands) as described previously.17
Standard Protocol Approvals, Registrations, and Patient Consents
Full ethical approval has been obtained for each European country contributing to the Registry study. The MRI 
study was approved by the medical ethics committee of the Leiden University Medical Center. All subjects 
gave written informed consent.
Table 1. Characteristics of the study populations
Group I† a Group II† b Group III† c
No. of subjects (n) 921 512 16
Male (%) 47.9 47.5 37.5
Age of onset, y 42.9 (12.0; 6−79) 42.9 (11.8; 9−79) -
Age at MRI, y - - 42.4 (10.1; 24−59)
Disease duration, y* 7.1 (5.3; 0−40.3) 7.0 (4.9; 0−29.5)  -
 UHDRS total motor score* 35.3 (21.4; 0−106) 34.7 (20.6; 0−105) -
UHDRS TFC score* 8.2 (3.7; 0−13) 8.2 (3.6; 0−13) -
Mutant CAG repeat size 44.9 (5.0; 36−90) 44.9 (4.5; 36−90) 42.4 (2.7; 40−49)
Normal CAG repeat size 18.7 (3.2; 9−37) ‡ 18.6 (3.1; 9−32) 17.8 (3.2; 9−23)
* Disease duration, total motor score and total functional capacity (TFC) score are indicated at the first study visit.
† All data are indicated as means (standard deviation; range).
‡ There was one homozygous subject in this cohort with 37 and 42 repeats; exclusion of this subject did not change 
the results.
a) The total Registry cohort with data available on age of onset and CAG repeat sizes. b) All the patients from the 
total Registry cohort with two or more follow-up measurements; patients with and without follow-up data did not 
differ with respect to age, sex, body mass index, age of onset, mutant and normal CAG repeat size, and disease 
duration, total motor score and total functional capacity at first visit (all p ≥ 0.223; unpaired t-tests and χ2-test) . c) 
Premanifest HD gene carriers. MRI = Magnetic Resonance Imaging, TFC = Total Functional Capacity, UHDRS 
= Unified Huntington Disease Rating Scale.
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Statistical analyses
To assess whether age of onset is influenced by the interaction between mutant and normal CAG repeat sizes, 
we used multiple linear regression. As the relation between age of onset and mutant CAG repeat size is known 
to be exponential3, we used the logarithmic transform of age of onset as the dependent variable. The sizes of the 
mutant and normal CAG repeats, and their interaction, were used as predictor variables. To examine whether 
clinical scores during the follow-up period were influenced by the interaction between mutant and normal 
CAG repeat number, we used linear mixed-effects models18 with the clinical scores as dependent variables. 
We used random effects to account for the correlation between the repeated measurements on each individual. 
In all models, both random intercepts and slopes were used for disease duration to reflect the heterogeneity 
in terms of baseline levels and evolution with time. Age of onset was always included as a covariate, since it 
can confound the relation between clinical phenotype and CAG repeat number.4 Other explanatory variables 
included mutant CAG repeat number and its interaction with disease duration, normal CAG repeat number and 
its interaction with disease duration, an interaction term between mutant and normal CAG repeat sizes, and an 
interaction term between disease duration and mutant and normal CAG repeat sizes. Thus, an interaction term 
in which disease duration is not included assesses whether two variables interact on the dependent variable 
at the mean time of follow-up, whereas an interaction term in which disease duration is included assesses 
whether an independent variable (or the combination of two independent variables in case of a three-way 
interaction) influences the rate of progression. In order to visualize the results, we drew regression lines based 
on the predictions of the mixed-effects models for different groupings of mutant and normal CAG repeat sizes, 
representing the association between clinical features and disease duration. In premanifest subjects, multiple 
linear regression was applied to assess whether CAG repeat sizes interact to affect basal ganglia volumes. 
Volumes of the caudate, putamen, globus pallidus, and their sum were used as dependent variables, while the 
sizes of the mutant and normal alleles, and their interaction, were used as predictor variables. In order to reduce 
multicollinearity, particularly with respect to the interaction terms, and simplify the interpretation of results, 
disease duration, age of onset, and mutant and normal CAG repeat sizes were centered around their respective 
means. We did not apply a specific correction for multiple testing because (1) based on previous literature 
we could formulate an a priori hypothesis presuming a relation between CAG repeat sizes interaction and 
disease severity and progression, and (2) there is a high degree of interdependence between various measures 
of clinical severity, i.e. the UHDRS scores cannot be regarded as independent of one another. Therefore, all 
tests were two-tailed and values of p < 0.05 were considered to be significant. Programming was performed in 
SPSS version 14.0 for Windows (SPSS Inc, Chicago, Ill, USA) and SAS version 9.1 (SAS Institute Inc., Cary, 
NC, USA).
RESULTS
Age of onset
The clinical characteristics of this cohort of HD patients (group I) are summarized in the second column of 
table 1. The interaction term between mutant and normal CAG repeat sizes was highly significant (table E-1). 
The inclusion of the interaction term raised the adjusted R2 from 0.529 to 0.534, indicating that the model with 
the interaction term included, can account for 53.4% of the variance in the age of onset. Model predicted best 
fit lines (figure 1), revealed that in the low range of mutant CAG repeat size, higher normal CAG repeat sizes 
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are related to a lower age of onset, while in the high range of the mutant repeat size, higher values of the normal 
repeat size are related to a higher age of onset. Thus, the association between mutant CAG repeat size and age 
of onset progressively weakens for higher normal CAG repeat sizes (figure 1).
Clinical severity and progression
The clinical characteristics of the HD patients 
of whom follow-up data were available (group 
II) are summarized in the third column of table 
1. Interaction between mutant and normal CAG 
repeat sizes significantly influenced the mean ― 
at average disease duration ― of the UHDRS 
total motor score, total cognitive score, and total 
functional capacity (TFC), but not the mean total 
behavioral score or body mass index (table E-2). 
The regression coefficients in table E-2 indicate 
that increasing normal CAG repeat size was 
associated with more severe symptoms in the low 
range of the mutant CAG repeat size, but with 
less severe symptoms in the high range of the 
mutant CAG repeat size. For example, in case of 
40 CAG repeats in the mutant allele, for each unit 
increase in the normal CAG repeat size the mean 
motor score increased with 0.80 points, the mean 
cognitive score decreased with 3.05 points, and 
the mean TFC score decreased with 0.10 points. 
However, in case of 50 CAG repeats in the mutant 
allele, for each unit increase in the normal CAG 
repeat size the mean motor score decreased with 
0.74 points, the mean cognitive score increased 
with 2.16 points, and the mean TFC score increased with 0.08 points. In addition, the rate of progression of 
the UHDRS total motor score was influenced by the interaction between the two CAG repeat sizes (table E-2). 
Model predictions of total motor score during follow-up revealed that, in the lower range of the mutant CAG 
repeat sizes, increasing normal CAG repeat size was associated with a faster rate of motor progression, while 
in the upper range of mutant CAG repeat size, increasing normal CAG repeat size was associated with a slower 
rate of motor progression (figure 2, appendix E-1). Similar plots were generated for the total cognitive score, 
total behavioral score, total functional capacity, and body mass index. Except for the total behavioral score, 
these graphs showed a similar pattern as the total motor score, although the differences were generally less 
pronounced (data not shown). 
Figure 1. Normal and mutant CAG repeat sizes 
interact to affect age of onset in HD patients. The 
relation between age of onset and mutant CAG repeat 
size progressively weakens with increasing normal 
CAG repeat size. Solid line, line with small dashes, 
and line with large dashes represent the relation 
between CAG repeat size in the mutant allele and age 
of onset for, successively, 10, 20 and 30 CAG repeats 
in the normal allele.
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Basal ganglia volumes in premanifest subjects
The clinical features of this cohort of premanifest HD gene carriers (group III) are displayed in the last column 
of table 1. Volumes of the basal ganglia as a whole, as well as the putamen alone, were significantly affected 
by the interaction between the mutant and normal CAG repeat sizes, while the interaction effect was borderline 
significant in case of the caudate nucleus (p = 0.091) and globus pallidus (p = 0.057) volumes (table E-3). 
Again, when accounting for the centering of the data, the direction of the interaction effect was opposite to that 
of the effect of the mutant CAG repeat size. This indicates that, for a given mutant repeat size, larger sizes of 
the normal repeat weaken the association between mutant repeat size and basal ganglia volume. 
     
DISCUSSION
We found that normal CAG repeat size interacts with mutant CAG repeat size to affect both clinical severity 
and progression in HD patients, as well as brain atrophy in premanifest HD mutation carriers. These findings 
represent a major extension upon previous reports on CAG repeat sizes interaction, all of which used age of 
onset as the sole outcome measure.10,11,13 Here we demonstrate that, in addition to age of onset, many signs 
and symptoms of HD, including motor, cognitive and functional indices, are also influenced by the interaction 
between CAG repeat sizes in the normal and mutant allele. As the effect of the interaction on basal ganglia 
volume could already be detected in premanifest subjects, our data suggest that the interplay between normal 
and mutant huntingtin (fragments) directly influences neuronal atrophy or loss and is thus an inherent feature 
of HD pathogenesis.
Figure 2. Normal and mutant CAG repeat sizes 
interact to affect disease progression in HD patients. 
The relation between motor progression and mutant 
CAG repeat size is different for various values of 
normal CAG repeat size. The graph shows model 
predicted best fit lines based on the median age of 
onset of 43 years for four different combinations of 
mutant and normal CAG repeat sizes: 40/10 (solid 
line and filled circles), 40/30 (solid line and open 
circles), 50/10 (dashed line and filled circles), and 
50/30 (dashed line and open circles). Note that for 
large normal CAG repeat sizes ― e.g. 30 in this case 
― the effect of the mutant CAG repeat size on disease 
progression is diminished, i.e. disease progression 
rate is very similar for 40/30 and 50/30 CAG repeat 
combinations. UHDRS = Unified Huntington Disease 
Rating Scale.
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Several models could account for our findings, including competitive polyglutamine length dependent 
interaction of normal and mutant huntingtin with numerous protein binding partners,19,20 mitochondrial 
energy production21 or transcriptional mechanisms.22 However, as mutant N-terminal huntingtin fragments 
can promote the fibrillogenesis and co-aggregation of normal huntingtin fragments, with an increasing rate 
for larger polyglutamine stretches in either the normal or the mutant range,23,24 the simplest model would be 
to assume that the rate of co-aggregate formation is proportional to the polyglutamine stretch in either the 
normal or the mutant protein.23,24 This could explain the observation that the association between mutant CAG 
repeat size and clinical and pathological severity was weakened with larger normal CAG repeat sizes, since 
increasing stretches of polyglutamine in normal huntingtin could lead to a stronger association with mutant 
protein fragments, promoting their co-aggregation and preventing them from aberrantly interfering with other 
proteins.20,25 Indeed, a number of studies have found that normal huntingtin can reduce the cellular toxicity 
of the mutant protein both in vitro and in vivo.7,26,27 However,  a stronger interaction between normal and 
mutant huntingtin could also result in a greater degree of loss of  normal huntingtin function.23 There is now 
considerable evidence indicating that normal huntingtin is essential for neuronal function and survival, that it 
can protect cells from a host of toxic stimuli, and that loss of normal huntingtin function is likely to be involved 
in HD pathogenesis.8,9,27-30 Therefore, the interaction between mutant and normal huntingtin could have both 
beneficial (i.e. mitigation of mutant protein toxicity) and detrimental (i.e. loss of normal huntingtin function) 
effects.23,25 The finding that in subjects with mutant CAG expansions in the low range, increasing size of the 
normal repeat correlated with more severe symptoms and pathology, suggests that in the low range of mutant 
polyglutamine stretches, the net effect of this interaction is likely to be detrimental due to loss of normal 
huntingtin function. Conversely, as in subjects with expansions in the high range increasing size of the normal 
repeat correlated with less severe symptoms and pathology, the net effect of this interaction in the high range 
of the mutant polyglutamine sequences is likely to be beneficial due to mitigation of mutant protein toxicity.
As we show that the normal HTT allele can also influence disease severity, our findings are in line with recent 
studies in transgenic mouse models of HD31 and indicate that HD displays an intermediate dominant phenotype 
in humans as well. These findings challenge the classical common view of HD as a disorder with complete 
dominance, which is largely based on the clinical evaluation of small groups of potential homozygotes prior to 
the discovery of the genetic mutation.32,33 More recent clinical, imaging and neuropathological assessment of 
genetically confirmed homozygote patients with HD, however, did indeed reveal an increased rate of disease 
progression.34 Additionally, our findings are supported by recent studies in transgenic HD mice with super-long 
CAG repeat expansions which show that homozygous transgenic mice with CAG repeat expansions of around 
400 in both transgenes do not exhibit a noteworthy acceleration of phenotype compared to mice with only one 
400 CAG transgene, whereas homozygous mice with one transgene in the 350 CAG range and one in the 400 
CAG range, do show an accelerated phenotype.35,36 Together these findings underscore that the exact as well as 
the relative sizes of the CAG repeat tract in both HTT alleles are important determinants of pathology in HD.
Potential limitations of our study include the lack of follow-up data on a subset of HD patients and the relatively 
short follow-up period. However, patients with and without longitudinal data did not differ in any particular 
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way (table 1), indicating that lack of follow-up in some cases is unlikely to have biased the results. As the 
Registry cohort continues to accrue, more precise estimates of the clinical effects of the CAG repeat sizes 
interaction will be possible in the future. 
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Table E-1. Effect of interaction between mutant and normal CAG repeat sizes on natural log-transform 
of age of onset in Huntington disease patients. 
Regression coefficients†
(95% CI) 
p-values
Mean value 3.711 (3.697, 3.725) <0.001
 mCAG‡ effect -0.047 ( -0.050, -0.044) <0.001
nCAG‡ effect 0.002 (-0.002, 0.006) 0.394
mCAG × nCAG‡ 
interaction effect
0.001 (0.001, 0.002) 0.001
 †) All values and effect sizes are centered around the mean mutant CAG repeat size of 44.901, and mean normal CAG 
repeat size of 18.673. CI = Confidence Interval. 
‡) mCAG = mutant CAG repeat size; nCAG = normal CAG repeat size.
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Appendix E-1. Estimating disease progression
The coefficients provided in table E-2 can be used to estimate the clinical scores of HD patients while accounting 
for age of onset,  as well as mutant and normal HTT CAG repeat sizes. For example, the following equation can 
be used to estimate the UHDRS total motor score:
Total motor score ≈ 37.182 + 0.620 × (age of onset - 42.853) + 3.242 × (disease duration – 6.996) + 2.401 × (mutant 
CAG repeat size – 44.861) + 0.231 × (mutant CAG repeat size – 44.861)(disease duration – 6.996) + 0.102 × (normal 
CAG repeat size – 18.633) + 0.004 × (normal CAG repeat size – 18.633)(disease duration – 6.996) – 0.164 × (mutant 
CAG repeat size – 44.861)(normal CAG repeat size – 18.633) – 0.024 × (mutant CAG repeat size – 44.861)(normal 
CAG repeat size – 18.633)(disease duration – 6.996)
The effect of the interaction between mutant and normal CAG repeat size on the total motor score can become 
substantial over time. This can be illustrated by using the above equation. Suppose individuals A and B both 
have an age of onset of 43 years and  an expansion of 40 CAG repeats in their mutant alleles, while the number 
of repeats in their normal alleles is different: 10 for person A and 30 for person B. Five years after disease 
onset, the UHDRS total motor score of person A will equal 16 points (≈ 37.182 + 0.620 × (43-42.853) + 3.242 
× (5 – 6.996) + 2.401 × (40 – 44.861) + 0.231 × (40 – 44.861)(5 – 6.996) + 0.102 × (10 – 18.633) + 0.004 × (10 
– 18.633)(5 – 6.996) – 0.164 × (40 – 44.861)(10 – 18.633) – 0.024 × (40 – 44.861)(10 – 18.633)(5 – 6.996)), 
whereas person B will have a score of 29 points. A considerable difference of 81% after only five years, that, 
in addition, will continue to increase over time (see also figure 2 in the manuscript). 
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ABSTRACT
Objective: Sleep disturbances are a prominent feature of Huntington’s disease (HD) and can substantially 
impair patients’ quality of life. However, sleep complaints and their association with other symptoms and signs 
of HD have not yet been assessed in large groups of patients or premanifest mutation carriers. Therefore, we 
aimed to (1) delineate the nature of subjective sleep disturbances, (2) identify important predictors of sleep 
impairment, and 3) evaluate the usefulness of the SCOPA-SLEEP questionnaire, a short instrument that can 
assess both daytime sleepiness (DS) and night-time sleep (NS), in a group of HD patients and premanifest 
mutation carriers. Subjects & methods: Using standardized questionnaires, DS, NS and depressed mood were 
assessed in 63 HD patients, 21 premanifest mutation carriers and 84 controls. Results: NS impairment was 
significantly more prevalent in HD patients compared with controls (58.1% vs. 34.9%, p=0.012), but DS was not 
(12.7% vs. 7.9%, p=0.560). Depression was the only independent predictor of NS impairment in HD patients, 
accounting for 19% of the variance. Compared with controls, both sleep onset latency and wake-up time were 
significantly delayed in HD patients. Moreover, in HD patients, later wake-up time was significantly associated 
with cognitive score (r=-0.43), total functional capacity (r=-0.54) and depressive symptoms (r=+0.47). The 
SCOPA-SLEEP questionnaire was a reliable and valid instrument for application in HD patients. Conclusions: 
HD is primarily accompanied by NS disturbances and a delayed sleep phase syndrome-like phenotype, which 
are associated with depression and lower cognitive as well as functional performance.
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat sequence in the gene encoding the protein huntingtin.1 The disease is characterized by 
motor impairment, cognitive deterioration, behavioral problems and progressive weight loss.1,2 However, 
disturbed sleep is also a prominent feature of the disease, substantially impairing the quality of life of both 
patients and caregivers.3 Polysomnographic and actigraphic findings in small groups of HD patients have 
documented an increased sleep onset latency, sleep fragmentation and frequent nocturnal awakenings, reduced 
sleep efficiency, delayed and shortened rapid eye movement (REM) sleep, increased periodic leg movements, 
as well as circadian rhythm disturbances.4-10 However, the exact nature of sleep complaints as well as their 
association with other symptoms and signs of the disease have not yet been studied in large groups of HD 
patients or premanifest mutation carriers.
Recently, it was shown that the sleep-wake disturbances in HD patients are partly reproduced in the transgenic 
R6/2 mouse model of the disease.9 Importantly, cognitive decline and decay of learning in R6/2 mice were 
alleviated by pharmacological imposition of sleep, suggesting that a similar strategy might be of benefit to 
HD patients.10,11 Moreover, apart from affecting alertness, attention, memory and executive control, lack of 
sleep is also considered a risk factor for developing depression.12 Conversely, recent clinical findings indicate 
that treatment of depressive symptoms may reduce sleep disruption in a number of  neurodegenerative and 
extrapyramidal conditions, especially Alzheimer’s and Parkinson’s disease.13,14 However, in order to provide 
rationale for the evaluation of comparable approaches in HD, it is first necessary to assess the association 
between sleep disruption and both cognitive impairment and depressive symptoms in HD patients.
Characterization of sleep problems in HD patients as well as the identification of contributing factors are 
of paramount importance for the design and implementation of novel therapeutic strategies. Therefore, the 
aims of the present study were to (1) delineate the nature of subjective sleep disturbances in HD patients and 
premanifest mutation carriers in comparison with non-mutation carrying control subjects, and (2) to assess 
the relation between sleep and various clinical characteristics, including cognitive impairment and depressive 
symptoms, in order to identify important predictors of sleep disturbances in HD patients. In addition, we 
evaluated the reliability and validity of the SCOPA-SLEEP questionnaire, a very short instrument that can 
assess both daytime sleepiness and night-time sleep,15 in patients with HD.
METHODS
Design and participants
HD patients and premanifest mutation carriers were recruited from the outpatient clinic of the department 
of Neurology of the Leiden University Medical Center (LUMC) between June 2007 and December 2008. 
Control subjects were recruited over the same period and were randomly selected non-mutation carrying 
family members, partners or acquaintances of participating patients, employees at our department or their 
acquaintances. Exclusion criteria for both groups were the diagnosis of a preexistent primary sleep disorder or 
a disease of the central nervous system unrelated to HD. All patients and premanifest mutation carriers were 
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seen once or twice a year as part of their regular care. Three weeks before the scheduled yearly appointments 
two identical postal surveys containing standardized questionnaires were sent to these subjects. The forms 
in one of the surveys were completed by the patients or premanifest mutation carriers themselves (or by the 
primary caregivers on their behalf) while, whenever possible, the other survey had to be completed by a non-
mutation carrying family member, the partner or an acquaintance. The patients and premanifest mutation 
carriers brought their survey to the scheduled appointment and simultaneously provided contact data for the 
control subject. When questionnaires were not fully completed or were not received within one month, subjects 
were reminded by phone. The study protocol was approved by the medical ethics committee of the LUMC and 
all participants provided written informed consent. 
Measurement instruments
The clinical condition of HD patients was assessed according to the motor, cognitive, behavioral and functional 
subscales of the Unified Huntington Disease Rating Scale (UHDRS).16 Premanifest status was defined as a 
score of <5 on the UHDRS motor subscale. The following standardized instruments were used in all subjects 
to assess sleep disturbances and depressive symptoms: Epworth’s Sleepiness Scale (ESS) [range (0-24)]17, 
the Pittsburgh Sleep Quality Index (PSQI) [range (0-21)]18, the SCOPA-SLEEP15, and the Beck Depression 
Inventory (BDI) [range (0-63]. The ESS evaluates daytime sleepiness; subjects must rate the chance of dozing 
off under eight different situations.16 The PSQI primarily evaluates night-time sleep, consisting of 19 self-
rated questions and five questions rated by the bed partner or roommate. The latter five questions are used for 
clinical information only and are not tabulated in the scoring of the PSQI.18 Scores are first grouped in seven 
domains which assess subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleep medication, and daytime dysfunction.18 The ESS and PSQI scales were included 
as they are frequently used and have previously been applied in small groups of HD patients.6 The SCOPA-
SLEEP questionnaire consists of two parts, one assessing daytime sleepiness (SCOPA-DS [range (0-18)]) and 
the other assessing night-time sleep (SCOPA-NS [range (0-15)]), and was originally developed for patients 
with Parkinson’s disease.15 However, since the items are not disease specific it can also be applied to other 
populations.15 The SCOPA-SLEEP questionnaire was included as it is quick and easy to administer, and can 
assess sleep problems both during the day and night. In all questionnaires higher scores indicate more severe 
impairment. 
Statistical Analysis
Mean differences between HD patients, premanifest mutation carriers, partners and other controls were assessed 
using χ2-tests and one-way analysis of variance (ANOVA). Using multiple linear regression, group differences 
were also assessed after correction for differences in age, sex, body mass index (BMI), depressive symptoms 
and medication use (differentiating between sleep medications, antidepressants, neuroleptics and a rest group). 
In order to assess differences in usual bed and wake-up times (circular variables) between groups, we used 
pairwise Watson-Williams F-tests.19 In HD patients, partial correlations, adjusting for age and sex, were used 
to assess the relation of each clinical variable ― such as BMI, CAG repeat size and various UHDRS subscores 
― with sleep disturbances and timing. To identify which predictor variables were independently associated 
with sleep impairment in HD patients, we also used a stepwise regression procedure (an independent predictor 
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of sleep impairment is a variable that remains significantly associated with sleep impairment after adjustment 
for the effects of other significant predictor variables); this latter approach ensured minimization of type I error 
in identifying predictors of sleep impairment in HD. The reliability of all sleep scales in the patient group was 
assessed with Cronbach’s α. Using Pearson’s correlation coefficients, the construct validity of the SCOPA-
SLEEP in HD patients was assessed by comparing responses on its day and night subdomains with those on 
the ESS and PSQI scales, respectively. All data are presented as means ± SD unless otherwise specified. All 
tests were two-tailed and values of p < 0.05 were considered significant. Programming was performed in SPSS 
version 16.0 for Windows (SPSS Inc., Chicago, IL) and Oriana version 2.02 for circular statistics (Kovach 
Computing Services, Wales, UK). 
RESULTS
Participants
In total, 168 subjects participated in this study (Table 1). Of these 84 were mutation carriers (63 had manifest 
HD and 21 were premanifest), and 84 were non-mutation carrying subjects. As sleep problems of the mutation 
carriers may affect the sleep quality of their partners, non-mutation carriers were further divided into a partner 
group and a group consisting of other controls (Table 1); in the remainder of this paper we will refer to these 
two groups as partners and controls, respectively. The four groups did not significantly differ with respect 
to age, sex, and BMI (all p > 0.454). Mutation carriers were significantly more depressed compared with 
non-carriers (p < 0.001), however, no difference between manifest and premanifest HD subjects was found 
(p=0.106). HD patients used significantly more antidepressants and neuroleptics compared to all other groups, 
while their use of sleep medication was significantly higher in comparison with controls only (Table 1). 
Table 1. Characteristics of the study participants
HD patients Premanifest 
mutation 
carriers
Partners Controls p-value
No. of participants 63 21 21 63 -
Sex (% men) 46.0 42.9 47.6 41.3 0.972†
Age, mean (SD), yr 48.5 (10.7) 44.4 (8.7) 48.3 (9.1) 47.4 (10.5) 0.454‡
BMI, mean (SD) 25.3 (4.0) 25.5 (3.4) 25.5 (4.9) 25.3 (4.6) 0.991‡
BDI score, mean (SD) 11.8 (9.4) 8.1 (8.4) 4.3 (5.7) 4.4 (4.6) <0.001‡
Sleep medication, n (%) 16 (25.4) 3 (14.3) 5 (23.8) 4 (6.3) 0.027†
Antidepressants, n (%) 23 (36.5) 1 (4.8) 4 (19.0) 1 (1.6) <0.001†
Neuroleptics, n (%) 17 (27.0) 1 (4.8) 0 0 <0.001†
Other medication, n (%) 29 (46.0) 9 (42.9) 11 (52.4) 16 (25.0) 0.105†
†) χ2-tests.
‡ ) One-way ANOVAs.
Legend: BDI = Beck’s Depression Inventory; BMI = Body Mass Index; HD = Huntington’s disease
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Night-time sleep impairment
There were no significant differences in the global PSQI or SCOPA-NS scores between HD patients and 
premanifest subjects or between premanifest subjects and controls  (Table 2). However, HD patients had 
significantly more night-time sleep impairment compared with controls as indicated by a higher percentage of 
patients having a PSQI score of 5 or higher (58.1% vs. 34.9%, p = 0.012), as well as by higher mean scores on 
both the PSQI and SCOPA-NS scales (Table 2). The differences in mean PSQI and SCOPA-NS scores remained 
significant when corrected for age, sex and BMI (β = 1.369, p = 0.037 for PSQI, and β = 1.44, p = 0.023 for 
SCOPA-NS (unstandardized coefficients)). In order to assess the nature of differences in sleep disturbances 
between groups, we also compared scores on the seven subdomains of the PSQI questionnaire separately 
(Table 2). HD patients experienced significantly more daytime dysfunction compared with premanifest 
subjects (p = 0.009). Moreover, compared with controls, HD patients had a significantly delayed sleep onset 
time, longer sleep duration, used more sleep medication and experienced more daytime dysfunction (Table 
2). These findings remained significant when adjusted for age, sex and BMI (data not shown). Although there 
were no differences in usual bed time between groups, the usual wake-up time was significantly delayed in HD 
patients compared to both partners and controls (Table 2). There was also a trend towards a delayed wake-up 
time in premanifest subjects compared to controls (p=0.087).
Table 2. Sleep characteristics of the study population
HD patients† Premanifest 
mutation 
carriers†
Partners† Controls†
PSQI global score 6.0 (3.9) a 5.2 (3.7) 5.3 (4.4) 4.7 (3.0)
        Sleep quality 0.9 (0.9) 0.9 (0.9) 0.9 (0.9) 0.8 (0.6)
        Sleep latency 1.3 (1.1) a 0.9 (0.9 (1.0) 1.0 (1.1) 0.8 (0.9)
        Sleep duration 0.5 (0.8) a, c 0.8 (0.9) 1.1 (0.8) 0.8 (0.8)
        Sleep efficiency 0.8 (1.1) 0.8 (1.1) 0.6 (1.0) 0.6 (1.0)
        Sleep disturbances 1.2 (0.6) 1.1 (0.5) 1.1 (0.4) 1.1 (0.4)
        Sleep medication 0.5 (1.1) a 0.3 (0.6) 0.5 (1.1) 0.1 (0.5)
        Daytime dysfunction 0.8 (0.8) a, b, c 0.4 (0.5) 0.3 (0.4) 0.5 (0.6)
Usual bed time, hh:mm 
(circular SD)
22:54 (01:53) 23:32 (01:58) 23:28 
(00:41)
23:14 
(01:51)
Usual wake-up time, 
hh:mm (circular SE)
08:11 (01:36) d, e 07:40 (01:17) 07:07 
(00:51)
07:06 
(01:07)
SCOPA-NS 4.5 (4.0) a 3.4 (3.4) 3.8 (4.2) 3.1 (2.6)
ESS score 4.5 (4.2) 4.5 (3.9) 5.1 (3.7) 4.8 (3.5)
SCOPA-DS 3.1 (3.6) 2.6 (3.5) 2.8 (3.2) 2.5 (2.6)
†) All data are indicated as mean total or subscores (SD)
a) p < 0.05 with respect to controls (ANOVA)
b) p < 0.05 with respect to premanifest mutation carriers (ANOVA)
c) p < 0.05 with respect to partners (ANOVA)
d) p < 0.01 with respect to controls (Watson-Williams F-test)
e) p < 0.01 with respect to partners (Watson-Williams F-test)
Legend: ESS = Epworth’s Sleepiness Scale; HD = Huntington’s disease; PSQI = Pittsburgh 
Sleep Quality Index; SCOPA-DS = Scales for outcomes in Parkinson’s disease-daytime 
sleep; SCOPA-NS = Scales for outcomes in Parkinson’s disease-night-time sleep
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As there were substantial differences in depressive symptoms between HD patients and controls, we repeated 
the analyses while correcting for the BDI score. After correction for the BDI score, differences in night-time 
sleep impairment between patients and controls became non-significant (p > 0.912 for differences in both 
PSQI and SCOPA-NS scores). This relation remained similar when also corrected for use of sleep medication, 
antidepressants, neuroleptics, and other drugs. 
Daytime sleepiness
There were no significant differences in mean ESS or SCOPA-DS scores between groups (Table 2). Correction 
for age, sex, BMI, depression and medication use did not change the results. Only 12.7% of HD patients had a 
ESS score of 10 or higher as compared to 7.9% of controls (p = 0.560). 
Reliability and validity of SCOPA-SLEEP in HD patients
The Cronbach’s α for SCOPA-NS was 0.89, which was higher than that for PSQI, with the corrected item-total 
correlations ranging from 0.44 to 0.88 (Table 3). Moreover, the scores on the SCOPA-NS and PSQI scales 
were highly correlated (r = +0.77, p < 0.001). Using the PSQI cutoff value of 4/5 to discriminate between 
good and bad sleepers as an external criterion for SCOPA-NS resulted in an area under the receiver operating 
characteristic curve of 0.85, with an optimal cutoff at 3/4, yielding a sensitivity of 0.81 and a specificity of 0.77. 
The Cronbach’s α for SCOPA-DS was 0.85, which was also higher than that of the comparable instrument ESS 
(Table 3). However, item 4 on 
the SCOPA-DS questionnaire 
had a corrected item-total 
correlation of zero as there 
were no HD patients who 
reported falling asleep while 
talking (Table 3), indicating 
that this question is not 
suitable for an HD population. 
The other corrected item-
total correlations of SCOPA-
DS were relatively high and 
ranged from 0.61 to 0.86 
(Table 3). There was also a 
strong correlation between 
scores on the SCOPA-DS 
and ESS questionnaires (r = 
+0.75, p <0.001). Applying 
the ESS cutoff value of 9/10 
to detect excessive daytime 
sleepiness as an external 
criterion for SCOPA-DS led 
Table 3. Reliability of sleep scales in HD patients
Cronbach’s α Corrected item-
total correlations
SCOPA-NS 0.89 0.44 – 0.88
  1: Difficulty falling asleep 0.79
  2: Been awake too often 0.81
  3: Lying awake too long 0.88
  4: Waking too early 0.44
  5: Had too little sleep 0.76
PSQI 0.72 -0.01 – 0.74
SCOPA-DS 0.85 0.00 – 0.86
  1: Falling asleep unexpectedly 0.76
  2: Falling asleep while sitting 0.86
  3: Falling asleep while watching TV 0.61
  4: Falling asleep while talking 0.00
  5: Difficulty staying awake 0.74
  6: Falling asleep considered a problem  0.66
ESS 0.77 0.69 – 0.77
Legend: ESS = Epworth’s Sleepiness Scale; HD = Huntington’s disease; 
PSQI = Pittsburgh Sleep Quality Index; SCOPA-DS = Scales for outcomes 
in Parkinson’s disease-daytime sleep; SCOPA-NS = Scales for outcomes in 
Parkinson’s disease-night-time sleep
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to an area under the receiver operating characteristic curve of 0.92, with an optimal cutoff at 3/4, yielding a 
sensitivity of 1.0 and a specificity of 0.78.
Predictors of night-time sleep and daytime sleepiness in HD patients
As SCOPA-SLEEP appeared more reliable than PSQI and ESS for application in HD patients, we used scores 
on SCOPA-NS and SCOPA-DS to assess the relation between various clinical measures and sleep impairment 
in HD patients. Of all clinical measures tested, only the BDI score significantly correlated with both night-time 
sleep impairment and daytime sleepiness (Table 4). Moreover, stepwise regression also identified BDI score 
as the only independent predictor of night-time sleep impairment, accounting for 19% of the variation in sleep 
disturbances. However, BDI score was not independently associated with daytime sleepiness in HD patients 
(Table 4).
Table 4. Correlates of night-time sleep impairment and daytime sleepiness in HD patients
SCOPA-NS score SCOPA-DS score
Correlation†
(r ; p-value)
Stepwise regression† 
(effect; SE)
Correlation†
(r ; p-value)
Stepwise 
regression † (effect 
(SE))
 BMI, kg/m2 -0.11 (0.404) - -0.09 (0.494) -
CAG repeat no. 0.23 (0.094) - 0.125 (0.363) -
TFC score 0.01 (0.956) - 0.05 (0.691) -
Motor score 0.02 (0.876) - -0.25 (0.058) -
Behavioral score -0.01 (0.943) - 0.01 (0.936) -
Cognitive score -0.07 (0.685) - 0.187 (0.282) -
BDI score 0.38 (0.002) ** 0.16 (0.071)* 0.27 (0.033) * -
†) All results are corrected for age and sex.
 * ) p < 0.05; ** p < 0.01.
Legend: BDI = Beck’s Depression Inventory; BMI = Body Mass Index; HD = Huntington’s disease; ESS = 
Epworth’s Sleepiness Scale; HD = Huntington’s disease; PSQI = Pittsburgh Sleep Quality Index; SCOPA-DS 
= Scales for outcomes in Parkinson’s disease-daytime sleep; SCOPA-NS = Scales for outcomes in Parkinson’s 
disease-night-time sleep; TFC = Total Functional Capacity
Circadian timing of sleep and cognition in HD patients
In order to assess whether circadian timing of sleep could affect cognitive functioning in HD patients, we 
examined the associations between usual bed and wake-up times and indices of cognitive performance in these 
subjects. UHDRS cognitive scores were available in 37 HD patients. Whereas the usual bed time was not 
significantly associated with the UHDRS cognitive scores, there were strong inverse associations between the 
usual wake-up time and the total cognitive score (r=-0.43, p=0.011; Figure 1A), and scores on the symbol digit 
modalities test (r=-0.45, p=0.003), and Stroop’s colour naming (r=-0.47, p=0.005), word reading (r=-0.40, 
p=0.010), and interference (r=-0.56, p=0.001) tests. There was also a trend for the association between wake-
up time and the verbal fluency test score (r=-0.30, p=0.076).  In addition, the wake-up time was progressively 
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delayed with more severe total functional impairment (r=-0.54, p<0.001; Figure 1B) and more depressive 
symptoms (r=0.47, p<0.001; Figure 1C), but not with motor score, mutant CAG repeat or BMI (all p ≥ 0.083). 
As cognitive impairment and total functional capacity were highly correlated (r=+0.71, p<0.001), it was 
not possible to assess the association between wake-up time and cognitive score independent of functional 
impairment. Importantly, however, the association between wake-up time and total cognitive score remained 
significant even after correction for the BDI score (r=-0.34, p=0.047).  
Figure 1. Habitual wake-up time is related to 
cognition, functional capacity and depression 
in HD patients. Habitual wake-up time is 
delayed with more cognitive disability (A), more 
functional impairment (B), and more depressive 
symptoms (C) in patients with HD. The outer 
lines denote the 95% confidence interval of the 
mean.
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DISCUSSION
To our knowledge, this is largest cohort of HD patients and premanifest mutation carriers whose subjective 
sleep quality and daytime somnolence have been systematically assessed in relation to clinical symptoms and 
signs. Our findings indicate that while night-time sleep impairment is indeed more prevalent in HD patients, 
daytime sleepiness appears unlikely to be a major issue in HD. We also show that depression is the most 
important clinical predictor of sleep impairment in HD patients. Moreover, our findings suggest a delayed 
sleep phase syndrome (DSPS)-like circadian rhythm disorder in HD patients which appears to be associated 
with lower cognitive performance. These findings indicate that treatment of depressive symptoms and re-
entrainment of the circadian rhythms could be evaluated as measures to enhance both sleep and cognitive 
functioning in HD patients.
In line with previous findings from a number of smaller-scale studies,4-10 we found that night-time sleep 
disturbances are almost twice as common in HD patients compared to controls. Importantly, while the usual 
bed time did not differ between the groups, sleep onset latency as well as the usual wake-up time were both 
significantly delayed in HD patients, suggesting a phase-shift in the circadian sleep/wake cycle towards 
later hours. This finding is particularly interesting as recently we also found a delayed onset of the diurnal 
melatonin rise in a group of early-stage HD patients,20 and is likewise suggestive of a DSPS-like circadian 
rhythm disorder. The pathophysiological basis of DSPS is presumed to lie within a slower endogenous clock 
with an abnormally long intrinsic circadian periodicity, resulting in a delayed phase position of the overt 
circadian rhythms, including those of melatonin and cortisol.21 Interestingly, recently we reported an increased 
rate of early day cortisol production in HD patients as well, which may also be a manifestation of delayed 
circadian rhythms in HD.22 Circadian rhythm disturbances in HD are likely to stem directly from pathology 
within the suprachiasmatic nucleus molecular oscillation, resulting from either the toxic effects of mutant 
huntingtin locally and/or arising from dysfunction of brain circuitry afferent to the suprachiasmatic nucleus,9,10 
but  additional studies are needed to pinpoint the exact underlying cause. Although a delayed sleep onset 
has been described previously in smaller groups of HD patients7,23,24, others have reported an earlier sleep 
onset and an advanced sleep phase.4 However, the latter study included only 25 HD subjects (including 2 
premanifest mutation carriers) and assessed bed and wake-up times during a single occasion in a laboratory 
setting, whereas we inquired about the usual bed and wake-up times in the previous month which are likely to 
be more representative of the habitual sleeping times.
Restoration of circadian rhythms by pharmacological imposition of sleep has been shown to improve cognition 
in R6/2 mice, suggesting that a similar strategy may be beneficial to HD patients.10,11 As our findings are 
reminiscent of a DSPS-like phenotype in HD patients that is associated with cognitive impairment, another 
approach that may be evaluated in these patients is melatonin and/or bright light treatment at the appropriate 
times so as to phase advance the clock.21,25,26 The administration of melatonin at the subjective dusk, and the use 
of bright light at the subjective dawn and avoidance of light in the subjective evening, could be used to phase 
advance the clock.21,25 However, we could not detect a significant association between cognitive performance 
and night-time sleep disturbances in HD patients, suggesting that circadian rhythm alterations rather than sleep 
impairment per se are related to cognitive disability in these subjects. Nevertheless, the lack of an association 
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between night-time sleep and cognitive scores could also be due to the use of subjective measures of sleep 
quality in this study. As particularly REM sleep and deep sleep are thought to be implicated in neurobehavioral 
and cognitive performance,27,28 and abnormalities have been reported in both of these sleep stages in HD,4,7,29 
future studies should focus on the exploration of the association between polysomnographic sleep measures 
and cognitive functioning in HD patients. 
Depressed mood is highly prevalent in HD patients, with estimates ranging from 33 to 69%,  and is an 
important determinant of their quality of life.30,31 Here we demonstrate that depressed mood is also the most 
important clinical predictor of sleep disturbances in HD patients. This finding extends upon a previous report6 
by showing that the association between depressive symptoms and sleep impairment is independent from other 
symptoms and signs of the disease including motor, cognitive and functional impairment. However, due to 
the bidirectional association between depression and sleep disturbances, it is difficult to differentiate between 
cause and effect.32 Depression is identified as the most frequent cause of chronic insomnia in both clinical and 
epidemiological studies,33,34 and as many as three quarters of individuals with DSPS have a past or current 
history of depression.35 Conversely, a number of longitudinal studies indicate that insomnia is a risk factor 
for developing both first-onset and recurrent depression.32,36,37 The co-morbidity of depression and insomnia 
may be explained by changes in systems that are involved in both mood and sleep regulation, especially 
the serotonergic and noradrenergic systems.38 Therefore, comprehensive treatment of depressive symptoms 
could help to resolve sleep complaints, whereas treatment of sleep problems and circadian rhythm alterations 
could help to bring about remission of depressive symptoms.39 Thus, simultaneous treatment of depressive 
symptoms, sleep problems and circadian rhythm changes in HD patients should be evaluated in future studies 
as the effects may be synergistic with regard to both mood and sleep improvement.
In this study we also assessed the performance of the SCOPA-SLEEP questionnaire in HD patients. Both its 
night and day subdomains revealed a high degree of internal consistency in this population. Moreover, the 
correlation with other scales that assess similar constructs was strong, indicating good construct validity. As 
our findings primarily indicate night-time sleep problems in HD patients, particularly SCOPA-NS may prove 
to be valuable for application in these patients as it takes very little time to complete while its reliability and 
consistency in this population are actually higher than those of more extensive and time-consuming scales such 
as the PSQI. 
In conclusion, our findings indicate mainly night-time sleep disturbances in HD patients and are suggestive 
of a DSPS-like phenotype associated with lower cognitive performance. Moreover, we identified depression 
as the principal predictor of sleep impairment in HD patients. As the mechanisms regulating sleep, mood and 
circadian rhythms show considerable overlap, comprehensive treatments aimed at alleviation of depressive 
symptoms and sleep impairment, as well as re-entrainment of circadian rhythms in HD patients may have 
synergistic effects and should be evaluated in future studies.
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ABSTRACT
Objective: Although autonomic function tests have revealed abnormalities of the autonomic nervous system in 
Huntington’s disease (HD), autonomic symptoms and their association with other symptoms and signs of HD 
have not yet been assessed in large groups of patients or premanifest mutation carriers. We therefore aimed 
to delineate the characteristics and correlates of autonomic symptoms in HD. Subjects & methods: Using 
the SCOPA-AUT and Beck Depression Inventory questionnaires, autonomic symptoms and depressed mood 
were assessed in 63 HD patients, 21 premanifest mutation carriers and 85 controls. The Unified Huntington’s 
Disease Rating Scale was used to assess other HD symptoms and signs. Results: Relative to controls, HD 
patients experienced significantly more gastrointestinal, urinary, cardiovascular and, in men, sexual problems. 
The most prevalent symptoms were swallowing difficulties, erection and ejaculation problems, dysphagia, 
sialorrhea, early abdominal fullness, straining for defecation, fecal and urinary incontinence, urgency, 
incomplete bladder emptying, and light-headedness while standing. Premanifest mutation carriers experienced 
significantly more swallowing difficulties and light-headedness on standing up compared with controls. In 
HD patients, autonomic symptoms were associated with a greater degree of functional disability, more severe 
depression and antidepressant drugs use; however, depression was the only independent predictor of autonomic 
dysfunction. Conclusions: Autonomic symptoms are highly prevalent in HD patients and may even precede 
the onset of motor signs. Moreover, autonomic dysfunction is related to functional disability and depression 
in HD.
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat sequence in the gene encoding the protein huntingtin.1 The disease is characterized by 
motor impairment, cognitive deterioration, behavioral problems and progressive weight loss.1,2 Although less 
well-known, autonomic nervous system (ANS) dysfunction can also accompany HD.3 Indeed, standardized 
ANS tests, including the blood pressure response to sustained handgrip,4,5 orthostatic blood pressure test,4-7 
sympathetic skin response,4,6,7 the pupillary light reflex latency,4 and heart rate variability assessment at rest 
and during various maneuvers,4-8 have revealed abnormalities in both the sympathetic and parasympathetic 
branches of the ANS in HD. 
Autonomic symptoms such as hyperhydrosis, micturition and swallowing difficulties,9-11 sexual dysfunction,12 
as well as complaints suggestive of orthostatic intolerance13,14 have been reported in small groups of HD 
patients. Moreover, although autonomic symptoms are thought to be most prominent in the advanced stages 
of the disease,15,16 complaints of possible autonomic origin such as dizziness after standing up, excessive 
perspiration and tachycardia have also been described in mildly disabled HD patients and even in otherwise 
asymptomatic mutation carriers.5 However, the extent of autonomic complaints as well as their association 
with other symptoms and signs of the disease have not yet been studied in large groups of HD patients or 
premanifest mutation carriers.
 
Therefore, the objectives of the present study were to (1) delineate the characteristics and frequency of 
autonomic symptoms in HD patients and premanifest mutation carriers in comparison with non-mutation 
carrying control subjects, and (2) to assess the relation between autonomic symptoms and various clinical 
characteristics in order to identify important predictors of autonomic problems in HD patients. 
METHODS
Design and participants
HD patients and premanifest mutation carriers were successively recruited from the outpatient clinic of the 
department of Neurology of the Leiden University Medical Center (LUMC) between June 2007 and December 
2008. Control subjects were recruited over the same period and were randomly selected non-mutation carrying 
family members, partners or acquaintances of participating patients, employees at our department or their 
acquaintances. Exclusion criteria for both groups were the diagnosis of a primary ANS disorder or a disease 
of the central nervous system unrelated to HD. All patients and premanifest mutation carriers were seen once 
or twice a year as part of their regular care. Three weeks before the scheduled annual appointments two 
identical postal surveys containing standardized questionnaires were sent to these subjects. The forms in one 
of the surveys were completed by the patients or premanifest mutation carriers themselves (or by the primary 
caregivers on their behalf) while, whenever possible, the other survey had to be completed by a non-mutation 
carrying family member, the partner or an acquaintance. The patients and premanifest mutation carriers brought 
their survey to the scheduled appointment and simultaneously provided contact data for the control subject. 
When questionnaires were not fully completed or were not received within one month, subjects were reminded 
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by phone. The study protocol was approved by the medical ethics committee of the LUMC and all participants 
gave written informed consent. 
Measurement Instruments
The clinical diagnosis of HD was made by a neurologist specialized in movement disorders (R.A.C.R.). The 
clinical condition of HD patients was assessed according to the motor, cognitive, behavioral and functional 
subscales of the Unified Huntington Disease Rating Scale (UHDRS).17 Premanifest status was defined as a score 
of <5 on the UHDRS motor scale. Symptoms of depression were evaluated by the Beck Depression Inventory 
(BDI).18 Autonomic symptoms were assessed using the SCOPA-AUT questionnaire.19 Although the SCOPA-
AUT questionnaire was originally developed for patients with Parkinson’s disease, the items cover a broad 
area of autonomic domains that may also be affected in HD.3 The SCOPA-AUT questionnaire was selected 
as it is quick and easy to administer and has already been demonstrated to have a good test-retest reliability 
in a Dutch population (both Parkinson’s disease patients and controls).19,20 The SCOPA-AUT consists of 25 
items assessing the following domains: gastrointestinal (7), urinary (6), cardiovascular (3), thermoregulatory 
(4), pupillomotor (1), and sexual (2 items for men and 2 items for women) dysfunction. The frequency of the 
problem was evaluated with four response options ranging from 0 (“never”) to 3 (“often”). The urinary and 
sexual regions have an additional response option, to indicate whether a subject used a catheter or had not been 
sexually active.19 In order to simplify comparison, the total and domain scores were all converted into relative 
scores with a range of 0 to 100, with higher scores indicating more severe impairment. In addition, to assess 
the relative frequency of each specific autonomic symptom in HD, the percentages within each participating 
group with item scores of ≥ 1 were compared.
Statistical Analysis
Mean differences between HD patients, premanifest mutation carriers, partners and other controls were assessed 
using χ2-tests and one-way analysis of variance (ANOVA) after a square-root transformation in case of non-
normal distribution. Tukey’s test (in case of equal variances) or Dunnett’s T3 test (in case of unequal variances) 
was used for post-hoc analysis. In HD patients, partial correlations were used to assess the relation of each clinical 
variable ― such as various UHDRS subscores and medication use (differentiating between sleep medications, 
antidepressants, neuroleptics and a rest group) ― with the total autonomic symptom score, while correcting 
for the effects of age and sex. To identify which predictor variables were independently associated with the 
total autonomic score in HD patients, we also used a forward stepwise regression procedure with entry and 
removal probabilities for F of 0.05 and 0.10, respectively. An independent predictor of autonomic dysfunction 
is a variable that remains significantly associated with autonomic symptom severity after adjustment for the 
effects of other significant predictor variables. Additionally, in HD patients, Spearman’s correlation coefficient 
was used to assess the association between motor impairment and each domain score separately, as well as to 
assess the correlates of sexual dysfunction. All tests were two-tailed and values of p < 0.05 were considered 
significant. The analyses were performed with SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL).
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RESULTS
Participants
In total, 169 subjects participated in this study (Table 1). Of these 84 were mutation carriers (63 had manifest 
HD and 21 were premanifest), and 85 were non-mutation carrying subjects. As autonomic problems, such 
as sexual dysfunction, of the mutation carriers may affect their partners, non-mutation carriers were further 
divided into a partner group and a group consisting of other controls (Table 1). The four groups did not 
differ with respect to age, sex, and BMI (all p > 0.453). Mutation carriers were significantly more depressed 
compared with non-carriers (p < 0.001), but the degree of depression did not differ between manifest and 
premanifest HD subjects (p=0.10). HD patients used significantly more antidepressant and neuroleptic drugs 
than the other groups (Table 1). 
Table 1. Characteristics of the study participants
HD patients Premanifest 
mutation 
carriers
Partners Controls p-value
No. of participants 63 21 21 64 -
Sex (% men) 29/34 (46.0) 9/12 (42.9) 10/11 (47.6) 27/37 (42.2) 0.959†
Age, mean (SD), yr 48.5 (10.7) 44.4 (8.7) 48.3 (9.1) 47.4 (10.4) 0.453‡
BMI, mean (SD) 25.3 (4.0) 25.5 (3.4) 25.5 (4.9) 25.3 (4.6) 0.997‡
BDI score, mean (SD) 11.8 (9.4) 8.1 (8.4) 4.3 (5.7) 4.6 (4.8) <0.001‡
Sleep medication, n (%) 16 (25.4) 3 (14.3) 5 (23.8) 5 (7.8) 0.052†
Antidepressants, n (%) 23 (36.5) 1 (4.8) 4 (19.0) 1 (1.6) <0.001†
Neuroleptics, n (%) 17 (27.0) 1 (4.8) 0 0 <0.001†
Other medication, n (%) 29 (46.0) 9 (42.9) 11 (52.4) 16 (25.0) 0.138†
†) χ2-tests.
‡ ) One-way ANOVAs.
Legend: BDI = Beck’s Depression Inventory; BMI = Body Mass Index; HD = Huntington’s disease
Autonomic symptoms: domains
The SCOPA-AUT items regarding sexual function were answered with ‘not applicable’ by a substantial 
minority in all groups, therefore, these items were not included for the calculation of the total score. Overall, 
patients with HD reported significantly more autonomic symptoms compared with both partners and controls 
as indicated by a higher total SCOPA-AUT score (Table 2). However, the total SCOPA-AUT score did not 
differ between HD patients and premanifest mutation carriers (p=0.33). Compared with partners and controls, 
HD patients experienced significantly more gastrointestinal, cardiovascular and, in men, sexual problems. HD 
patients also reported significantly more gastrointestinal and male sexual problems than premanifest mutation 
carriers (Table 2). In general, the autonomic domain scores of premanifest mutation carriers were in between 
those of HD patients and non-mutation carriers. 
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Table 2. Autonomic symptoms severity (range 0 to 100) and frequency (% with an item score ≥ 1) in the 
study population.
HD patients Premanifest Partners Controls p-value1 
Total score (median, IQR)2 16 (10-24) a,c 14 (7-18) 7 (4-12) 10 (6-14) <0.001**
Gastrointestinal domain (median, 
IQR)2
14 (5-19) a,b,c 5 (2-10) e 0 (0-5) 5 (0-10) <0.001**
Swallowing/choking (%) 71a,b,c 48d,e 5f 16 <0.001**
Sialorrhea (%) 32a,b,c 0 0 11 <0.001**
Dysphagia (%) 35a,c 14 5 8 <0.001**
Early abdominal fullness (%) 32a 24 25 16 0.206
Constipation (%) 11 10 5 9 0.882
Straining for defecation  (%) 37c 33 10 27 0.134
Fecal incontinence (%) 16a 5 0 3 0.021*
Urinary domain (median, IQR)2 22 (11-39) 17 (11-22) 11 (7-17) 17 (11-26) 0.066*
Urgency (%) 44a,b,c 19 5 27 0.003**
Urinary incontinence (%) 32a 14 10 14 0.038*
Incomplete emptying (%) 27c 14 5 20 0.164
Weak stream of urine (%) 29 14 10 20 0.264
Frequency (%) 68 81 70 78 0.507
Nocturia (%) 78 81 70f 89 0.189
Cardiovascular domain (median, 
IQR)2
0 (0-11) a 0 (0-11) 0 (0-8) 0 (0-0) 0.047*
Light-headed when standing up (%) 33a 38d 25 17 0.123
Light-headed when standing for some 
time (%)
16a 5 0 3 0.021*
Syncope in the past 6 months (%) 5 0 0 0 0.165
Thermoregulatory domain (median, 
IQR)2
17 (0-25) 17 (0-29) 8 (0-25) 17 (0-25) 0.751
Hyperhidrosis during the day (%) 37 43 30 42 0.742
Hyperhidrosis during the night (%) 41 52 45 48 0.784
Cold intolerance (%) 38 33 25 27 0.491
Heat intolerance (%) 44 38 35 33 0.590
Pupillomotor domain (median, IQR)2 0 (0-0) 0 (0-33) 0 (0-33) 0 (0-33) 0.855
Over-sensitive for bright light (%) 24 33 35 30 0.711
Sexual domain: men (median, IQR)2 33 (0-58) a,b,c 0 (0-8) 0 (0-0) 0 (0-0) 0.004**
Erection problem (%) 67a,b,c 22 11 22 <0.001**
Ejaculation problem (%) 59a,b,c 0 11 19 <0.001**
    ‘Not applicable’ (%) 21 0 10 7 0.275
Sexual domain: women (median, IQR)2 0 (0-17) 8 (0-42) 0 (0-17) 8 (0-29) 0.562
Women: Vaginal lubrication (%) 53 42 55 49 0.904
Women: Problem with orgasm (%) 53 67 46 51 0.755
‘Not applicable’ 38 33 36 24 0.633
¹) Differences in means were assessed by one-way analysis of variance (after a square-root transformation in 
case of non-normal distribution) with Tukey’s test (in case of equal variances) or Dunnett’s T3 test (in case of 
unequal variances) for post-hoc analysis. Differences in proportions were assessed by the χ2-test. * p<0.05; ** 
p<0.01
2) To simplify comparison, the total and domain scores were all converted into relative scores with a range of 
0 to100. IQR = interquartile range
a)  Patients vs. controls (p<0.05)
b)  Patients vs. premanifest mutation carriers (p<0.05)
c)  Patients vs. partners (p<0.05) 
d)  Premanifest mutation carriers vs. control (p<0.05)
e)  Premanifest mutation carriers vs. partners (p<0.05)
f)  Partners vs. controls (p<0.05) 
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Autonomic symptoms: frequency      
The largest differences between HD patients relative to controls existed for the frequency of swallowing/
choking (71 vs. 16%), erection problems (67 vs. 22%), ejaculation problems (59 vs. 19%), dysphagia (35 vs. 
8%), and sialorrhea (32 vs. 11%) (Table 2). Other relatively prevalent autonomic symptoms in HD patients 
were early abdominal fullness, straining for defecation, fecal and urinary incontinence, urgency, incomplete 
bladder emptying, and light-headedness while standing (up). Of these symptoms, only swallowing difficulties, 
sialorrhea, urgency, and erection and ejaculation problems were also more frequent in HD patients compared 
to premanifest mutation carriers. Premanifest mutation carriers experienced significantly more swallowing 
difficulties and light-headedness on standing up compared with controls (Table 2).          
Predictors of autonomic dysfunction in HD patients
Only UHDRS functional indices, i.e. total functional capacity, functional assessment and independence 
score, were significantly associated with the total autonomic dysfunction score in HD patients (Table 3). The 
total score also positively correlated with depressive symptoms as well as use of antidepressant drugs (both 
p<0.045). Moreover, stepwise regression identified depressive symptoms as the only independent predictor of 
autonomic dysfunction, accounting for 32% of the variation (Table 3). Motor impairment was not significantly 
associated with any domain score in HD patients.(all p ≥ 0.171). 
Table 3. Correlates of autonomic dysunction in HD patients
SCOPA-AUT total score
Correlation†
(r ; p-value)
Stepwise regression† 
(effect; SE)
Motor score -0.00 (0.975) -
TFC -0.37 (0.006) ** -
Functional assessment -0.35 (0.008) ** -
Independence score -0.28 (0.038) * -
Cognitive score -0.10 (0.574) -
Behavior score 0.04 (0.796) -
BDI 0.57 (<0.001) ** 0.46 (0.18) **
BMI 0.22 (0.086) -
Normal CAG repeat size 0.01 (0.923) -
Mutant CAG repeat size 0.03 (0.833) -
Sleeping medication 0.23 (0.081) -
Antidepressants 0.26 (0.045) * -
Neuroleptics 0.13 (0.303) -
Rest -0.04 (0.735) -
†)   All results are corrected for age and sex.
 * ) p < 0.05; ** p < 0.01.
Legend: BDI = Beck’s Depression Inventory; BMI = Body Mass Index; HD = 
Huntington’s disease; HD = Huntington’s disease; SCOPA-AUT = Scales for 
outcomes in Parkinson’s disease-autonomic symptoms; TFC = Total Functional 
Capacity
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As the items regarding sexual function were gender specific and not included in the total SCOPA-AUT score, 
we assessed this domain separately. In male HD patients, sexual dysfunction was significantly associated with 
all UHDRS functional indices (r from -0.49 to -0.61, p≤0.028), BMI (r=+0.54, p=0.012), depressive symptoms 
(r=+0.52, p=0.017), and use of antidepressants (r=+0.54, p=0.013). In female HD patients, however, sexual 
dysfunction was only significantly related to the behavioural score (r = -0.48, 0.045).
DISCUSSION
To our knowledge, this is the largest cohort of HD patients and premanifest mutation carriers whose autonomic 
symptoms have been systematically assessed in relation to other clinical symptoms and signs. We found a range 
of autonomic symptoms in HD patients, particularly in the gastrointestinal, urinary, cardiovascular and male 
sexual domains, some of which were also present in premanifest mutation carriers. These findings indicate 
that, autonomic symptoms are highly prevalent in HD patients and may even precede the onset of motor signs. 
In addition, we found that a greater degree of autonomic dysfunction in HD patients was associated with more 
functional disability as well as more depressive symptoms.
The most prominent complaints in HD patients concerned the gastrointestinal tract and included swallowing 
difficulties, dysphagia and sialorrhea. These symptoms may partly be accounted for by skeletal muscle 
incoordination due to striatal pathology.10 However, the absence of an association between gastrointestinal 
symptoms and UHDRS motor score, as well as the relatively high prevalence of swallowing difficulties even 
in premanifest mutation carriers suggest that ANS dysfunction is also likely to contribute to gastrointestinal 
problems in HD. This notion is further supported by the comparatively high prevalence of other symptoms 
in HD patients, including early abdominal fullness, straining for defecation, urgency, incomplete bladder 
emptying, and postural dizziness, which cannot be ascribed to motor impairment alone. Nevertheless, although 
our findings suggest that ANS dysfunction is likely to contribute to the various symptoms enlisted in Table 
2, we cannot exclude other potential contributing factors such as endocrine and peripheral abnormalities.3,21 
Therefore, further studies simultaneously applying both subjective and objective measures, such as the 
composite autonomic scoring scale,22 should be undertaken to more accurately delineate the role of ANS 
dysfunction in the pathogenesis of the aforementioned symptoms in HD.
   
Interestingly, while erection and ejaculation problems were very prominent in male HD patients, sexual 
dysfunction was not obvious in female patients. However, relatively more HD patients than controls, and 
relatively more females than males, answered ‘not applicable’ to one or both of the sexual items in the 
questionnaire, which could indicate sexual hypofunction.12 Our results may therefore represent underestimates 
of the actual prevalence of sexual dysfunction in, particularly female, HD patients. 
Autonomic dysfunction was associated with both functional disability and depression in HD patients. Due to 
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the cross-sectional nature of our study, it is impossible to differentiate between cause and effect. However, 
autonomic symptoms are unlikely to be secondary to functional impairment, as by definition, autonomic 
functions are not under voluntary control. It is rather more likely that symptoms such as dysphagia, sialorrhea, 
and fecal and urinary incontinence could lead to social embarrassment, isolation and a negative impact on 
daily functioning. On the other hand, the relation between autonomic dysfunction and depression, which is 
also found in other patient populations,20 is harder to explain since depression itself can be accompanied by 
several vegetative symptoms such us loss of libido.23 In fact, depression was the only independent predictor 
of autonomic dysfunction in HD  patients, indicating that its effect on autonomic symptoms is independent of, 
e.g., functional disability. Although antidepressant use was correlated with the extent of autonomic complaints 
in HD patients, adjustment for the severity of depressive symptoms rendered this relation insignificant, 
suggesting that the association between depression and autonomic dysfunction is unlikely to be secondary to 
medication. Longitudinal studies of autonomic symptoms are needed to more precisely delineate the temporal 
association between depression to autonomic dysfunction in HD. 
There are no reasons to suspect damage to the peripheral nervous system in HD,5-7 so the site of autonomic 
dysfunction is more likely found in the central autonomic network including the hypothalamus and its 
connections to the cortex, limbic system, brainstem and spinal cord.24 Substantial hypothalamic pathology 
has indeed been found in both HD patients and animal models of the disease.3,25 Recently, a significant loss of 
dopamine D2 receptors as well as microglia activation was found in the hypothalamus of both HD patients and 
premanifest mutation carriers.26 As these abnormalities as well as neuronal inclusions of mutant huntingtin were 
seen throughout the hypothalamus,26,27 hypothalamic damage might account for the autonomic dysfunction 
that encompasses both sympathetic and parasympathetic functions.4-7 Further studies combining autonomic 
functional tests with whole brain, and in particular hypothalamic, assessment are needed to more accurately 
pinpoint the sites of pathology within the central autonomic network in HD.   
In conclusion, autonomic symptoms are highly prevalent in HD patients, may even precede the onset of motor 
signs, and are related to functional disability and depression.
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PART II
HYPOTHALAMIC PATHOLOGY
IN
HUNTINGTON’S DISEASE
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“Here in this well-concealed spot [referring to the hypothalamus], almost 
to be covered with a thumbnail, lies the very main spring of primitive 
existence – vegetative, emotional, reproductive – on which with more 
or less success, man has come to superimpose a cortex of inhibitions.”
Harvey Cushing Papers relating to the Pituitary Body, Hypothalamus, 
and Parasympathetic Nervous Systme. Charles C. Thomas, Springfield 
and Baltimore, 1932.
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ABSTRACT
To evaluate whether hypocretin-1 (orexin-A) and melanin-concentrating hormone (MCH) neurotransmission 
are affected in patients with Huntington’s  disease (HD), we immunohistochemically stained hypocretin and 
MCH neurons and estimated their total numbers in the lateral hypothalamus of both HD patients and matched 
controls. In addition, hypocretin-1 levels were determined in prefrontal cortical tissue and post-mortem 
ventricular cerebrospinal fluid (CSF) using a radioimmunoassay. The total number of hypocretin-1 neurons 
was significantly reduced by 30% in HD brains (p=0.015), while the total number of MCH neurons was not 
significantly altered (p=0.100). Levels of hypocretin-1 were 33% lower in the prefrontal cortex of HD patients 
(p=0.025), but ventricular CSF levels were similar to control values (p=0.306). Neuronal intranuclear and 
cytoplasmic inclusions of mutant huntingtin were present in all HD hypothalami, although with a variable 
distribution across different hypothalamic structures. We found a specific reduction in hypocretin signalling 
in patients with HD as MCH cell number was not significantly affected. It remains to be shown whether the 
moderate decrease in hypocretin neurotransmission could contribute to clinical symptoms. As the number of 
MCH expressing neurons was not affected, alterations in MCH signalling are unlikely to have clinical effects 
in HD patients.
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Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the IT15 gene on chromosome 4. Choreiform movements, 
psychiatric and behavioural problems and cognitive impairment characterize HD.16 Other debilitating but 
less well-known features of the disease are weight loss, sleep disturbances and autonomic nervous system 
dysfunction,2 the causes of which are poorly understood. HD is neuropathologically characterized by 
generalized atrophy and cell death in the striatum and cerebral cortex and the presence of neuronal intranuclear 
and cytoplasmic inclusions of mutant huntingtin, particularly in the neocortex and neostriatum.8,41 Substantial 
hypothalamic atrophy and cell death have also been reported,18,20,21 however, the presence of HD inclusions has 
not been investigated so far in different hypothalamic structures. 
Hypocretin/orexin and melanin-concentrating hormone (MCH) are neuropeptides that are synthesized in the 
lateral hypothalamus by two distinct neuronal populations.30,31,36 These neuropeptides both play a key role 
in the regulation of body energy metabolism, sleep-wake cycles and autonomic functions.17,30,33,43 Moreover, 
recent animal studies implicate the MCH system in the modulation of several behavioural modalities, most 
notably stress, depression and sexual behaviour .30,34 A relation has also been demonstrated between hypocretin 
release and some psychiatric symptoms.5,32 Potential alterations in hypocretin and/or MCH signalling might 
thus contribute to some symptoms in HD patients, particularly weight loss, sleep disturbances and autonomic 
dysfunction as well as some behavioural disorders like increased rates of depression and anxiety in these 
subjects.16
Recently, it was demonstrated that the R6/2 mouse, the most widely used model of HD that expresses the 
first exon of the HD gene with ~150 CAG repeats, exhibits a progressive and massive loss of hypocretin-1 
immunopositive neurons in the lateral hypothalamic area .27 This loss amounted to 71% at the end stage (12 
weeks) and was accompanied by loss of neuronal nuclear antigen (NeuN)-immunopositive neurons.27 On the 
other hand, the YAC128 mouse model of HD with the full-length mutant HD gene with ~120 CAG repeats, 
shows a 10% loss of hypocretin-1 immunopositive neurons at 12 months.4 Furthermore, MCH cell number was 
reported to be decreased by 38% in the hypothalamus of twelve week old R6/2 mice, while MCH peptide levels 
were reduced by 57%.39 Atrophy and a decreased density of hypocretin-1 expressing neurons in single coronal 
sections from the lateral hypothalamus have also been observed in HD patients.27 Nevertheless, four recent 
papers reported normal hypocretin-1 concentrations in the cerebrospinal fluid (CSF) of HD patients.3,4,11,24
In order to validate and extend the above findings in patients with HD we applied a four-way approach. First, we 
estimated the total numbers of both hypocretin-1 and MCH expressing neurons in the lateral hypothalamus of 
HD patients and matched controls. This allowed testing for the specificity of potential changes in the neuronal 
numbers. Second, we measured hypocretin-1 levels in post-mortem ventricular CSF because this could better 
reflect hypocretin-1 production than spinal measurements.7,10 Third, hypocretin-1 contents in peptide extracts 
from cerebral cortex were assessed, since this has been shown to be a more sensitive technique compared to 
CSF measurements.10,28 And finally, we also investigated various hypothalamic regions, including the lateral 
hypothalamus, for the presence of neuronal intranuclear and cytoplasmic inclusions.
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MATERIALS AND METHODS
Post-mortem material
Autopsy hypothalami from eight HD patients and eight controls (matched for age, sex, post-mortem delay and 
fixation time) were obtained through the Netherlands Brain Bank (NBB). Ventricular CSF was available in 7 of 
these HD patients and one of the controls; therefore CSF from six additional controls (matched for age, sex and 
post-mortem delay) was used for comparison (Table 1). Frozen prefrontal cortical tissue from a second group 
of 19 HD patients and 16 controls was obtained through the Leiden University Medical Centre HD pathology 
archives (Table 2). HD brains were graded according to the scheme of Vonsattel et al. for neuropathological 
disease severity.41 All HD patients had clinical features and a positive family history of the disease; one patient 
(#1; Table 2) had infantile HD and was studied separately as there are indications that infantile and classical 
HD may differ neuropathologically.35 The diagnosis of HD was genetically confirmed (i.e. CAG repeat lengths 
≥ 40) in all but one of these patients (#HD-8, Table 1). However, the latter patient’s brain showed HD pathology 
grade II and the presence of neuronal intranuclear and cytoplasmic inclusions combined with a positive family 
history of the disease further consolidated the diagnosis. Exclusion criteria for control subjects were primary 
neurological and/or psychiatric disorders and glucocorticoid therapy during the final premortal illness period, 
except two controls who had suffered strokes and were used for prefrontal cortex hypocretin-1 measurements 
(#C-4 and #C-14; Table 2).
Hypocretin-1 and MCH immunohistochemistry
The hypothalami were fixed in 10% PBS (pH 7.4) formalin at room temperature and were paraffin embedded 
and serially sectioned at 6 μm in rostro-caudal direction. Every 100th section was stained with thionin for 
orientation. The lateral hypothalamus, from the level where the fornix abuts the paraventricular nucleus up 
to the posterior border of the corpora mamillaria, was stained at 600 μm intervals in every two consecutive 
sections. One of the sections was stained with a hypocretin-1 and the other with a MCH monoclonal antibody 
(Phoenix Pharmaceuticals, Inc., Belmont, CA; catalog no. H-003-30 and H-070-47, respectively). The sections 
were visualized according to the avidin-biotin complex method using diaminobenzidine-nickel solution to 
finish the staining as described previously.13 
N-terminal huntingtin immunohistochemistry
Using thionin staining for orientation, nine to ten sections were chosen so that large parts of the following 
hypothalamic (and adjacent) structures would be contained in at least two coronal cuts: the suprachiasmatic 
nucleus, the supraoptic nucleus, the paraventricular nucleus, the infundibular nucleus, the diagonal band 
of Broca, the nucleus basalis of Meynert, the ventromedial nucleus, the dorsomedial nucleus, the lateral 
hypothalamus/perifornical area, the tuberomamillary nucleus, the lateral tuberal nucleus and the supramamillary 
area (the supramamillary area was contained in only one coronal cut). These sections were stained with a 
monoclonal antibody against the N-terminus of human huntingtin (Chemicon, Temecula, CA; batch no. 5374) 
after pretreatment by boiling in citrate buffer (pH 6.0) for 20 minutes. The sections were processed according 
to the avidin-biotin complex method using diaminobenzidine-nickel solution and counterstained with Harris’s 
Hematoxylin for nuclear staining.   
Antibody specificity
The specificity of the hypocretin-1 antibody has been confirmed previously.9 To test the specificity of 
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Table 1. Clinicopathological details of HD patients and control subjects.
Sex Age
(yrs)
Age 
of 
onset 
(yrs)
PMD 
(h)
Fix 
(d)
Brain 
weight 
(g)
Grade CAG 
repeat 
length
Cause of death MCH 
cell no.
Hcrt-1 
cell 
no.
Hcrt-1 
levels 
in CSF 
(pg/
ml)
Patients HD-1 M 57 42 07:30 53 1162 3-4 46 Cachexia 76987 42088 536
HD-2 F 50 35 05:40 55 1292 2-3 47 Pneumonia N.A. 24022 595
HD-3 M 79 54 06:15 34 1001 4 44 Pneumonia and 
sepsis
75652 29890 422
HD-4 F 67 56 06:05 41 1289 1 45 Unknown 102436 50863 531
HD-5 M 49 40 05:45 49 1122 3 54 Cachexia 
secondary to 
pneumonia.
N.A. 20448 468
HD-6 F 80 58 07:15 49 906 2 41 Pneumonia 76620 36023 404
HD-7 M 61 39 10:25 48 1380 3 43 Pneumonia 77846 27880 481
HD-8 M 54 41 03:50 80 1212 2 - Sudden death N.A. 42569 N.A.
Median
Percentile
25th:
75th: 
59.0
51.0
76.0
41.5
39.3
55.5
6:10
5:41
7:26
49.0
42.8
54.5
1187.0
1031.3
1291.3
- 45.0
43.0
47.0
76987
76136 
90141
32957
24987
42449
Controls  
 
C-1a M 58 - <17:00 96 1408 - - Aorta dissection 77237 49105 N.A.
C-2a F 49 - <13:30 165 1437 - - Metastasized 
cervix 
carcinoma.
89347 56250 N.A.
C-3a M 79 - <3:00 53 1435 - - Haemorrhage 
from leaking 
aorta prosthesis
84652 36231 N.A.
C-4a F 68 - 05:45 32 1153 - - Unknown N.A. 52900 N.A.
C-5a M 49 - <12:40 40 1404 - - Sudden death 118604 54638 N.A.
C-6a,b F 82 - 05:30 36 1280 - - Myocardial 
infarction
N.A. 60972 409
C-7a M 61 - 13:50 52 2220 - - Carcinoma of 
the oesophagus
94776 27912 N.A.
C-8a M 54 - <08:00 59 1350 - - Hepatocellular 
carcinoma
86792 53216 N.A.
C-9b  M 56 - 5:25 - 1522 - - Cardiac 
infarction
N.A. N.A. 536
C-10b F 51 - 7:40 - 1156 - - Sepsis N.A. N.A. 640
C-11b M 79 - 6:00 - 1392 - - Mestastasized 
adenocarcinoma
N.A. N.A. 631
C-12b F 69 - 4:20 - 1186 - - Heart failure N.A. N.A. 549
C-13b M 53 - 14:25 - 1341 - - Heart failure N.A. N.A. 581
C-14b M 61 - 12:05 - 1460 - - Heart failure N.A. N.A. 336
Group a:
Median
Percentiles
25th:
75th:
59.5
50.3
76.3
10:20
5:33
13:45
52.5
37.0
86.8
1406.0
1297.5
1436.5
88070
82798
100733
53058
39450
55847
-
Group b:
Median
Percentiles
25th:
75th:
61.0
53.0
79.0
6:00
5:25
12:05
- 1341.0
1186.0
1460.0
- - 549.0
409.0
631.0
a) Hypothalamic material from these controls was available for Hcrt-1 and/or MCH immunohistochemistry.
b) Ventricular CSF from these controls was available for Hcrt-1 radioimmunoassay.
Legend: Fix = fixation time, PMD = post-mortem delay, Grade = Vonsattel et al’s grade, N.A. = not available. Hcrt-1, hypocretin-1.
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Table 2. Clinicopathological data of subjects used for hypocretin brain tissue measurement.
subject 
no.
Age at 
death
Sex Grade CAG Cause of death Hcrt-1
tissue content 
(pg/g)
Infantile HD 1a  19 F 3 86 Cachexia                    1097
Adult HD 2   34 M 3 52 Unknown             389
3   40 F 3 41 Suicide                       530
4    44 M N.A. 50 Pneumonia                   343
5 45 M 4 53 Recurrent aspiration pneumonia    198
6    49 M 3 47 Respiratory  insufficiency                 743
7   51 M 3 46 Bronchopneumonia           360
8   51 M 3 45 Unknown                       584
9 53 F 2 47 Pulmonary embolism                   511
10  54 M 3 43 Pneumonia                  198
11   55 F 3 47 Metast. Grawitz tumor         617
12 57 F 3 43 Pulmonary embolism                  278
13 57 M 4 49 Bronchopneumonia              275
14    57 M 3 47 Unknown                         665
15   63 F 3 43 Basilar artery thrombosis 1066
16   66 F 3 41 Squamous cell lung carcinoma        443
17   69 F 2 42 Aspiration pneumonia            725
18    75 M 3 43 Unknown                          302
19   77 M 3 39 Bronchopneumonia              376
Median 54.5 3.0 45.5 416.4
Percentiles
(25th – 75 th)
48.0 – 63.8 2.5 – 3.0 42.8 – 47.5 295.8 – 629.4
Controls 1 37 M - - Myocardial infarction 996
2   46 M - - Cardiac arhythmia 364
3   48 M - - Myocardial infarction 665
4    52 M - - Stroke            688
5 60 F - - Pneumonia 433
6    63 F - - Leptomeningeal metastasis      737
7   64 M - - Myocardial infarction 1368
8   67 F - - Aortic Dissection                858
9 68 M - - Pneumonia 697
10  70 M - - Metastasized carcinoma      1282
11   71 M - - Cardiomyopathy               573
12 74 M - - Metastasized carcinoma      243
13 76 M - - Aortic Dissection                638
14    79 F - - Stroke 892
15   83 M - - Leptomeningeal metastasis      358
16   86 M - - Myocardial infarction 570
Median 67.5 676.6
Percentiles
(25th – 75 th)
54.0 -75.5 467.5-883.9
a) This patient had juvenile HD and was therefore studied separately.
Legend: Grade = Vonsattel et al’s grade, CAG = CAG repeat length, Hcrt-1, hypocretin-1, N.A. = not available.
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the MCH antibody, a dot blot was performed,40 adding a dilution of  1:1000 anti-MCH onto 2% gelatin-
coated nitrocellulose paper (0.1-μm pore size) containing different spots with 20 pmol MCH, hypocretin-1, 
somatostatin (1–14), somatostatin (1–28), galanin, MCH-1 receptor, β-lipotropin, substance-P, α -melanocyte-
stimulating hormone, luteinizing hormone-releasing hormone, adrenocorticotropic hormone (1–39), 
neurotensin, oxytocin, corticotropin-releasing hormone , agouti-related protein (83–132), neuropeptide-Y, 
growth hormone-releasing hormone (1– 40), arginine-vasopressin, desacetylmelanocyte-stimulating hormone, 
neuropeptide EI, glycoprotein hormone receptor and cocaine- and amphetamine-regulated transcript. The 
next day, the nitrocellulose sheet was incubated with secondary antibody, avidin-biotin peroxidase complex, 
and diaminobenzidinenickel solution to finish the staining. The only spot that showed staining was the one 
containing MCH. Specificity was further confirmed by the absence of staining in hypothalamic sections using 
antiserum preadsorbed with the human MCH peptide fixed overnight with 4% formaldehyde onto gelatin-
coated nitrocellulose filter paper, 0.1 μm, and the presence of staining when preadsorbed with α-melanocyte-
stimulating hormone peptide, which did not differ from unadsorbed serum. 
Quantification of hypocretin-1 and MCH neuronal numbers 
An estimate of the total number of hypocretin-1 and MCH immunoreactive (IR) cells was made using an 
image analysis system (ImagePro version 4.5, Media Cybernetics, Silver Spring) connected to a camera (JVC 
KY-F553CCD) and plain objective microscope (Zeiss Axioskop with Plan-NEOFLUAR Zeiss objectives, 
Carl Zeiss GmbH, Jena, Germany). In every section randomly selected fields, covering in total 15% of a 
manually outlined area containing all the hypocretin-1 or MCH IR cells, were counted by the same person 
(NAA) who was blinded to the diagnosis. Each positively stained profile containing a nucleolus was counted.10 
Calculation of the total number of hypocretin-1 IR neurons was performed by a conversion program based 
upon multiplication of the neuronal counts by sample frequency of the sections as described previously.14 
Mean (± SD) number of sections quantified per subject was 10.2 ± 1.5 for hypocretin-1 and 11.5 ± 2.3 for 
MCH. The coefficient of variation (i.e. SD / mean x 100%) of this method was 3.4% for hypocretin-1 and 4.5 
% for MCH (calculated by counting one complete control twice).
Hypocretin-1 measurements in cerebral cortex and CSF 
One gram of frozen prefrontal cortex was used for hypocretin-1 measurements (Table 2). The most rostral part 
of the prefrontal cortex was chosen, as this cortical region is densely innervated by hypocretin neurons resulting 
in high hypocretin-1 concentrations.29 The tissue samples were boiled for 10 minutes in 10.0 ml of MilliQ water, 
cooled to room temperature, acidified using glacial acetic acid and HCl (final concentration: 1.0 M and 20.0 
mM respectively), homogenized and centrifuged. The supernatant was acidified again with an equal volume of 
0.1% trifluoracetic acid and vacuum dried. Samples were resuspended in 500 μl of radioimmunoassay buffer 
and centrifuged at 3000 rpm for 10 minutes before measurements. Immediately after collection, ventricular 
CSF was centrifuged at 2500 rpm for 10 minutes and the supernatant was stored at -80°C until hypocretin-1 
levels were measured using a commercially available radioimmunoassay (Phoenix Pharmaceuticals, Belmont, 
USA). All measurements were conducted in duplicate 100 μl aliquots in a single assay run. The detection limit 
was 50 pg/ml and intra-assay variability was less than 5%. We used a validated reference sample to adjust 
levels to previously reported values.10,28  
Assessment of neuronal intranuclear and cytoplasmic inclusions
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The presence or absence of neuronal intranuclear inclusions and cytoplasmic inclusions (i.e. inclusions 
in dystrophic neurites) in the hypothalamic regions of interest were assessed by one of us (NAA) at ×100 
magnification.8 For each region two coronal sections were investigated. The percentage of HD patients who 
had either neuronal intranuclear or cytoplasmic inclusions of mutant huntingtin was calculated per structure 
(Table 4).
Statistics
All data are presented as medians (25th – 75th percentile). Differences between the groups were statistically 
evaluated by the Mann-Whitney U (MWU) test, the Wilcoxon signed rank (WSR) test or the χ2-test. Spearman’s ρ 
correlation test was performed to assess all correlations. Differences in clock time of death (circular parameter) 
between controls and patients with HD were tested with the Watson’s two-sample test of homogeneity.23 Tests 
were two-tailed and values of p < 0.05 were considered to be significant. Local linear regression was used to 
fit curves to the standardized pooled data (Figure 2).22
RESULTS
Hypocretin-1 and MCH neurons in HD patients and controls
Subject characteristics
There were no significant differences in age, sex, post-mortem delay, fixation time and clock time of death 
between the HD and the control group (all p ≥ 0.27 (Table 1)).
Distribution of hypocretin-1- and MCH neurons
The intensity of hypocretin-1 and MCH immunostaining showed no obvious differences between the HD and 
the control group (Figure 1). Hypocretin-1 IR neurons were restricted to the perifornical region in the lateral 
hypothalamus as previously described.9 MCH IR neurons were mainly confined to the same areas although 
they were more widely disseminated than hypocretin-1 IR neurons. The first hypocretin-1 IR neurons emerged 
in the lateral hypothalamus at the junction of the fornix and the paraventricular nucleus and were followed by 
the first MCH IR neurons. However, the rostro-caudal distance between the location of the first hypocretin-1 
neurons and that of the first MCH neurons did not significantly differ from zero (either in patients (n = 8) or 
controls (n = 8) or both groups combined (respective p-values by WSR test: 0.168, 0.336 and 0.085)) (Figure 
2). At subsequent levels the fornix was surrounded by both hypocretin-1 and MCH IR cell bodies throughout 
its entire course up to the mamillary bodies. The number of hypocretin-1 IR neurons peaked just before the 
fornicomamillary junction, whereas the peak number of MCH IR neurons was seen after this junction in the 
supramamillary area (Figure 2); the rostro-caudal distance between the two peaks was calculated in each 
individual and was significantly larger than zero (all p ≤ 0.011 by WSR test, either in patients (1200 μm [1200-
1800]) or controls (1500 μm [1200-2250]), or both groups combined (1200 μm [1200-1800]). 
Hypocretin-1 and MCH cell numbers
The total number of hypocretin-1 IR neurons in the lateral hypothalamus of HD patients was significantly 
reduced by 30 % compared to values in matched controls (32,957 (24,987 – 42,449) vs. 53,058 (39,450 – 
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55,847); p = 0.015; Figure 3). As the available hypothalamic material of two controls and three HD patient 
(#C-4, #C-6 and #HD-2, #HD-5 and #HD-8, respectively (Table 1)) did not contain the caudal part of the 
MCH area, these cases were excluded from subsequent calculations of the total number of MCH IR neurons. 
Exclusion of these subjects did not alter group comparability. There was a trend towards a decrease in the 
total number of MCH IR neurons in HD patients (HD: 76,987 (76,136 – 90,141); controls: 88,070 (82,798 – 
100,733); p = 0.100; Figure 3). 
Figure 1. Representative photographs of hyocretin-1 and MCH IR neurons in the lateral hypothalamus of two 
control subjects (A and C, #C-4 and #C-2 respectively) and two patients with HD (B and D, #HD-6 and #HD-1 
respectively) with neuronal counts at or around the median (Table 1). The pictures were taken from slides with 
the highest numbers of immunoreactive neurons. The illustrations show a modest reduction in the number of 
hypocretin-1 IR neurons in the HD brain (A and B) while the number of MCH IR neurons is not significantly 
affected (C and D). Scale bar 250 µm. 
             
             
Effects of age of onset, CAG repeat length, disease duration and Vonsattel et al’s grade on hypocretin-1 and 
MCH cell numbers in HD
There was a positive trend for the relation between age of onset of HD (defined as the age at which the 
clinical diagnosis was first made) and hypocretin-1 IR neuronal numbers (r = 0.64, p = 0.086), but not MCH 
neuronal numbers (r = 0.21, p = 0.645). In HD patients, the total hypocretin-1 and MCH cell numbers were 
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not significantly associated with either CAG repeat length, duration of illness or Vonsattel et al’s grades of 
neuropathological disease severity (Table 3).41
Figure 2. Distribution patterns of hypocretin-1 and MCH IR neurons in the lateral hypothalamus of controls 
and HD patients. In order to present data from all subjects in the same diagrams, the individual distribution 
patterns were standardized in rostro-caudal direction for the anatomical distance between the point where 
the fornix abuts the paraventricular nucleus  (black arrows; at the level of  line ‘A’ in the upper cartoon) and 
the fornicomamillary junction (grey arrows; at the level of line ‘B’ in the upper cartoon). This procedure was 
performed separately for the control and the HD group. In addition, local linear regression was used to fit curves 
to the standardized pooled data in order to clarify the underlying distribution patterns (kernel = Gaussian, 
bandwidth value = 1.0). Note that the overall rostro-caudal dispersion of hypocretin-1 and MCH IR neurons 
does not appear to be noticeably different between control and HD subjects. Upper cartoon: A schematic 
sagittal view of the hypothalamus; the paraventricular nucleus and the mamillary bodies are indicated in dark. 
Lower cartoon: A schematic coronal view of the hypothalamus midway between lines ‘A’ and ‘B’ in the upper 
cartoon; the perifornical area and the lateral hypothalamus are indicated in dark (adapted from (36)). Hcrt-
1, hypocretin-1; 3V, third ventricle; Fx, fornix; LH, lateral hypothalamus; DM, dorsomedial nucleus; VM, 
ventromedial nucleus; TMN, tuberomamillary nucleus; INF, infundibular nucleus; OT, optic tract.
Ventricular CSF hypocretin-1 content
The two groups were well matched for age, sex and post-mortem delay (all p > 0.80) (Table 2). Furthermore, 
there were no significant correlations between these variables and hypocretin-1 CSF contents in HD patients, 
controls or the combined group (all p > 0.11). The CSF contents of hypocretin-1 was not different between 
HD patients and controls (HD: 481 pg/ml (422 – 536); controls: 549 pg/ml (409 – 631); p = 0.306, Figure 4), 
nor was there a significant correlation between the hypocretin cell counts and CSF levels in the 8 subjects (7 
HD patients and 1 control) in whom both measurements were available (r = -0.238; p = 0.570). There were 
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no significant correlations between CSF hypocretin-1 levels and other (clinical) disease parameters (Table 3).
Table 3. Spearman’s ρ correlations (p-values) between post-mortem findings and other (clinical) disease 
parameters in HD patients. The only significant correlation was between the prefrontal cortex Hcrt-1 levels 
and Vonsattel et al.’s grade of neuropathological disease severity. Trends were visible for the relations between 
Hcrt-1 cell number and age of onset and between MCH cell number and disease duration. 
Age at death Age of onset Disease duration Grade CAG repeat no.
Hcrt-1 cell no. 0.452 (0.260) 0.643 (0.086) -0.096 (0.820) -0.482 (0.227) -0.429 (0.337)
MCH cell no. -0.500 (0.391) -0.200 (0.747) -0.821 (0.089) -0.700 (0.188) 0.300 (0.624)
Ventricular CSF
Hcrt-1 levels
-0.607 (0.148) -0.607 (0.148) -0.436 (0.328) -0.090 (0.848) 0.571 (0.180)
Prefrontal cortex
Hcrt-1 levels
0.078 (0.760) -0.417 (0.265) 0.192 (0.620) -0.666 
(0.004)*
-0.179 (0.476)
* Correlation is significant at the 0.01 level.
Hypocretin-1 concentration in prefrontal cortex 
The two groups did not differ with respect to gender, but the HD group was significantly younger (p = 0.034) 
(Table 2). However, hypocretin-1 concentrations were not significantly correlated with age (either in HD 
patients, controls, or the combined groups (all p ≥ 0.37)). Hypocretin-1 concentration in controls was 676.6 
(467.5 – 883.9) pg/gram of wet brain tissue, which is comparable to previously reported values (28). Compared 
to controls mean hypocretin-1 cortical levels were 33% lower in adult HD patients (416.4 pg/g (295.8 – 629.4); 
p = 0.025). Furthermore, the prefrontal hypocretin-1 levels in these patients were significantly associated with 
the Vonsattel et al’s grades (r = -0.666, p = 0.004), but not with other (clinical) disease parameters (Table 3). 
The patient with infantile HD had the highest levels of cortical hypocretin among all the HD patients studied 
(Table 2). Since the prefrontal tissues belonged to subjects whose hypocretin cell counts were unavailable, we 
could not relate the prefrontal cortex levels of hypocretin-1 to the hypocretin cell counts.
Neuronal intranuclear and cytoplasmic inclusions in HD hypothalami
N-terminal huntingtin-positive neuronal intranuclear and cytoplasmic inclusions were observed in all HD 
hypothalami (Figure 5). Cytoplasmic inclusions were far more abundant than intranuclear inclusions which 
were seen only sporadically. Intranuclear inclusions were most consistently observed in the neurons of the 
tuberomamillary nucleus. The HD inclusions were not uniformly distributed among the various hypothalamic 
and adjacent structures (Table 4). Only in relatively few patients cytoplasmic inclusions were present in the 
most rostral hypothalamic structures (i.e. the suprachiasmatic, the supraoptic, and the paraventricular nuclei), 
while intranuclear inclusions could not be detected at all in these areas.   
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Table 4. Neuronal inclusions in nuclei of HD hypothalami and adjacent regions. 
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% 
patients 
50 0 50 0 63 0 100 25 100 25 100 13 100 0 100 25 75 13 100 75 100 0
Legend: Type = type of neuronal inclusions; C = cytoplasmic inclusions (i.e. inclusions in dystrophic 
neurites); I = intranuclear inclusions; - = inclusions absent; + = inclusions present. The last row indicates, 
per structure, the percentage of HD patients who had neuronal inclusions of the specified type. SCN, 
suprachiasmatic nucleus; SON, supraoptic nucleus; PVN, paraventricular nucleus; INF, infundibular 
nucleus; DBB, diagonal band of Broca; NBM, nucleus basalis of Meynert; VMN, ventromedial nucleus; 
DMN, dorsomedial nucleus; LH, lateral hypothalamus; PFA, perifornical area; NTL, lateral tuberal 
nucleus; TMN, tuberomamillary nucleus; SMA, supramamillary area.
Figure 3. The total numbers of hypocretin-1 and 
MCH IR neurons in the lateral hypothalamus of 
control subjects and HD patients. The total number of 
hypocretin-1 IR neurons is significantly decreased in 
HD, while there is only a trend towards a reduction 
in the total number of MCH IR neurons (MWU-test: 
n = 16, p = 0.015 for Hcrt-1 and n = 11, p = 0.100 
for MCH). Outliers (defined as data points which lie 
1.5 times the interquartile range below the first or 
above the third quartile) are symbolized by ‘○’. Hcrt-1, 
hypocretin-1. 
Figure 4. Compared to 
controls, hypocretin-1 
levels were significantly 
lower in the prefrontal 
cortex of HD patients 
(MWU-test: p = 0.025), 
but not in their CSF 
(MWU-test: p = 0.306). 
Hcrt-1, hypocretin-1.
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DISCUSSION
In this study, we demonstrate a significant 
reduction by about 30% in the total number 
of hypocretin-1 neurons in the lateral 
hypothalamus of HD patients. This decrease 
appears to be relatively specific as the total 
number of MCH neurons was not significantly 
altered. Hypocretin-1 levels in the prefrontal 
cortex were reduced to the same extent, but 
ventricular CSF levels were unchanged. 
Furthermore, we describe the distribution of 
intranuclear and cytoplasmic inclusions of 
mutant huntingtin in the lateral hypothalamus 
and various other hypothalamic and adjacent 
structures in patients with HD. 
Recently the density of hypocretin-1 neurons was assessed in single coronal sections from the lateral 
hypothalamus of HD patients and found to be decreased.27 However, cell density is subject to substantial 
variation depending on both the rostro-caudal level of the sections (Figure 2) and the cutting direction. 
Therefore, in this study we systematically counted the total number of hypocretin-1 expressing neurons and 
were able to unequivocally confirm a significant but moderate decrease in the number of these neurons in HD 
patients. A positive trend was also visible for the relation between hypocretin-1 cell number and age of onset 
in HD patients paralleling findings by Kremer et al.21 who found an association between neuronal numbers in 
the lateral tuberal nucleus and age of onset in HD. 
We corroborated the specificity of the reduction in hypocretin-1 neuronal numbers by assessing the total 
number of MCH neurons as well. Since the reduction in hypocretin-1 neuronal numbers was more pronounced 
than that in MCH neuronal numbers, hypocretin neurons appear to be more vulnerable to the pathogenic 
mechanisms underlying HD. Interestingly, a recent study in rat hypothalamic slice cultures showed that 
24-hours of incubation with N-methyl-D-aspartate (NMDA) resulted in a marked decrease in the number 
of hypocretin-1 neurons, whereas MCH neurons in the same cultures were relatively spared.19 Moreover, 
examinations of the effects of several endogenous glutamate receptor agonists highlighted quinolinic acid as an 
endogenous excitotoxin that could cause selective loss of hypocretin-1 neurons as compared to MCH neurons 
by activating NMDA receptors.19 Therefore, NMDA receptor-mediated excitotoxicity could be involved in the 
greater susceptibility of hypocretin-1 neurons in HD patients, a pathomechanism that has also been proposed 
for the massive neuronal loss in the lateral tuberal nucleus of these patients.21 
To further assess hypocretin neurotransmission in HD, we also examined hypocretin-1 contents in the 
prefrontal cortex and ventricular CSF. Whereas the mean levels of hypocretin-1 were about 30% lower in the 
Figure 5. Examples of neuronal intranuclear (arrow) and 
cytoplasmic (arrowheads) inclusions of mutant huntingtin 
in the tuberomamillary nucleus of one HD patient (#HD-
7; obj. ×60 oil).      
Chapter 6
114
prefrontal cortex of HD subjects and correlated with Vonsattel et al’s grades, ventricular CSF hypocretin-1 
contents did not differ between patients and controls. The latter finding is in accordance with four recent papers 
that reported normal hypocretin-1 concentrations in the CSF of HD patients.3,4,11,24 The apparent discrepancy 
between the findings in the CSF and those in the hypothalamus and the prefrontal cortex of HD patients could 
be accounted for by the fact that a mean reduction of approximately 30% in the number of hypocretin-1 
neurons is probably not large enough to be reflected in the CSF.3,11,24 This assumption is supported by the fact 
that a reduction by half in the number of hypocretin neurons in PD patients only causes a 25% decrease in 
hypocretin-1 levels in the ventricular CSF.10 Accordingly, rat studies indicate that a 73% decline in hypocretin 
neuronal numbers is needed to decrease CSF hypocretin-1 levels by half.12 Yet another possibility is impaired 
clearance of hypocretin-1 from the CSF in HD. 
So far, hypocretin signalling has been studied in two animal models of HD. The R6/2 mouse model is reported 
to have a loss of more than 70% in both hypocretin-1 expressing neurons and hypocretin-1 CSF levels, whereas 
the YAC128 mouse model exhibits a reduction of 10% in the number of hypocretin-1 neurons. Moreover, 
R6/2 mice are reported to have a loss of almost 40% in the number of MCH expressing neurons while their 
hypothalamic MCH levels are reduced by nearly 60%.39 The discrepancy between our findings and those 
from these transgenic mice could be accounted for by the existence of several confounding variables. First, 
these transgenic mouse models have very large CAG repeat expansions (> 120 repeats) and resemble juvenile 
HD more than the adult form of the disease.25 An intriguing possibility is thus that juvenile HD patients 
might indeed exhibit more extensive pathology of the hypocretin system. In this study, we could measure 
hypocretin-1 levels in the prefrontal cortex of only one juvenile HD patient (Table 2). Surprisingly, this case 
appeared to have the highest levels of cortical hypocretin among all the HD patients studied. This finding may, 
however, be due to the stronger cortical atrophy that accompanies the juvenile variant of HD compared to the 
adult form of the disease .35 Second, the mild reduction in hypocretin in the YAC128 mice may be due to the 
fact that these mice, unlike the R6/2 mice and several human patients, were not (close to) end stage at the time 
of assessment (i.e. 12 months). Thus, several variables may confound the comparisons between various animal 
models and the human condition and should, therefore, be taken into consideration when comparing animal 
and human data.
Hypocretin deficiency is the primary pathophysiological cause of narcolepsy, a sleep-wake disorder 
characterized by excessive daytime sleepiness and REM-sleep dissociation phenomena such as cataplexy, 
i.e. a sudden weakening of posture muscle tone usually triggered by emotion.26 Although R6/2 mice exhibit 
episodes of behavioural arrest closely resembling those seen in hypocretin knock-out mice and transgenic 
mice with specific ablation of hypocretin-containing neurons,6,15 it remains to be shown whether the modest 
decrease of hypocretin-1 signalling in adult HD patients could contribute to clinical symptoms, particularly 
sleep disturbances.42 Unfortunately, due to the retrospective nature of our study we could not relate our post-
mortem findings to clinical signs and symptoms. This stresses the need for systematic post-mortem brain tissue 
collection of clinically well-documented patients for future neuropathological studies. 
In this report we also present an estimation of the total number of MCH neurons in the human brain and their 
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relative distribution with respect to hypocretin-1 neurons. Our results confirm those from a recent study38 
and suggest that MCH neurons are indeed more abundant in the human hypothalamus and have a wider 
rostro-caudal distribution than hypocretin-1 neurons, which is also in accordance with findings in rodents.1,37 
Even though MCH and hypocretin-1 neurons start to appear at about the same level rostrally, MCH neurons 
are relatively more abundant in the posterior hypothalamus. Whether this finding could be accounted for 
by the existence of several distinct MCH subpopulations along the rostro-caudal axis as opposed to a more 
homogenous hypocretin population1,37 remains to be elucidated. As we could not find a clear reduction in the 
number of MCH neurons in HD patients, alterations in MCH levels are unlikely to have clinical implications 
in HD.
In this study we have assessed neuronal numbers by counting immunopositive neurons by means of a 
technique that has been validated and applied previously.9,10,38 It should be stressed that it is in principle 
impossible to distinguish the loss of an immunocytochemical neuronal marker from the loss of the neurons 
in a heterogeneous and anatomically loosely defined brain structure such as the lateral hypothalamus. 
 
Interestingly, neuronal intranuclear and cytoplasmic inclusions were not uniformly present in various 
hypothalamic and adjacent structures in HD patients. This finding may indicate that various hypothalamic 
nuclei are differentially affected by inclusion formation despite their close anatomical juxtaposition in the 
hypothalamus. Elucidation of the underlying mechanisms of this heterogeneity may lead to better understanding 
of why certain neuronal populations are more susceptible to HD pathology than others.
In conclusion, we found a specific reduction by about 30% in hypocretin signalling in patients with HD. It 
remains to be shown whether this moderate decrease in hypocretin signalling could contribute to clinical 
symptoms. As MCH cell number was not clearly affected in HD patients, alterations in MCH neurotransmission 
are unlikely to have clinical effects in HD. 
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“The functions of the supra-renal capsules…are almost or altogether unknown. 
The large supply of blood which they receive from three separate sources; 
their numerous nerves, derived immediately from the semilunar ganglia and 
solar plexus; their early development in the foetus; their unimpaired integrity 
to the latest period of life; and their peculiar gland-like structure; all point to 
the performance of some important office.”
Thomas Addison On The Constitutional And Local Effects Of Disease Of The 
Supra-Renal Capsules. Samuel Highley, London, 1855. 
“The facts which Addison has published seem to lead to the conclusion that 
these little organs are essential to life.”
Charles Edouard Brown-Séquard Recherches expérimentales sur la 
physiologie et al pathologie des capsules surrénales. Archives Général de 
Médecine 1856(2); 385.
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ABSTRACT
Context: Huntington’s disease (HD) is a fatal hereditary neurodegenerative disorder characterized by motor, 
cognitive and behavioral disturbances. Hypothalamic-pituitary-adrenal (HPA) axis dysfunction could 
contribute to a number of HD signs and symptoms, however, no data are available on cortisol diurnal variations 
and secretory dynamics in HD patients. Objective: To perform a detailed analysis of HPA axis function in HD 
patients in relation to clinical signs and symptoms. Design, setting & participants: Twenty-four hour cortisol 
secretion was studied in eight early-stage, medication-free HD patients and eight age-, sex- and body mass 
index (BMI)-matched controls in a clinical research laboratory. Cortisol levels were measured every 10-min. 
Main outcome measures: Multi-parameter auto-deconvolution and cosinor regression were applied to quantify 
basal, pulsatile and total cortisol secretion rates as well as diurnal variations in cortisol levels. Results: Total 
cortisol secretion rate  and the amplitude of the diurnal cortisol profile were both significantly higher in HD 
patients compared with controls (3490 ± 320 vs. 2500 ± 220 nmol/L/24h, p = 0.023 and 111 ± 14 vs. 64 ± 8 
nmol/L, p = 0.012, respectively). Cortisol concentrations in patients were particularly increased in the morning 
and early afternoon period. In HD patients, mean 24 h cortisol levels significantly correlated with total motor 
score, total functional capacity as well as BMI. Conclusions: HPA axis hyperactivity is an early feature of HD 
and is likely to result from a disturbed central glucocorticoid feedback due to hypothalamic pathology. HPA 
axis dysfunction may contribute to some signs and symptoms in HD patients.
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat size in the gene encoding the protein huntingtin.1 The disease is characterized by chorea, 
cognitive deterioration, and psychiatric and behavioral problems.1 Other debilitating but less well-known 
features of HD are weight loss, sleep disturbances and autonomic nervous system dysfunction, the causes of 
which are poorly understood.2,3 However, as neuronal inclusions of mutant huntingtin, the neuropathological 
hallmark of HD, and substantial atrophy and cell loss have been reported in the hypothalamus of HD patients, 
neuroendocrine perturbations may be involved.2,4-6 
Recently, progressive alterations in the hypothalamic-pituitary-adrenal (HPA) axis function were reported in 
the R6/2 mouse, the most widely used transgenic model of HD.7 R6/2 mice show progressive increases in 
serum and urine corticosterone levels which is accompanied by a Cushing-like syndrome.7 Increased urine 
and serum cortisol levels have also been reported in HD patients.7-10 However, these studies applied a single 
or a few baseline measurements, which is clearly not adequate to assess either the pulsatile nature of cortisol 
secretion or its robust diurnal rhythmicity. Apart from mean levels, both the pulsatile secretion patterns and the 
diurnal variations are thought to be essential for normal hormone function.11 Indeed, substantial diurnal rhythm 
disturbances, attributed to aberrant signaling by the suprachiasmatic nucleus (SCN), have been described in 
both HD patients and animal models.12,13 As the activity of the suprachiasmatic nucleus, the body’s master 
clock, is accurately reflected in the diurnal fluctuations of plasma cortisol levels,14,15 we hypothesized that both 
the diurnal rhythmicity of plasma cortisol and its secretion pattern are likely to be perturbed in HD patients. 
We tested this hypothesis by applying circadian rhythmicity analysis and deconvolution of 24 h plasma cortisol 
concentration profiles in both early stage HD patients and healthy matched controls. 
SUBJECTS AND METHODS 
Subjects 
Eight early-stage HD patients and eight healthy control subjects, matched for age, sex, and body 
mass index (BMI), were enrolled in the study. Clinical details are summarized in Table 1. In the 
patient group, mutant CAG repeat size ranged between 41 and 50. The clinical diagnosis of HD 
was made by a neurologist specialized in movement disorders (R.A.C.R.). The Unified Huntington’s 
Disease Rating Scale (UHDRS) was used to assess HD symptoms and signs.16 All subjects were free 
of medication. Subjects were eligible for participation after exclusion of hypertension, any known 
(history of) pituitary disease, recent intentional weight change (>3 kg weight gain or loss within the 
last 3 months), and any other chronic conditions except HD. Written informed consent was obtained 
from all subjects. The study was approved by the ethics committee of the Leiden University Medical 
Center. 
Clinical protocol 
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Subjects were admitted to the Clinical Research Center for 24 h blood sampling. Two women (one 
patient and one control) were postmenopausal, the other women were studied in the early follicular 
phase of their menstrual cycle. A cannula was inserted into an antecubital vein 45 min before the start 
of blood sampling at 1630 h. Blood samples were collected with S-monovetten (Sarstedt, Etten-Leur, 
The Netherlands) from a three-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/ml) 
infusion (500 ml/24 h) to keep the cannula from clotting. Sampling was performed through a long 
line to prevent sleep disruption by investigative manipulations. During 24 h, blood was collected 
in serum tubes at 10-min intervals. Blood was allowed to clot and, within 60 min of sampling, all 
tubes were centrifuged at 4000 rotations/min at 4 ºC for 20 min, and plasma was stored at -80 ºC 
until assay. Three standardized meals were served at 0900, 1300, and 1900 h (Nutridrink, 1.5 kcal/
ml, 1500–1800 kcal/d; macronutrient composition per 100 ml: protein, 5 g; fat, 6.5 g; carbohydrate, 
17.9 g; Nutricia, Zoetermeer, The Netherlands). Subjects remained sedentary except for bathroom 
visits. Twenty-four hour urine was collected for the determination of creatinine, catecholamines and 
cortisol concentrations. No daytime naps were allowed. Lights were switched off at 2300 h and, the 
next morning, subjects were awakened at 0730 h. 
Body composition
Bioelectrical impedance analysis was used to assess lean body mass and fat percentage at 0800 h. 
Assays 
Plasma cortisol was measured by radioimmunoassay (GammaCoatTM, DiaSorin, Stillwater, Minnesota, 
USA). The detection limit of the assay was 25 nmol/L, and the interassay variation ranged from 2 
to 4%. Urine cortisol levels were assessed by the same assay after purification over a C18 column. 
Samples from each patient and matched control were handled in the same run. Urine creatinine was 
measured by a fully automated P 800 Modular system (Roche, Almere, the Netherlands). Urinary 
epinephrine, norepinephrine and dopamine concentrations were assessed by high performance liquid 
chromatography with electron capture detection (ESTA-Coulochem, Chelmsford, MA, USA).
Calculations and statistics 
Deconvolution analysis. A recently developed, fully automatic, multi-parameter deconvolution procedure, 
AutoDecon, was used to estimate various specific measures of secretion and plasma disappearance rate of 
cortisol, considering all plasma hormone concentrations and their dose-dependent intra-sample variance 
simultaneously.17 The AutoDecon process is a statistically based algorithm to test the significance of hormone 
secretion events, obviating the subjective nature of previously used deconvolution methods.17 Apart from the 
initial concentration and the basal secretion rate, which both were initialized to zero, the AutoDecon algorithm 
requires only two approximations of the parameter values that are to be estimated: (1) The standard deviation 
of the Gaussian-shaped secretion events (SecretionSD) which is generally initialized as half of the data-
sampling interval, and (2) a starting values for the elimination parameter, or hormone half-life.17 Thus, for 
10-min sampled data, the SecretionSD was initialized to 5-min together with a starting value for the cortisol 
half-life of 65-min.18 To account for intrinsic errors in the estimates of hormone secretion and removal rates, 
the AutoDecon algorithm was then used to find the best fits for both parameters.18 The following parameters 
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of the cortisol time series were estimated: number of secretory bursts, secretory burst half-duration (duration 
at half-maximal amplitude), mean mass secreted per burst, hormone half-life, basal secretion rate, pulsatile 
secretion rate, and total secretion rate.
Diurnal rhythmicity analysis. Twenty-four-hour variations in plasma cortisol concentrations were assessed by 
cosinor regression, an algorithm that fits a cosine function to the data using repeated nonlinear regression.19 This 
analysis estimates an acrophase, which is the clock time during the 24 h period at which hormone concentration 
is maximal; a mesor, which is the average value about which the diurnal rhythm oscillates; and an amplitude, 
which is half the difference between the peak and nadir values of the 24 h concentration series. Furthermore, in 
order to assess the effects of distinct circadian time frames on possible cortisol secretion differences between 
patients and controls more accurately, we divided the 24 h cortisol concentration series into six equal epochs in 
which we compared mean cortisol concentrations between patients and controls. The time epochs were defined 
as follows: (I) 1630 h – 2030 h, (II) 2030 h – 0030 h, (III) 0030 h – 0430 h, (IV) 0430 h – 0830 h, (V) 0830 
h – 1230 h, and (VI) 1230 h – 1630 h. 
Approximate entropy (ApEn). ApEn is a model-independent statistic used to quantify the regularity of a time 
series, in which is measured, within a predefined tolerance r given a pattern of window length m, the likelihood 
of a similar pattern in the next incremental window.20 Greater regularity yields smaller ApEn values, whereas 
greater independence among sequential values of a time series yields larger ApEn values. ApEn parameters 
of m = 1 and r = 20% of the intra-series standard deviation were used, the statistical suitability of which has 
been established previously.21 Data are also presented as normalized ApEn ratios, defined by the mean ratio of 
absolute ApEn to that of 1000 randomly shuffled versions of the same time series.  
Statistical analysis. Results are expressed as mean ± standard error (SE) unless otherwise specified. Unpaired 
t tests were used to assess group differences. Repeated measures analysis of variance (ANOVA) was used to 
compare mean cortisol levels between patients and controls during specific time epochs within the circadian 
cycle. Spearman’s correlation coefficient was applied to assess all correlations. All tests were two-tailed and 
significance level was set at p < 0.05. Statistical analyses were performed using SPSS for Windows (release 
14.0, SPSS, Inc., Chicago, IL). 
RESULTS 
Subjects 
The HD and the control group did not differ with respect to age, gender, BMI, body fat percentage, or 
lean body mass (all p ≥ 0.754, Table 1).  
Deconvolution analysis of cortisol time series
The average 24 h plasma cortisol concentration profiles of HD patients and controls are displayed in Figure 1. 
Illustrations of representative cortisol concentration profiles and corresponding secretion rate profiles in one 
HD and the matched control subject are presented in Figure 2. Deconvolution analysis showed that the total 24 
h cortisol secretion rate was significantly higher in HD patients compared with controls (3490 ± 320 vs. 2500 ± 
220 nmol/L/24 h, p = 0.023). In addition, there was also a trend for a higher total pulsatile cortisol secretion rate 
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(2830 ± 330 vs. 2060 
± 180 nmol/L/24 h, 
p = 0.058). Basal 
cortisol secretion 
rate, number of 
secretion bursts, and 
mean hormone mass 
secreted per burst all 
tended to be higher 
as well, although 
these measures did 
not reach statistical 
significance (p ≥ 
0.155). Details of 
all deconvolution-
derived cortisol 
secretory kinetics are presented in Table 2.
Diurnal rhythmicity analysis 
The results of the cosinor analysis of plasma 
cortisol concentration series are listed in Table 3. 
The acrophase of the cosine fit occurred in the early 
morning for both patients and controls and was 
not significantly different. However, the amplitude 
of the cosine function describing the diurnal 
plasma cortisol oscillations round the mean was 
significantly higher in HD patients compared with 
controls (111 ± 14 vs. 64 ± 8 nmol/L, p = 0.012). 
There was also a trend for a higher mesor in HD 
patients than in controls (p = 0.099). Repeated 
measures ANOVA demonstrated that the mean 
plasma cortisol concentrations were significantly 
higher in HD patients compared with controls 
during epochs V (i.e. 0830 h – 1230 h; 320 ± 20 vs. 
220 ± 20 nmol/L, p = 0.002) and VI (i.e. 1230 h – 
1630 h; 250 ± 20 vs. 160 ± 20 nmol/L, p = 0.007), 
but not during epochs I to IV (i.e. 1630 h – 0830 h; 
all p ≥ 0.133). Therefore, using the deconvolution 
best fit models, we estimated pulsatile and total 
cortisol secretion rates for epochs I-IV and V-VI 
separately. This analysis revealed that while pulsatile and total cortisol secretion rates did not significantly 
differ between HD and control subjects during the 1630 h to 0830 h period (pulsatile secretion: 1860 ± 290 vs. 
Table 1. Characteristics of the study population
HD patients† Controls† p-value‡
Male/female 5/3 5/3 -
Age (y) 46.3 (3.8) 47.6 (3.6) 0.804
BMI 23.9 (1.1) 24.2 (0.7) 0.829
Fat (%) 25.4 (2.8) 25.8 (2.7) 0.927
Lean body mass (kg) 57.1 (3.6) 55.5 (3.3) 0.754
BDI score 7.0 (1.8) 3.3 (0.8) 0.085
Mutant CAG repeat size 44.9 (1.0) - -
Disease duration (y) 5.1 (1.1) - -
UHDRS motor score 20.3 (6.4) - -
UHDRS behavioral score 10.5 (4.7) - -
TFC score 11.8 (0.8) - -
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by unpaired t-tests.
Abbreviations: BDI = Beck Depression Inventory; BMI = Body Mass Index; 
TFC = Total Functional Capacity; UHDRS = Unified Huntington’s Disease 
Rating Scale. 
Figure 1.  Mean plasma cortisol concentrations in 
HD and control subjects. Sampling started at 1630 
h and was continued at 10-min intervals for 24 h. 
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Table 2. Deconvolution analysis of 24 h plasma cortisol concentrations.
HD patients† Controls† p-value‡
Half-life (min) 69.5 ± 5.1 79.6 ± 5.1 0.187
Pulse half-duration 
(min)
22.1 ± 4.2 15.5 ± 3.2 0.241
Pulse frequency 
(no./24 h)
14.4 ± 1.3 14.1 ± 0.5 0.863
Mean mass secreted 
per pulse (nmol/L)
250 ± 30 200 ± 20 0.155
Basal production rate 
(nmol/L/24 h)
0.45 ± 0.13 0.31 ± 0.06 0.340
Pulsatile production 
rate (nmol/L/24 h)
2830 ± 330 2060 ± 180 0.058
Total production rate  
(nmol/L/24 h)
3490 ± 320 2500 ± 220 0.023*
Percent pulsatile (%) 81 ± 5.1 83 ± 3.4 0.760
†) Values are indicated as mean ± SE.
‡) Differences between groups were assessed by unpaired t-tests: * p < 0.05
Figure 2. Deconvolution analysis of cortisol time-series. The AutoDecon deconvolution analysis provided 
excellent fits to the data of individual subjects. Representative 24 h cortisol concentration profiles with fitted 
curves in a patient with HD (A) and the matched control subject (B). The lower panel depicts the corresponding 
deconvolution estimated secretory profiles in the same patient (C) and control (D).
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1540 ± 200 nmol/L/24 h, p = 0.382; total secretion: 2300 ± 290 vs. 1840 ± 210 nmol/L/24 h, p = 0.277), they 
were almost two-fold higher in HD patients during the 0830 h to 1630 h period (pulsatile secretion: 970 ± 90 
vs. 510 ± 60 nmol/L/24 h, p = 0.001; total secretion: 1190 ± 80 vs. 660 ± 70 nmol/L/24 h, p << 0.001). 
Regularity of plasma cortisol concentration time series
The ApEn values of the plasma cortisol time series in HD patients were not significantly different from those 
in controls (0.94 ± 0.08 vs. 0.90 ± 0.06, p = 0.673). The same held for ApEn ratios (0.51 ± 0.04 vs. 0.49 ± 0.03, 
p = 0.789).  
Urine analysis
Urine cortisol levels were also higher in HD patients, although the difference failed to reach statistical 
significance due to substantial inter-individual variability (114 ± 26 vs. 82 ± 13 nmol/L; p = 0.302). There were 
no significant differences in urinary adrenalin, noradrenalin and dopamine levels (all p ≥ 0.10).
Cortisol levels in relation to clinical 
phenotype
In HD patients, mean 24 h cortisol 
concentration significantly correlated with 
total motor score, total functional capacity 
and BMI (Table 4).  
Cortisol levels in relation to mutant CAG 
repeat size
Although mutant CAG repeat size was not 
significantly related to mean cortisol levels 
(Table 4), it did significantly correlate with both 
24 h pulsatile cortisol secretion rate (r = 0.76, p = 
Table 4. Clinical correlates of cortisol levels in 
Huntington’s disease patients
Mean 24 h cortisol level 
[nmol/L]†
Motor score 0.74 (0.037) *
Behavioral score -0.11 (0.779)
BDI score 0.15 (0.733)
TFC -0.88 (0.004) **
BMI -0.52 (0.037) *
CAG repeat size 0.20 (0.643)
†) Values are indicated as Spearman’s (p-value): * p 
< 0.05, ** p < 0.01
Abbreviations: AUC = Area Under the Curve; BDI 
= Beck Depression Inventory; BMI = Body Mass 
Index; TFC = Total Functional Assessment; UHDRS 
= Unified Huntington’s Disease Rating Scale. 
Table 3. Cosinor analysis of diurnal cortisol concentrations.
HD patients† Controls† p-value‡
Amplitude (nmol/L) 111 ± 14 64 ± 8 0.012*
Mesor (nmol/L) 233 ± 24 186 ± 11 0.099
Acrophase (hh:mm) 07:26 ± 01:46 05:25 ± 02:19 0.503
†) Values are indicated as mean ± SE.
‡) Differences between groups were assessed by unpaired t-tests: * p < 0.05
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0.030) and pulse half duration (r = 0.85, p = 0.007). There were also trends for the associations between CAG 
repeat size and mean cortisol mass secreted per burst (r = 0.68, p = 0.062) and total 24 h cortisol secretion rate 
(r = 0.61, p = 0.108).
 
DISCUSSION
We present the first detailed description of cortisol secretory dynamics in patients with HD. We found 
that the total 24 h cortisol production rates were significantly elevated in HD patients. The increase 
in cortisol production was primarily confined to the morning and early afternoon period. In addition, 
circadian rhythmicity analysis revealed a significantly higher amplitude of the diurnal cortisol 
concentration profile in HD patients. These findings point towards a disturbed central glucocorticoid 
feedback regulation in HD patients and indicate that HPA axis dysfunction is an early feature of the 
disease.
The negative feedback inhibition of cortisol production is regulated by two receptor subtypes in the brain: The 
high-affinity mineralocorticoid receptors (MRs) in the hippocampus that determine basal cortisol levels, and 
the low-affinity glucocorticoid receptors (GRs) in the hypothalamus (primarily the paraventricular nucleus 
(PVN)), pituitary, cortex and elsewhere in the brain, that constrain cortisol secretion during the circadian peak 
or acute stress.22 Cortisol preferentially binds to high-affinity receptors before filling low-affinity receptors.23 
Therefore, the effect of MRs predominates in the early nocturnal period when cortisol levels are low, whereas 
the effect of GRs dominates in the morning, when cortisol levels are highest.22 As in HD patients the differences 
in cortisol levels were mainly confined to the morning and early afternoon period, disturbed GR function is 
likely to underlie increased cortisol production in HD patients. Our hypothesis of diminished hypothalamic 
feedback as the primary cause of elevated plasma cortisol levels in HD patients would imply either decreased 
regularity (i.e. increased ApEn) of plasma cortisol concentration time series and/or decreased coupling between 
ACTH and cortisol secretion.24 As cortisol ApEn did not differ between HD patients and controls, our findings 
are consistent with decreased coupling between ACTH and cortisol secretion in HD, however, additional 
experiments are required to confirm or refute this hypothesis.
Impaired GR function may result from pathology of brain structures enriched in GRs, such as the hypothalamic 
PVN. Indeed, there are indications for PVN pathology in HD,25,26 although additional quantitative morphometric 
studies are needed to pinpoint its exact nature.2 Transcriptional dysregulation caused by mutant huntingtin might 
also play a role, while direct interaction of GRs with mutant huntingtin is unlikely as suggested by Diamond 
et al. 27 In turn, loss of GR function may aggravate HD pathology as aggregation and nuclear localization of 
mutant huntingtin fragments containing the expanded polyglutamine stretch can be modulated by the GR, a 
well-characterized transcriptional regulator.27The increased diurnal amplitude of plasma cortisol levels in HD 
patients is also likely to be centrally mediated, resulting from pathology of hypothalamic structures directly 
involved in the autonomic innervation of the adrenal cortex, namely the PVN and the SCN.14,28 Utilizing a 
neuronal pathway between the SCN, the parvocellular subdivision of the PVN (containing both autonomic 
and CRH neurons), and the adrenal cortex,28,29 the SCN is thought to exert an inhibitory effect on cortisol 
release.30 Indeed, apart from PVN pathology,2 there are also indications that the SCN is affected in HD. Marked 
disruption of expression of the circadian clock genes mPer2, mBmal1, and prokineticin 2 in the SCN have been 
reported in the R6/2 mouse model of HD.12,13 Furthermore, the expression levels of both vasoactive intestinal 
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polypeptide  and its receptor VPAC2 in the SCN were recently shown to be decreased in the R6/2 mice.31
Our findings extend previous reports of increased cortisol levels in HD patients7,9,10 and indicate that elevated 
plasma cortisol levels in HD subjects are secondary to a higher pulsatile cortisol production. Moreover, we 
found that pulsatile cortisol secretion, which is secondary to pulsatile ACTH release and is thus thought to 
reflect intermittent hypothalamic drive,11 correlated with mutant CAG repeat size in HD patients. This finding 
suggests that increased cortisol secretion in HD is likely to result from central interference of the genetic 
mutation with HPA axis function rather than being secondary to other neuropsychiatric features of the disease. 
Even mildly elevated cortisol levels are associated with a number of clinically significant health effects as 
illustrated by findings of, e.g.,  plasma lipid disturbances, hypertension, insulin resistance, and impaired 
cognition in patients with subclinical Cushing’s syndrome and major depressive disorder in whom cortisol 
elevations are not as great as in the classic Cushing’s syndrome.32-34 Therefore, despite the absence of obvious 
Cushingoid features in HD patients, increased cortisol production is likely to adversely affect their health. 
Moreover, although our patients were all in an early stage of the disease, we found significant correlations 
between mean 24 h plasma cortisol levels and the UHDRS total motor score, total functional capacity and BMI, 
indicating that increases in cortisol levels are likely to be progressive and may become even more clinically 
relevant in the latter stages of the disease. Indeed, HD patients exhibit a number of symptoms and signs that 
might partly be attributed to hypercortisolism, such as memory deficits, mood disturbances, skeletal muscle 
atrophy, impaired glucose tolerance and decreased hippocampal volume.35-39 However, larger scale studies are 
needed to confirm an association between high cortisol levels and clinical phenotype in HD patients. This is 
important as antiglucocorticoid therapy may also hold therapeutic potential for HD patients.40
Limitations of this study are the absence of detailed data on ACTH secretion, and dynamic tests exploring the 
integrity of the HPA axis. Therefore, additional experiments exploring the 24 h ACTH secretion characteristics 
in association with cortisol levels are required and would thus allow for the calculation of the feedback and 
feed-forward coupling by the cross-ApEn metrics.11 In addition, challenge tests such as the dexamethasone 
suppression test and the CRH test are needed to more fully assess feedback and/or feed-forward effects at 
various levels of control within the HPA ensemble in HD patients.11
In conclusion, we found that cortisol production rate is specifically increased in the morning and early 
afternoon period in early-stage, medication-free HD patients. Our findings indicate disturbed central 
glucocorticoid feedback in HD patients, which is likely to result from pathology of the SCN and PVN nuclei 
of the hypothalamus.  
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ABSTRACT
Background: Huntington’s disease (HD) is a fatal hereditary neurodegenerative disorder caused by an increased 
CAG repeat size in the huntingtin gene. Apart from neurological impairment, the disease is also accompanied 
by progressive weight loss, abnormalities in glucose homeostasis and a higher prevalence of diabetes mellitus, 
which may partly be caused by disturbed growth hormone (GH) and ghrelin secretion. Therefore, we aimed 
to perform a detailed analysis of GH and ghrelin secretion in HD patients in relation to clinical signs and 
symptoms. Methods: In nine early-stage, medication-free HD patients and nine age-, sex- and body mass index 
(BMI)-matched controls, we measured serum GH levels every 10 min for 24 h and assessed ghrelin response 
to food intake. Multi-parameter auto-deconvolution and approximate entropy analysis were applied to quantify 
basal, pulsatile and total GH secretion rates as well as the regularity of GH secretion. Results: We found no 
significant differences in GH and ghrelin secretion characteristics between HD patients and controls (total 
GH secretion: 137 ± 36 vs. 181 ± 43 mU/L/24h, respectively; p=0.439). However, in HD patients, both GH 
secretion and its irregularity as well as the degree of postprandial ghrelin suppression significantly increased 
with worsening motor and functional impairment (all p<0.05). Moreover, postprandial ghrelin suppression 
also increased with decreasing body weight and higher CAG repeat number (both p<0.05). Conclusions: These 
findings suggest changes in the regulation of GH and ghrelin secretion dynamics in early stage HD patients that 
could become more prominent in the later stages of the disease. 
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Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat size in the gene encoding the protein huntingtin.1 The disease is characterized by 
motor disturbances, cognitive deterioration, and psychiatric and behavioural problems.1 Progressive weight 
loss and muscle wasting are also hallmarks of the disease, both in HD patients 2-6 and several transgenic 
mouse models of the disease.7,8 Moreover, profound abnormalities in glucose homeostasis as well as a higher 
prevalence of diabetes mellitus have been reported in HD patients, which are also evident in the transgenic 
models.9,10 The cause of these peripheral signs is largely unknown, although hypothalamic dysfunction, and 
subsequent endocrine alterations may be involved.2,11
The somatotropic axis, which plays an essential role in body energy homeostasis, is among the hypothalamic-
endocrine axes that could be affected in HD.2,11 Exaggerated growth hormone (GH) responses have been 
observed following administration of L-dopa12, apomorphine13, bromocriptine14, arginine15,16, insulin17-19 
and muscimole13, whereas paradoxical GH responses have been reported after glucose12,20-22, L-dopa20 or 
bromocriptine20,23 administration. Increased mean serum GH concentrations have also been found in HD 
patients 24,25. However, others have not been able to detect abnormalities in GH release.21,26 These discrepancies 
are likely due to the use of a few baseline measurements of GH levels or long blood sampling intervals which 
are not adequate to assess either the pulsatile nature of GH secretion or its total daily production.27 
Elevated plasma levels of ghrelin, an orexigenic hormone of gastric origin which stimulates GH release,28 have 
also been reported in HD patients.29,30 Ghrelin, like GH, is an endogenous regulator of energy homeostasis; 
ghrelin levels increase with fasting and fall postprandially, thereby signaling mealtime hunger and satiety to 
the brain.28,31 However, the relation between GH and ghrelin secretion, as well as the association between 
postprandial ghrelin suppression and clinical phenotype has not been investigated in HD patients. 
We postulated that GH secretion patterns are likely to be perturbed in HD patients. Moreover, as GH has 
profound effects on fat and muscle tissue, we hypothesized that  the total daily GH production in HD patients 
would be associated with body weight, as well as fat and lean body mass. In addition, we postulated that ghrelin 
secretion and its relation to GH levels and clinical phenotype may be perturbed in HD patients. We tested these 
hypotheses by deconvolution analysis of 24 h serum GH concentration profiles and simultaneous assessment 
of plasma ghrelin response to food intake in both early stage HD patients and healthy matched controls. 
SUBJECTS AND METHODS 
Subjects 
Nine early-stage HD patients and nine healthy control subjects, matched for age, sex, and body mass index 
(BMI), were enrolled in the study. Clinical details are summarized in Table 1. In the patient group, mutant CAG 
repeat size ranged between 41 and 50. The clinical diagnosis of HD was made by a neurologist specialized in 
movement disorders (R.A.C.R.). The Unified Huntington’s Disease Rating Scale (UHDRS) was used to assess HD 
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symptoms and signs.32 
None of the subjects 
used medication, except 
one HD patient who 
discontinued paroxetine 
use three weeks prior 
to study. Subjects were 
eligible for participation 
after exclusion of 
hypertension, any 
known (history of) 
pituitary disease, recent 
intentional weight 
change (>3 kg weight 
gain or loss within the 
last 3 months), and any 
other chronic conditions 
except HD as assessed by clinical examination and routine laboratory tests. Written informed consent was 
obtained from all subjects. The study was approved by the ethics committee of the Leiden University Medical 
Center.
Clinical protocol 
Subjects were admitted to the Clinical Research Center for 24 h blood sampling. Two women (one 
patient and one control) were postmenopausal, the other women were studied in the early follicular 
phase of their menstrual cycle. A cannula was inserted into an antecubital vein 45 min before the start 
of blood sampling at 1630 h. Blood samples were collected with S-monovetten (Sarstedt, Etten-Leur, 
The Netherlands) from a three-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/ml) 
infusion (500 ml/24 h) to keep the cannula from clotting. Sampling was performed through a long line 
to prevent sleep disruption by investigative manipulations. During 24 h, blood was collected in serum 
tubes at 10-min intervals for GH measurements. From 0840 h to 1100 h ― i.e. 20 min before to 2 
h after the start of breakfast which was consumed between (but not including) 0900 and 0920 h ― 
blood was also collected in separate EDTA tubes for the assessment of ghrelin levels. While blood in 
the serum tubes was allowed to clot, the EDTA tubes were immediately put on ice. Within 60 min of 
sampling, all tubes were centrifuged at 4000 rotations/min at 4 ºC for 20 min, and serum and plasma 
were stored at -80 ºC until assay. Three standardized meals were served at 0900, 1300, and 1900 h 
(Nutridrink, 1.5 kcal/ml, 1500–1800 kcal/d; macronutrient composition per 100 ml: protein, 5 g; fat, 
6.5 g; carbohydrate, 17.9 g; Nutricia, Zoetermeer, The Netherlands). Subjects remained sedentary 
except for bathroom visits. Twenty-four hour urine was collected for the determination of creatinine 
and catecholamines concentrations. No daytime naps were allowed. Lights were switched off at 2300 
h and, the next morning, subjects were awakened at 0730 h. 
Table 1. Characteristics of the study population
HD patients† Controls† p-value‡
Male/female 6/3 6/3 -
Age [y] 47.1 (3.4) 48.6 (3.3) 0.764
BMI 24.1 (1.0) 24.3 (0.6) 0.876
Fat [%] 25.5 (2.4) 25.6 (2.4) 0.985
Lean body mass [kg] 57.3 (3.2) 56.2 (3.0) 0.800
Waist-to-hip ratio 0.89 (0.03) 0.94 (0.02) 0.147
Mutant CAG repeat size 44.4 (1.0) - -
Disease duration [y] 5.7 (1.1) - -
UHDRS motor score 22.2 (6.0) - -
TFC score 11.7 (0.7) - -
Functional Assessment 23.3 (0.7) - -
Independence score 94.4 (2.8) - -
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by unpaired t-tests.
Abbreviations: BMI = Body Mass Index; FAS = Functional Assessment; TFC 
= Total Functional Capacity; UHDRS = Unified Huntington’s Disease Rating 
Scale. 
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Body composition
Bioelectrical impedance analysis was used to assess lean body mass and fat percentage at 0800 h. 
Assays 
Serum GH was measured by time-resolved fluoroimmunoassay (DELFIA® hGH, PerkinElmer Life 
and Analytical Sciences, Wallac Oy, Turku, Finland). The detection limit of the assay was 0.03 mU/L, 
and the interassay variation ranged from 1.6 to 8.4%. Plasma total ghrelin levels were measured by 
radioimmunoassay (LINCO Research, St. Charles, MO, USA) with a detection limit of 93 pg/mL, 
and an interassay variation ranging from 14.7 to 17.8%. Samples from each patient and matched 
control were handled in the same run. Total serum insulin-like growth factor (IGF)-1 and insulin-like 
growth factor binding protein (IGFBP)-3 concentrations were also measured by radioimmunoassay 
as previously described.33 Glycosylated hemoglobin (HbA1c) levels were measured with an high 
performance liquid chromatography (HPLC) system (Variant, Biomed, Hercules, CA, USA). 
Urine creatinine was measured by a fully automated P 800 Modular system (Roche, Almere, the 
Netherlands). Urinary epinephrine, norepinephrine and dopamine concentrations were assessed by 
HPLC with electron capture detection (ESTA-Coulochem, Chelmsford, MA, USA).
Calculations and statistics 
Deconvolution analysis. A recently developed, fully automatic, multi-parameter deconvolution procedure, 
AutoDecon, was used to estimate various specific measures of secretion and serum disappearance rate of GH, 
considering all serum hormone concentrations and their dose-dependent intra-sample variance simultaneously.34 
The AutoDecon process is a statistically based algorithm to test the significance of hormone secretion events, 
obviating the subjective nature of previously used deconvolution methods.34Apart from the initial concentration 
and the basal secretion rate, which both were initialized to zero, the AutoDecon algorithm requires only two 
approximations of the parameter values that are to be estimated: (1) The standard deviation of the Gaussian-
shaped secretion events (SecretionSD) which is generally initialized as half of the data-sampling interval, and 
(2) a starting value for the elimination parameter, or hormone half-life.34 Thus, for 10-min sampled data, the 
SecretionSD was initialized to 5-min together with a starting value for the GH half-life of 16-min.35 To account 
for intrinsic errors in the estimates of hormone secretion and clearance rates, the AutoDecon algorithm was then 
used to find the best fits for both parameters.35 The following parameters of the GH time series were estimated: 
number of secretory bursts, secretory burst half-duration (duration at half-maximal amplitude), mean mass 
secreted per burst, hormone half-life, basal secretion rate, pulsatile secretion rate, and total secretion rate.
Diurnal rhythmicity analysis. To assess the effects of distinct circadian time frames on possible GH secretion 
differences between patients and controls, we divided the 24 h GH concentration series into six equal epochs 
in which we compared mean GH concentrations between patients and controls. The time epochs were defined 
as follows: I, 1630 h to 2030 h; II, 2030 h to 0030 h; III, 0030 h to 0430 h; IV, 0430 h to 0830 h; V, 0830 h to 
1230 h; and VI, 1230 h to 1630 h.
Approximate entropy (ApEn). ApEn is a model-independent statistic used to quantify the regularity of a time 
series, in which is measured, within a predefined tolerance r given a pattern of window length m, the likelihood 
of a similar pattern in the next incremental window.36 Greater regularity yields smaller ApEn values, whereas 
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greater independence among sequential values of a time series yields larger ApEn values. ApEn parameters 
of m = 1 and r = 20% of the intra-series standard deviation were used, the statistical suitability of which has 
been established previously.36 Data are also presented as normalized ApEn ratios, defined by the mean ratio of 
absolute ApEn to that of 1000 randomly shuffled versions of the same time series.  
Statistical analysis. Results are expressed as mean ± standard error (SE) unless otherwise specified. Unpaired 
t tests and repeated measures analysis of variance (RM-ANOVA) were used to assess differences in means 
between the two groups. Pearson’s correlation coefficient was applied to assess all correlations. The effects 
of group and time on total ghrelin levels were also tested using RM-ANOVA..All tests were two-tailed and 
significance level was set at p < 0.05. Statistical analyses were performed using SPSS for Windows (release 
16.0, SPSS, Inc., Chicago, IL). 
RESULTS 
Subjects 
The HD and the control group did not differ with respect to age, sex, BMI, body fat or lean body 
mass (all p ≥ 0.15 , Table 1). There were also no significant differences in serum HbA1c or urinary 
creatinine, epinephrine, norepinephrine and dopamine levels (all p ≥ 0.10).
Deconvolution analysis of GH time series
Mean 24 h GH concentrations were not significantly different between HD patients and controls (2.20 ± 
0.54 vs. 2.83 ± 0.59 mU/L, p = 0.441; Figure 1). This was also the case when each of the six circadian 
time frames was analyzed separately (all p ≥ 0.276 by 
RM-ANOVA). The number of GH pulses as well as 
basal, pulsatile and total GH secretion rates tended to 
be lower in HD patients, but the differences did not 
reach statistical significance (all p ≥ 0.077). Details 
of all deconvolution-derived GH secretory kinetics 
are presented in Table 2. Total 24 h GH production 
was not significantly associated with HbA1c levels in 
either patients or controls.
Regularity of serum GH concentration time series
The ApEn values of the serum GH time series were 
not significantly different between HD patients and 
controls (0.45 ± 0.07 vs. 0.52 ± 0.07, p = 0.488). The 
same held for ApEn ratios (0.39 ± 0.03 vs. 0.41 ± 0.03, 
p = 0.681). However, only in HD patients GH ApEn 
Figure 1.  Mean serum GH concentrations in 
HD and control subjects. Sampling started at 
1630 h and was continued at 10-min intervals 
for 24 h. 
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values significantly correlated with GH mean levels (r = +0.78, p = 0.013), number of secretion bursts (r = 
+0.70, p = 0.039), total pulsatile secretion (r = +0.86, p = 0.003) and total secretion (r = +0.87, p = 0.002), 
while none of these relations was significant in controls (all p ≥ 0.227). Results were similar when ApEn ratios 
were used instead of ApEn values (data not shown).
IGF-1 and IGFBP3 levels
There were no significant differences between HD patients and controls in mean serum levels of 
either IGF-1 (19.01 ± 1.25 vs. 20.32 ± 2.75 nmol/L, p = 0.671) or IGFBP3 (3.97 ± 0.23 vs. 3.47 ± 0.21 
nmol/L, p = 0.131). There was a trend for the association between IGF-1 and HbA1c levels in HD patients (r 
= +0.63, p = 0.068), but not in controls (r = +0.10, p = 0.791).
Ghrelin levels
Baseline ghrelin levels (defined as the mean concentration of ghrelin in three samples obtained 
immediately before breakfast) were not significantly different between HD and control subjects (922 
± 94 vs. 784 ± 86 pg/mL, p = 0.297), neither were mean ghrelin levels after meal consumption (731 
± 67 vs. 635 ± 51 pg/mL, p = 0.271). Ghrelin levels significantly decreased after the start of meal 
consumption (RM-ANOVA: F(11) = 40.760 and p << 0.001 for the time effect), but there was no 
group × time interaction effect (F(11) = 0.718 and p = 0.720) indicating similar rates of decrease in 
ghrelin levels between HD patients and controls (Figure 2). However, while mean ghrelin levels 
before and after breakfast did not correlate with GH secretion in either patients or controls, only in 
HD patients the ratio of post- to preprandial ghrelin levels was inversely related to GH mean levels (r 
Table 2. Deconvolution analysis of 24 h serum GH concentrations.
HD patients† Controls† p-value‡
Half-life (min) 15.4 ± 1.1 15.5 ± 1.1 0.996
Pulse half-duration 
(min)
28.6 ± 4.0 27.2 ± 2.1 0.775
Pulse frequency 
(no./24 h)
14.6 ± 1.8 18.1 ± 0.5 0.077
Mean mass secreted 
per pulse (mU/L)
9.1 ± 1.9 9.7 ± 2.6 0.865
Basal production rate 
(mU/L/24 h)
4.9 × 10-3 ± 9.3 × 10-4 7.7 × 10-3 ± 2.7 × 10-3 0.354
Pulsatile production 
rate (mU/L/24 h)
130 ± 35 170 ± 40 0.459
Total production rate  
(mU/L/24 h)
137 ± 36 181 ± 43 0.439
Percent pulsatile (%) 93 ± 1.8 94 ± 0.9 0.623
†) Values are indicated as mean ± SE.
‡) Differences between groups were assessed by unpaired t-tests: * p < 0.05
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= -0.78, p = 0.014), total pulsatile secretion 
(r = -0.87, p = 0.002) and total secretion (r 
= -0.87, p = 0.002); i.e. postprandial ghrelin 
suppression was greater in HD patients with 
high GH secretion (Figure 3). On the other 
hand, the later relations were all positive and 
non-significant in controls (r between +0.33 and 
+0.49, all p ≥ 0.177) (Figure 3). Likewise, the 
ratio of post- to preprandial ghrelin levels was 
significantly associated with GH ApEn values 
in HD patients (r = -0.69, p = 0.038), but not 
in controls (r = -0.18, p = 0.647); i.e. greater 
postprandial ghrelin suppression was associated 
with more irregular GH secretion in HD. Ghrelin 
levels were not related to HbA1c levels in either 
patients or controls (all p ≥ 0.532).
GH secretion in relation to clinical 
phenotype
Greater daily GH secretion was significantly 
associated with a lower body weight in both 
HD patients and controls (Table 3). However, only in HD patients a higher GH secretion rate was also 
associated with a lower lean body mass. Moreover, in HD patients a higher total daily GH secretion 
rate was significantly related to a greater degree of motor as well as functional impairment (Table 3), 
while there was a trend for the association 
with CAG repeat size (r = +0.63, p =0.072). 
Similarly, higher GH ApEn values were 
associated with more severe scores on the 
UHDRS motor (r = +0.79, p = 0.012), total 
functional capacity (r = -0.89, p = 0.001), 
functional assessment (r = -0.84, p = 0.004), 
and independence (r = -0.92, p < 0.001) 
scales (Figure 4); results were similar when 
ApEn ratios were used instead of ApEn values 
(data not shown).
Ghrelin secretion in relation to clinical 
phenotype
Fasting ghrelin levels were not significantly 
associated with clinical phenotype, except for 
a significant inverse association with lean body 
Figure 2.  Mean plasma ghrelin concentrations 
before and after food intake in HD and control 
subjects. Ghrelin levels were measured every 10 min 
from 0840 h to 1100 h (i.e. 20 min before to 2 h after 
the start of breakfast which was consumed between 
0900 and 0920 h (gray and black arrow, respectively).
Figure 3.  Postprandial ghrelin suppression and GH 
secretion. Only in HD patients, postprandial ghrelin 
suppression was significantly associated with daily GH 
production (r = -0.87, p = 0.002).
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mass in controls (r 
= - 0.68, p = 0.043). 
However, a number 
of differences 
became apparent 
between HD patients 
and controls when 
the ratio between 
post- to preprandial 
ghrelin levels was 
assessed. In controls, 
this ratio was 
negatively associated 
with body fat mass, 
whereas in HD 
patients this ratio was 
positively, although 
not significantly, 
associated with body fat (Table 3). Conversely, in HD patients, but not in controls, the post- to preprandial 
ghrelin ratio significantly increased with higher body weight; i.e. postprandial ghrelin suppression was smaller 
in patients with a higher body weight. Moreover, in HD patients this ratio was also significantly related to the 
length of the CAG repeat mutation, as well as the degree of motor and functional impairment; i.e. postprandial 
ghrelin levels decreased relatively more in HD patients with a higher CAG repeat number, and a greater degree 
of motor and functional impairment (Table 3).
 DISCUSSION
In this study we present the first detailed 
description of 24 h GH secretory dynamics 
in patients with HD. In addition, we provide a 
detailed description of ghrelin release in relation 
to food intake and GH secretion in these patients. 
Although mean GH and ghrelin secretion 
characteristics were not different between early 
stage HD patients and controls, there were 
interesting differences between the groups in 
the way GH and ghrelin secretion were related 
to body composition. Moreover, various GH and 
ghrelin secretion characteristics were related 
to disease severity in HD patients. Thus, our 
findings indicate subtle changes in the regulation 
of GH and ghrelin secretion dynamics in early 
stage HD patients that are likely to become more 
pronounced in the later stages of the disease.
Table 3. Clinical correlates of GH and ghrelin secretion in Huntington’s 
disease patients and 
controls
  
GH 
(total 24 h secretion)
Ghrelin 
(post-/preprandial ratio)
HD patients† Controls† HD patients† Controls†
Body weight [kg] -0.83** -0.84** 0.79* 0.02
BMI [kg/m²] -0.55 -0.86 ** 0.59 -0.57
Fat mass [kg] -0.36 -0.54 0.43 -0.78*
Lean body mass [kg] -0.67 * -0.50 0.58 0.53
CAG repeat size 0.63 - -0.69* -
Motor score 0.75 * - -0.68* -
TFC -0.92 ** - 0.82** -
FAS -0.93 ** - 0.87** -
IS -0.91 ** - 0.78* -
†) Values are indicated as Pearson’s correlation coefficients: * p < 0.05, ** p < 0.01.
Abbreviations: BMI = Body Mass Index; FAS = Functional Assessment; GH = 
growth hormone; HD = Huntington’s disease; IS = Independence Score; TFC = 
Total Functional Capacity. 
Figure 4.  GH secretion regularity and functional 
capacity. In HD patients, GH secretion becomes less 
regular (i.e. the approximate entropy increases) with 
decreasing total functional capacity (r = -0.89, p = 
0.001). 
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The regulation of GH secretion is a complex process.37 Most GH secretion occurs in pulses which are generated 
by interactions among  GH-releasing hormone (GHRH), ghrelin and somatostatin under negative feedback 
control by both GH and IGF-1.37 GHRH and somatostatin are secreted by specialized and interconnected 
mediobasal and periventricular neurons into hypophyseal portal blood and then transported to the anterior 
pituitary gland where GHRH stimulates and somatostatin inhibits GH release. Systemic GH and IGF-1 
exert negative feedback on GH secretion primarily via hypothalamic actions, which enhance the secretion of 
somatostatin and limit the release of GHRH.37 Ghrelin further amplifies GH release by acting on GH-secreting 
cells in the pituitary, as well as GHRH and somatostatin neurons in the hypothalamus.37
We found no major differences in GH secretion characteristics between our group of HD patients and controls. 
Therefore, it can be assumed that the system giving rise to  pulsatile GH release is relatively intact in early stages 
of HD. However, there were strong associations between disease severity and GH secretion in the HD group. 
In addition, the regularity of GH secretion decreased (increasing ApEn) with worsening clinical phenotype 
in these patients, indicating that also the feedback control of GH release becomes less tight with continuing 
disease progress. A recent study in more advanced HD patients indeed found comparatively larger differences 
in both GH and IGF-1 levels than we found in our cohort of early stage patients.38 These findings, therefore, 
suggest that the intricate interplay between GHRH and somatostatin neurons and their responsiveness to GH, 
IGF-1 and ghrelin is likely to become deranged with disease progression. Deregulated GH secretion is thus 
likely to underlie the exaggerated and paradoxical GH responses that have been reported previously in later 
stage HD patients.12-23 
Ghrelin secretion is thought to be triggered by the sympathetic nervous system,31 whereas as yet unidentified 
postgastric feedback mechanisms transmitting visceral information to the brain appear to underlie meal-
related suppression of plasma ghrelin.39 These ghrelin secretion pathways seem to be relatively spared in 
early stages of HD as fasting ghrelin levels as well as postprandial suppression of ghrelin release were not 
significantly different between early stage patients and controls. Importantly, however, while body fat mass 
was inversely associated with postprandial ghrelin suppression in controls, this relation was reversed in HD 
patients, accounting for the positive association between body weight and postprandial ghrelin suppression in 
this group. Moreover, postprandial ghrelin suppression also increased with a higher number of CAG repeats 
in the mutant huntingtin gene. These finding are interesting in view of our recent discovery of an increased 
rate of weight loss in both HD patients and R6/2 transgenic mice with higher CAG repeat number3; as ghrelin 
is a potent stimulator of food intake,40 stronger inhibition of postprandial ghrelin release in HD patients with 
higher CAG repeat sizes may lead to less energy intake and, thereby, contribute to the increased rate of weight 
loss in these subjects.3 Apart from CAG repeat size, more severe motor as well as functional impairment 
were also associated with a greater degree of postprandial ghrelin suppression, suggesting that despite the 
relative preservation of the mechanisms involved in ghrelin release in early stages of HD, ghrelin secretion 
may become deregulated in the later stages of the disease. 
Ghrelin is the endogenous ligand of the GH secretagogue receptors and stimulates GH secretion when 
administered peripherally or centrally.40 Nevertheless, ghrelin is thought not to be physiologically involved in 
the regulation of GH secretion, since its circulating levels are not correlated with those of GH.41 Accordingly, 
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in our control group we found no significant associations between ghrelin and GH secretion characteristics. In 
the HD group, however, a greater degree of postprandial ghrelin suppression was associated with both higher, 
as well as more irregular GH secretion. These findings suggest that, in the context of HD, the GH secretory 
ensemble may become increasingly sensitive to peripheral signals such as ghrelin. 
Progressive pathology of structures involved in the regulation of both GH and ghrelin secretion, particularly 
the GHRH and somatostatin neurons in the hypothalamus, may account for our findings.2,11 Somatostatin 
immunoreactivity is indeed greatly reduced in the lateral tuberal nucleus of HD patients.42 However, since the 
somatostatin neurons in the periventricular nucleus are thought to be primarily involved in the neurohumoral 
regulation of GH secretion,43 further neuropathological studies are warranted to assess to what extent these 
neurons are affected in HD. Also a reduced number of hypocretin (also known as orexin) neurons has been 
found in the lateral hypothalamus of HD patients.43-45 As plasma ghrelin can interact with hypocretin neurons46 
and hypocretin can inhibit GH secretion,47 progressive loss of hypocretin neurons may also account for the 
association between deregulated GH and ghrelin secretion and disease severity in our cohort of HD patients. 
A potential limitation of our study could be the assessment of hormone levels during one circadian cycle. 
However, considering that HD is a slowly progressive disorder and that homeostatic control mechanisms within 
the human somatotropic axis strongly preserve the day to day pattern of GH release across a wide spectrum 
of ages and body compositions,48,49 our results are unlikely to have been affected by the assessment of only 
one circadian cycle. Another potential limitation of our study is the relatively small number of participants. 
Nevertheless, this limitation is offset by the rigorous assessment and modeling of diurnal hormone secretion 
patterns which is unfeasible in larger groups of subjects.  
In conclusion, our findings suggest subtle changes in the regulation of GH and ghrelin secretion dynamics in 
early stage HD patients that may become more prominent in the later stages of the disease. The assessment of 
postprandial ghrelin suppression, in particular, is a relatively simple procedure that should be evaluated as a 
potential biomarker to assess disease progression in future studies.
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ABSTRACT
Background: Huntington’s disease (HD) is a progressive hereditary neurodegenerative disorder caused by 
an increased CAG repeat size in the HTT gene. Recently a loss of hypothalamic dopamine D2 receptors was 
demonstrated in HD. Activation of dopamine D2 receptors is known to inhibit both thyrotropic and lactotropic 
axes function. Hence, we postulated that loss of hypothalamic D2 receptors in HD patients may give rise to 
disturbed thyrotropic and lactotropic axes activity, contributing to symptoms such as unintended weight loss. 
Methods: In nine early-stage, unmedicated HD patients (6 males, 3 females) and nine age-, sex- and body mass 
index-matched controls, we measured serum levels of TSH and prolactin (males only) every 10 min for 24 h. 
Multi-parameter auto-deconvolution and approximate entropy analysis were applied to quantify basal, pulsatile 
and total TSH and prolactin secretion rates as well as the regularity of hormone release. Results: Compared with 
controls, TSH and prolactin secretion tended to be slightly, but not significantly, higher in HD patients (TSH: 
1.13±0.14 vs. 0.91±0.19 mU/L, p=0.365; prolactin: 4.91±0.42 vs. 4.83±0.26 μg/L, p = 0.872). However, in HD 
patients total T3 and T4 levels were significantly higher (T3: 1.60±0.05 vs. 1.35±0.09, p=0.027; T4: 91.9±3.9 
vs. 81.3±3.1, p=0.047), while prolactin secretion was significantly more irregular (ApEn ratios: 0.61±0.04 vs. 
0.48±0.04, p=0.037). Total T3 levels were negatively associated with motor impairment (r=-0.72, p=0.030), 
whereas increasing free T4 levels were associated with a larger mutant CAG repeat size (r=+0.68, p=0.044). 
Conclusion: Our findings indicate a mild hyperactivity of the thyrotropic axis and a disturbed regulation of the 
lactotropic axis in HD, both consistent with disrupted hypothalamic-pituitary dopamine signaling. 
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Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HTT gene, resulting in a long polyglutamine tract in the 
N-terminus of the encoded protein huntingtin.1 It is characterized by motor disturbances, cognitive decline 
and behavioral problems.1 Progressive weight loss and muscle wasting are also hallmarks of the disease, both 
in HD patients 2-6 and several transgenic mouse models of the disease.7,8 Moreover, abnormalities in glucose 
homeostasis as well as a higher prevalence of diabetes mellitus have been reported in HD patients, which are 
also evident in the transgenic models.9,10 The cause of these peripheral signs is largely unknown, although 
hypothalamic dysfunction and subsequent endocrine alterations may be involved.2,11
Both the thyrotropic and lactotropic axes are intimately involved in the complex neuroendocrine regulation 
of body weight and metabolism.12,13 Relatively few studies have, however, evaluated hypothalamic-pituitary-
thyroid axis function in HD patients. Although basal levels of total thyroxine (T4), triiodothyronine (T3), 
free T4, and thyroid-stimulating hormone (TSH) have been reported to be similar between HD patients and 
normal controls,14,15 others have found an impaired TSH response to thyrotropin-releasing hormone (TRH) 
stimulation.16 Moreover, in a retrospective chart review study of 97 HD patients residing in long-term care 
facilities, the most commonly prescribed drug for problems ‘unrelated’ to HD was found to be levothyroxine.17 
Compared to thyrotropic axis function, lactotropic axis activity in HD patients has been investigated more 
intensively.18 Nevertheless, as prolactin levels in HD patients have been reported to be unchanged,14,19-22 
increased,15,23 or even decreased,24,25 it still remains unknown whether the lactotropic axis is indeed affected in 
HD or whether altered prolactin levels are merely a consequence of anti-dopaminergic medication use in HD. 
The discordances in findings regarding thyrotropic and lactotropic axes functioning in HD are likely due to the 
use of a few baseline measurements of hormone levels or long blood sampling intervals which are not adequate 
to assess either the pulsatile nature of TSH and prolactin secretion or their total daily production rates.26 
Recently a loss of hypothalamic dopamine D2 receptors was demonstrated in both early stage HD patients 
as well as premanifest HD mutation carriers.27 Activation of dopamine D2 receptors is known to inhibit both 
thyrotropic and lactotropic axes function.28,29 Therefore, we postulated that loss of hypothalamic D2 receptors 
in HD patients may give rise to disturbed thyrotropic and lactotropic axes activity, contributing to the disrupted 
energy homeostasis in these subjects. We tested this hypothesis by deconvolution analysis of 24 h serum 
TSH and prolactin concentration profiles as well as assessment of thyroid hormone levels in both early stage, 
medication-free HD patients and healthy matched controls. 
SUBJECTS AND METHODS 
Subjects 
Nine early-stage HD patients and nine healthy control subjects, matched for age, sex, and body mass index 
(BMI), were enrolled in the study. Thyroid axis function was assessed in all participants. However, as estrogens 
can have a marked impact on prolactin secretion,12 lactotropic axis activity was assessed in male subjects only. 
Clinical details are summarized in Table 1. In the patient group, mutant CAG repeat size ranged between 
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41 and 50. The clinical 
diagnosis of HD was 
made by a neurologist 
specialized in 
movement disorders 
(R.A.C.R.). The Unified 
Huntington’s Disease 
Rating Scale (UHDRS) 
was used to assess HD 
symptoms and signs.30 
None of the subjects 
used medication, except 
one male HD patient 
who discontinued 
paroxetine (t
1/2
 ≈ 21 h) 
use three weeks prior to study. Subjects were eligible for participation after exclusion of hypertension, any 
known (history of) pituitary disease, recent intentional weight change (>3 kg weight gain or loss within the 
last 3 months), and any other chronic conditions except HD as assessed by clinical examination and routine 
laboratory tests. Written informed consent was obtained from all subjects. The study was approved by the 
medical ethics committee of the Leiden University Medical Center.
Clinical protocol 
Subjects were admitted to the Clinical Research Center for 24 h blood sampling. Two women (one patient 
and one control) were postmenopausal, the other women were studied in the early follicular phase of their 
menstrual cycle. A cannula was inserted into an antecubital vein 45 min before the start of blood sampling 
at 1630 h. Blood samples were collected with S-monovetten (Sarstedt, Etten-Leur, The Netherlands) from a 
three-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/ml) infusion (500 ml/24 h) to keep the 
cannula from clotting. Sampling was performed through a long line to prevent sleep disruption by investigative 
manipulations. During 24 h, blood was collected in serum tubes at 10-min intervals. Blood was allowed to 
clot and, within 60 min of sampling, all tubes were centrifuged at 4000 rotations/min at 4 ºC for 20 min, 
and plasma was stored at -80 ºC until assay. Three standardized meals were served at 0900, 1300, and 1900 
h (Nutridrink, 1.5 kcal/ml, 1500–1800 kcal/d; macronutrient composition per 100 ml: protein, 5 g; fat, 6.5 
g; carbohydrate, 17.9 g; Nutricia, Zoetermeer, The Netherlands). Subjects remained sedentary except for 
bathroom visits. Twenty-four hour urine was collected for the determination of creatinine, catecholamines 
and cortisol concentrations. No daytime naps were allowed. Lights were switched off at 2300 h and, the next 
morning, subjects were awakened at 0730 h. 
Body composition
Bioelectrical impedance analysis was used to assess lean body mass and fat percentage at 0800 h. 
Assays 
Table 1. Characteristics of the study population
HD patients1 Controls1 p-value2
Male/female 6/3 6/3 -
Age [y] 47.1 (3.4) 48.6 (3.3) 0.764
BMI 24.1 (1.0) 24.3 (0.6) 0.876
Fat [%] 25.5 (2.4) 25.6 (2.4) 0.985
Lean body mass [kg] 57.3 (3.2) 56.2 (3.0) 0.800
Waist-to-hip ratio 0.89 (0.03) 0.94 (0.02) 0.147
Mutant CAG repeat size 44.4 (1.0) - -
Disease duration [y] 5.7 (1.1) - -
UHDRS motor score 22.2 (6.0) - -
TFC score 11.7 (0.7) - -
1) Values are indicated as mean (SE).
2) Differences between groups were assessed by unpaired t-tests.
Abbreviations: BMI = Body Mass Index; TFC = Total Functional Capacity; 
UHDRS = Unified Huntington’s Disease Rating Scale. 
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Serum TSH and prolactin levels were measured by time-resolved immunofluorometic assays (Delfia, Wallac 
Oy, Turku, Finland). The detection limit of the TSH assay was 0.01 mU/L, and the interassay variation 
ranged from 3.1 to 8.3% at very low levels. The detection limit of the prolactin assay was 0.05 μg/L, and 
the interassay variation ranged from 2.7 to 3.8%. Serum T4 and T3 levels were measured with Abbott Axsym 
(Abbott Laboratories, Abbott Park, IL). Free T4 concentrations were estimated using electrochemiluminescence 
immunoassays (Roche Diagnostic Nederland BV, Almere, The Netherlands). Urinary epinephrine, 
norepinephrine and dopamine concentrations were assessed by high performance liquid chromatography with 
electron capture detection (ESTA-Coulochem, Chelmsford, MA, USA).
Calculations and statistics 
Deconvolution analysis. A recently developed, fully automatic, multi-parameter deconvolution procedure, 
AutoDecon, was used to estimate various specific measures of secretion and  disappearance rate of TSH and 
prolactin, considering all plasma hormone concentrations and their dose-dependent intra-sample variance 
simultaneously.31-33 The standard deviation of the secretion events was initialized to 5-min. For TSH, a 
fixed two-component half-life was assumed with 18-min for the first component and 92-min for the second 
component, with a relative contribution of 32% of the slow component to the total elimination.34 For prolactin, 
a starting one-component half-life of 45-min was assumed,35 and the AutoDecon algorithm was then used to 
find the best fit.36 The following parameters of the TSH and prolactin time series were estimated: number of 
secretory bursts, secretory burst half-duration (duration at half-maximal amplitude), mean mass secreted per 
burst, hormone half-life, basal secretion rate, pulsatile secretion rate, and total secretion rate.
Diurnal rhythmicity analysis. Twenty-four-hour variations in plasma hormone concentrations were assessed by 
cosinor regression, an algorithm that fits a cosine function to the data using repeated nonlinear regression.37 This 
analysis estimates an acrophase, which is the clock time during the 24 h period at which hormone concentration 
is maximal; a mesor, which is the average value about which the diurnal rhythm oscillates; and an amplitude, 
which is half the difference between the peak and nadir values of the 24 h concentration series. 
Approximate entropy (ApEn). ApEn is a model-independent statistic used to quantify the regularity of a time 
series, in which is measured, within a predefined tolerance r given a pattern of window length m, the likelihood 
of a similar pattern in the next incremental window.38 Greater regularity yields smaller ApEn values, whereas 
greater independence among sequential values of a time series yields larger ApEn values. ApEn parameters 
of m = 1 and r = 20% of the intra-series standard deviation were used, the statistical suitability of which has 
been established previously.39 Data are also presented as normalized ApEn ratios, defined by the mean ratio of 
absolute ApEn to that of 1000 randomly shuffled versions of the same time series.  
Statistical analysis. Results are expressed as mean ± standard error (SE) unless otherwise specified. Unpaired 
t tests were used to assess differences in means between the two groups. Pearson’s correlation coefficient was 
applied to assess all correlations. All tests were two-tailed and significance level was set at p < 0.05. Statistical 
analyses were performed using SPSS for Windows (release 16.0, SPSS, Inc., Chicago, IL). 
RESULTS 
Subjects 
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The HD and the control group did not differ with respect to age, sex, BMI, body fat or lean body mass (all p 
≥ 0.15 , Table 1). There were also no significant differences in urinary creatinine, epinephrine, norepinephrine 
and dopamine levels (all p ≥ 0.10). 
Deconvolution analysis of TSH time series
Mean 24 h TSH and prolactin concentrations were not significantly different between HD patients and controls 
(TSH: 1.13 ± 0.14 vs. 0.91 ± 0.19 mU/L, p = 0.365; prolactin: 4.91 ± 0.42 vs. 4.83 ± 0.26 μg/L, p = 0.872; 
Figure 1). The number of TSH and prolactin pulses as well as their basal, pulsatile and total secretion rates 
were also similar in the patient and control group (all p ≥ 0.342). Details of all deconvolution-derived SH and 
prolactin secretory kinetics are presented in Table 2.
Diurnal rhythmicity analysis 
TSH and prolactin displayed significant diurnal variations, both in patients and in controls (Figure 1). However, 
the acrophase, amplitude and mesor of the TSH and prolactin concentration series were not significantly 
different between HD patients and controls (all p ≥ 0.353).
   
Regularity of TSH and prolactin concentration time series
The ApEn values and ApEn ratios of the TSH time series were similar between HD patients and controls (both 
p  ≥ 0.712). However, the ApEn values of the prolactin time series were significantly higher in HD patients 
compared with controls (1.06 ± 0.08 vs. 0.80 ± 0.09, p = 0.048). The same held for ApEn ratios (0.61 ± 0.04 vs. 
0.48 ± 0.04, p = 0.037), indicating significantly more irregular prolactin secretion in HD patients (Figure 2).
Table 2. Deconvolution analysis of 24 h serum TSH prolactin concentrations.
TSH Prolactin
HD patients1 Controls1 HD patients1 Controls1
Basal secretion rate2 16.8 (1.8) 12.8 (2.6) 75.4 (27.8) 44.8 (13.1)
Pulsatile secretion 
rate2
10.4 (1.9) 9.2 (2.5) 59 (11) 62 (7)
Total secretion rate2 27.2 (3.6) 22.0 (4.7) 134 (38) 106 (17)
Percent pulsatile 
[%]
36.0 (3.0) 37.8 (4.4) 48.5 (4.5) 61.5 (7.5)
Pulse half-duration 
[min]
50.3 (5.7) 57.2 (9.7) 41.5 (11.4) 30.3 (9.0)
Pulse frequency 
[no./24 h]
11.4 (1.2) 10.9 (1.4) 15.7 (1.2) 17.3 (1.2)
Mean mass secreted 
per pulse3 
0.94 (0.20) 0.87 (0.22) 4.2 (1.2) 3.8 (0.7)
1) Values are indicated as mean  (SE). There were no significant differences between HD patients and 
controls (unpaired t-tests).
2) Secretion rates are in mU/L/24 h for TSH, and ug/L/24 h for prolactin.
3) Mean mass secreted per pulse is in mU/L for TSH, and ug/L for prolactin.
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Thyroid hormone levels
Fasting levels of both T3 and T4 were 
significantly higher in HD patients compared 
with controls (T3: 1.60 ± 0.05 vs. 1.35 ± 0.09, 
p = 0.027; T4: 91.9 ± 3.9 vs. 81.3 ± 3.1, p = 
0.047). However, while free T4 levels also 
tended to be higher in HD patients (15.1 ± 
0.70 vs. 14.2 ± 0.46), the difference did not 
reach statistical significance (p = 0.343).
Thyrotropic and lactotropic axes activity in 
relation to clinical phenotype
In HD patients, total daily TSH and prolactin 
secretion rates were not significantly 
associated with BMI, motor score, total 
functional capacity or mutant CAG repeat 
size (all p ≥ 0.17). However, higher total T3 
levels were significantly associated with less 
motor impairment (r = -0.72, p = 0.030). 
Moreover, increasing mutant CAG repeat 
size was significantly related to higher free 
T4 levels (r = +0.68, p = 0.044). Trends also 
existed for the associations between total T4 
levels and mutant CAG repeat size (r = +0.63, 
p = 0.069), and total T4 levels and BMI (r = 
-0.64, p = 0.064).
DISCUSSION
In this study we rigorously evaluated 
thyrotropic and lactotropic axes function in 
a group of early stage, medication-free HD 
patients. Although daily TSH production rates 
were similar between HD patients and matched controls, thyroid hormone levels were significantly higher 
in HD patients, consistent with a mild hyperactivity of the hypothalamic-pituitary-thyroid axis. Total daily 
prolactin production rates were also similar between HD patients and controls, however, prolactin secretion 
was significantly more irregular in HD patients. 
Thyroid hormones (T4 and T3) are critically involved in the regulation of systemic energy homeostasis and 
Figure 1.  Mean serum TSH (A) and prolactin (B) 
concentrations in HD and control subjects. Sampling 
started at 1630 h and was continued at 10-min intervals 
for 24 h. 
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their secretion is tightly regulated by a complex 
interplay of positive and negative feedback 
loops.40 Hypothalamic TRH induces pituitary 
TSH secretion which then stimulates the synthesis 
and release of thyroid hormones by the thyroid 
gland. Although TSH synthesis and secretion 
are primarily controlled by the stimulatory 
action of TRH and the negative feedback 
restraint by thyroid hormones, other factors 
such as dopamine exert important modulatory 
effects.40 Dopamine has a dual influence on TSH 
secretion: it inhibits TSH synthesis and release 
through D2 receptor
 activation at the level of 
the pituitary thyrotropes, whereas it stimulates 
TRH secretion by the hypophysiotropic 
neurons located in the paraventricular nucleus.29 
Using positron emission tomography with 
11C-raclopride, a specific D2 receptor ligand, 
Politis et al.27 recently demonstrated a loss of 
D2 receptors in the hypothalamus of both early 
stage HD patients and premanifest HD mutation 
carriers. Moreover, in the R6/2 transgenic mouse 
model  of HD a loss of D2 receptors has also been 
reported at the level of the anterior pituitary.41 Therefore, our finding of a mild thyrotropic axis hyperactivity 
in HD patients may, at least partly, be attributed to a specific pattern of hypothalamic and pituitary D2 receptor 
loss. The modest decrease of hypothalamic D2 receptors (by about 28%) in early stage HD patients,
27 may 
explain the relatively mild increase in the activity of the thyrotropic axis in our cohort. 
Altered hypothalamic-pituitary dopamine signaling may also underlie the significantly more irregular pattern 
of prolactin release in HD patients. There is now ample evidence that dopamine of tubero-infundibular 
origin, delivered through long portal vessels into the sinusoid capillaries of the anterior pituitary, is the major 
physiological regulator of prolactin release.12 Hypothalamic dopamine inhibits the basally high-secretory tone of 
pituitary lactotrophs by binding to D2 receptors expressed on their cell membranes.
28 Prolactin in turn regulates 
the activity of the tubero-infundibular neurons via a short-loop feedback mechanism.28 Hence, pathology of 
the tubero-infundibular dopaminergic system, located in the hypothalamic infundibular nucleus (i.e. the human 
homologue of the arcuate nucleus in rodents), or loss of pituitary D2 receptor expression as described in the 
R6/2 mice41 could both underlie the irregular pattern of prolactin secretion in HD patients. The diminished 
regularity of prolactin secretion even in our cohort of early, unmedicated HD patients may also account for 
the inconsistencies in findings from previous studies on prolactin levels in HD subjects,14,15,19-25 since due to 
the irregular pattern of prolactin release single or a few baseline measurements are likely to yield ambiguous 
outcomes. It remains to be established to what extent the irregular pattern of prolactin secretion in HD could 
lead to abnormal responses to physiological stimuli of prolactin release such as stress.12 Neuropathological 
Figure 2. Prolactin secretion regularity in HD patients 
and controls. Compared with controls, the approximate 
entropy (ApEn) ratio of prolactin secretion is higher in 
HD patients (0.48 ± 0.04 vs. 0.61 ± 0.04, p=0.037), 
indicating significantly more irregular prolactin 
release. 
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evaluation of the infundibular nucleus, as well as in vivo assessment of pituitary D2 receptor binding in HD 
patients could provide more mechanistic insights into the basis of this abnormality in prolactin secretion.
Interestingly, when assessed in relation to clinical characteristics, higher free T4 levels were associated with 
larger mutant CAG repeat sizes. In addition, there was an inverse trend for the relation between total T4 levels 
and BMI in HD patients. As thyroid hormones are known to increase energy expenditure, elevated thyroid 
hormone levels in early stage HD patients that seem to increase with mutant CAG repeat size, may contribute 
to the lower BMI in HD mutation carriers,5,6 and possibly account for the association between mutant HTT 
CAG repeat size and weight loss in HD.3 As mutant CAG repeat size was not associated with TSH secretion, 
its association with free T4 levels is more likely to be mediated peripherally, for example, by a direct effect of 
mutant huntingtin on tissue deiodinases that are found throughout the body.13,42 However, larger scale studies in, 
especially early stage and neuroleptic-free, HD patients are needed to confirm these preliminary associations.
In conclusion, we found a mild hyperactivity of the hypothalamic-pituitary-thyroid axis, as well as a more 
irregular pattern of prolactin secretion in HD patients compared with matched controls. These findings are 
consistent with disrupted hypothalamic-pituitary dopamine signaling in HD. Further neuropathological, 
imaging and functional studies are necessary to unveil the cause of these abnormalities and provide rationale 
for potential endocrine-based therapies for HD.
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ABSTRACT
Background. Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an increased 
number of CAG repeats in the huntingtin gene. A hallmark of HD is unintended weight loss, the cause of which 
is unknown. Objective. To perform a detailed analysis of adipose tissue function in HD patients as abnormal 
fat tissue function could contribute to the weight loss. Design, setting & participants. In a clinical research 
laboratory, twenty-four-hour plasma concentrations of leptin, adiponectin and resistin were studied in nine 
early-stage, medication-free HD patients and nine age-, sex- and body mass index (BMI)-matched controls. 
Measurements. Leptin was measured every 20 min whereas adiponectin and resistin were measured hourly. 
Auto-deconvolution and cosinor regression were applied to quantify secretion characteristics of leptin and 
diurnal variations in leptin, adiponectin and resistin levels. Results. Plasma levels and diurnal rhythmicity of 
leptin, adiponectin and resistin were not significantly different between HD patients and controls. However, 
although leptin production increased with higher BMI and fat mass in controls, no such relation was present 
in HD patients. Moreover, when corrected for fat mass, mean plasma leptin concentration as well as basal, 
pulsatile and total secretion rates increased with the size of the CAG repeat mutation (r=+0.72 to r=+0.80;all 
p<0.05). Both higher pulsatile leptin secretion and higher mean adiponectin levels were associated with a 
greater degree of motor and functional impairment in HD patients. Conclusions. CAG repeat size dependent 
interference of the HD mutation with adipose tissue function may contribute to weight loss in HD patients. 
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Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by an increased number of CAG repeats in the huntingtin gene.1 It is characterized by motor disturbances, 
cognitive decline and behavioral problems.1 Unintended weight loss is also a hallmark of the disease, both in 
HD patients 2-5 and several mouse models of the disease.6,7 Weight loss frequently leads to general weakening 
and a decline in the quality of life of HD patients.8 On the other hand, a higher Body Mass Index (BMI) 
has been associated with a slower rate of disease progression.9 The cause of weight loss in HD is unknown, 
although decreased caloric intake, increased motor activity or a higher metabolic rate, due to both central and 
peripheral defects, may be involved.2,3 
Interestingly, weight loss in HD patients is accompanied by substantial loss of body fat stores.4,10,11 Moreover, 
abnormal fat cell function has been reported in several mouse models of HD.6,12,13 As adipose tissue and release 
of endocrine and paracrine factors, so called ‘adipokines’, by fat cells take center stage in the regulation of 
feeding and body weight14, defects in fat metabolism may partly contribute to weight loss in HD patients.6 
However, adipokine secretion characteristics have hardly been studied in patients with HD. Single baseline 
measurements of leptin, the most important adipokine, have yielded conflicting results, showing either 
unchanged or decreased levels in HD patients.15-19 Moreover, there are no reports available on leptin secretory 
dynamics and diurnal variation, both of which are thought to be essential for normal hormone function20; 
particularly in light of recent reports of substantial circadian rhythm disturbances in HD21, these aspects should 
be accounted for. In addition, levels of the two other major adipokines, i.e. adiponectin and resistin, have not 
been assessed so far in HD patients.
We hypothesized that altered adipose tissue function may contribute to weight loss in HD patients. Thus, in 
order to assess adipose tissue function and its relation to body weight in HD patients, we assessed 24 h plasma 
leptin, adiponectin and resistin concentration profiles in both early-stage HD patients and matched healthy 
control subjects. Moreover, we assessed whether mutant huntingtin could interfere with adipokine secretion in 
a CAG repeat size dependent manner, which might account for our recent finding of increased weight loss in 
HD patients with a higher mutant CAG repeat size.3  
SUBJECTS AND METHODS 
Subjects 
Nine early-stage HD patients and nine healthy control subjects,  matched for age, sex, and body mass index 
(BMI), were enrolled in the study. Clinical details are summarized in Table 1. In the patient group, mutant CAG 
repeat size ranged between 41 and 50. The clinical diagnosis of HD was made by a neurologist specialized in 
movement disorders (R.A.C.R.). The Unified Huntington’s Disease Rating Scale (UHDRS) was used to assess 
HD symptoms and signs.22 All subjects were free of medication, except one HD patient who discontinued 
paroxetine use three weeks prior to study. Subjects were eligible for participation after exclusion of hypertension, 
any known (history of) pituitary disease, recent intentional weight change (>3 kg weight gain or loss within the 
last 3 months), and any other chronic conditions except HD as assessed by clinical examination and routine 
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laboratory tests. Written 
informed consent was 
obtained from all subjects. 
The study was approved by 
the ethics committee of the 
Leiden University Medical 
Center. 
Clinical protocol 
Subjects were admitted 
to the Clinical Research 
Center for 24 h blood 
sampling. Two women (one 
patient and one control) 
were postmenopausal, the 
other women were studied 
in the early follicular phase of their menstrual cycle. A cannula was inserted into an antecubital vein 45 min 
before the start of blood sampling at 1630 h. Blood samples were collected with S-monovetten (Sarstedt, 
Etten-Leur, The Netherlands) from a three-way stopcock that was attached to a 0.9% NaCl and heparin (1 U/
ml) infusion (500 ml/24 h) to keep the cannula from clotting. Sampling was performed through a long line to 
prevent sleep disruption by investigative manipulations. During 24 h, blood was collected in serum tubes at 
20-min intervals. Blood was allowed to clot and, within 60-min of sampling, all tubes were centrifuged at 4000 
rotations/min at 4 ºC for 20 min, and plasma was stored at -80 ºC until assay. Three standardized meals were 
served at 0900, 1300, and 1900 h (Nutridrink, 1.5 kcal/ml, 1500–1800 kcal/d; macronutrient composition per 
100 ml: protein, 5 g; fat, 6.5 g; carbohydrate, 17.9 g; Nutricia, Zoetermeer, The Netherlands). Twenty-four hour 
urine was collected for the determination of creatinine and catecholamine concentrations. Subjects remained 
sedentary except for bathroom visits. No daytime naps were allowed. Lights were switched off at 2300 h and, 
the next morning, subjects were awakened at 0730 h. 
Body composition
Bioelectrical Impedance Analysis (BIA) was used to assess fat mass, lean body mass and fat percentage at 
0800 h. 
Assays 
Plasma leptin, adiponectin and resistin were all measured by radioimmunoassay (Linco Research, St. Charles, 
MO, USA). The coefficients of variation ranged from 3.0 to 5.1% for leptin, 6.3 to 8.1% for adiponectin, and 
3.2 to 5.4% for resistin. The detection limits of the assays were 0.5 μg/L for leptin, 1.0 mg/L for adiponectin, 
and 0.15 μg/L for resistin. Samples from each patient and matched control were handled in the same run. 
Urine creatinine was measured by a fully automated P 800 Modular system (Roche, Almere, the Netherlands). 
Urinary epinephrine, norepinephrine and dopamine concentrations were assessed by high performance liquid 
chromatography with electron capture detection (ESTA-Coulochem, Chelmsford, MA, USA).
Table 1. Characteristics of the study population
HD patients† Controls† p-value‡
Male/female 6/3 6/3 -
Age [y] 47.1 (3.4) 48.6 (3.3) 0.764
BMI 24.1 (1.0) 24.3 (0.6) 0.876
Fat [%] 25.5 (2.4) 25.6 (2.4) 0.985
Lean body mass [kg] 57.3 (3.2) 56.2 (3.0) 0.800
Waist-to-hip ratio 0.89 (0.03) 0.94 (0.02) 0.147
Mutant CAG repeat size 44.4 (1.0) - -
Disease duration [y] 5.7 (1.1) - -
UHDRS motor score 22.2 (6.0) - -
TFC score 11.7 (0.7) - -
Functional Assessment 23.3 (0.7) - -
Independence score 94.4 (2.8) - -
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by unpaired t-tests.
Abbreviations: BMI = Body Mass Index; FAS = Functional Assessment; 
TFC = Total Functional Capacity; UHDRS = Unified Huntington’s Disease 
Rating Scale. 
Adipokines in Huntington’s disease patients 
165
Calculations and statistics 
Deconvolution analysis. A recently developed, fully automatic, multiparameter deconvolution procedure, 
AutoDecon, was used to estimate various specific measures of secretion and plasma disappearance rate of 
leptin, considering all plasma hormone concentrations and their dose-dependent intra-sample variance 
simultaneously.23 The AutoDecon process is a statistically based algorithm to test the significance of hormone 
secretion events, obviating the subjective nature of previously used deconvolution methods.23 Apart from the 
initial concentration and the basal secretion rate, which both were initialized to zero, the AutoDecon algorithm 
requires only two approximations of the parameter values that are to be estimated: (1) The standard deviation of 
the Gaussian-shaped secretion events (SecretionSD) which is generally initialized as half of the data-sampling 
interval, and (2) and an estimate of the elimination parameter, or hormone half-life.23 Thus, for 20-min sampled 
data, the SecretionSD was initialized to 10-min, while a fixed two-component leptin half-life was assumed 
with 3.4-min for the first component and 71-min for the second component, with a relative contribution of 
81% of the slow component to the total elimination (J.D. Veldhuis, personal communication). The following 
parameters of the leptin time series were estimated: number of secretory bursts, secretory burst half-duration 
(duration at half-maximal amplitude),  mean mass secreted per burst, basal secretion rate, pulsatile secretion 
rate, and total secretion rate. As adiponectin and resistin levels were assessed hourly, deconvolution of the 
adiponectin and resistin time series was not possible.
Diurnal rhythmicity analysis. Twenty-four hour variations in plasma leptin, adiponectin and resistin 
concentrations were assessed by cosinor regression, an algorithm that fits a cosine function to the data using 
repeated nonlinear regression. This analysis estimates an acrophase, which is the clock time during the 24 
h period at which hormone concentration is maximal; a mesor, which is the average value about which the 
diurnal rhythm oscillates; and an amplitude, which is half the difference between the peak and nadir values of 
the 24 h concentration series.   
Statistical analysis. Results are expressed as mean ± standard error (SE) unless otherwise specified. Unpaired 
t tests were used to assess group differences. Pearson’s correlation coefficient was applied to assess all 
correlations. All tests were two-tailed and significance level was set at p < 0.05. Statistical analyses were 
performed using SPSS for Windows (release 14.0, SPSS, Inc., Chicago, IL). 
RESULTS 
Subjects 
The HD and the control group did not differ with respect to age, sex, BMI, body fat percentage, or lean body 
mass (all p ≥ 0.15 , Table 1). There were also no significant differences in urinary creatinine, epinephrine, 
norepinephrine and dopamine levels (all p ≥ 0.10).
Leptin levels and deconvolution analysis of leptin time series
The average 24 h plasma leptin concentration profiles of HD patients and controls are displayed in Figure 1. 
Mean 24 h leptin concentration did not differ significantly between patients and controls (8.4 ± 3.1 vs. 7.4 ± 3.2 
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μg/L, p = 0.823). Basal, pulsatile and total leptin secretion rates were also not significantly different between 
the two groups (all p ≥ 0.785), although they tended to be higher in HD patients. Details of all deconvolution-
derived leptin secretory kinetics are presented in Table 2. Results were similar when leptin levels and secretory 
dynamics in each individual were expressed per kilogram body fat (data not shown). 
Adiponectin and resistin levels
The average 24 h plasma adiponectin and resistin 
concentration profiles of HD patients and controls 
are shown in Figure 2. Although throughout the 
circadian cycle adiponectin levels were higher 
and resistin levels were lower in HD patients 
compared with controls, the two groups did not 
differ significantly with respect to mean 24 h levels 
of adiponectin (9.6 ± 1.9 vs. 8.0 ± 1.6 mg/L, p = 
0.540) or resistin (12.0 ± 1.7 vs. 13.8 ± 1.6 μg/L, p 
= 0.469). Results remained similar when expressed 
per kilogram body fat (data not shown).
 Figure 1.  Mean plasma leptin concentrations in 
HD patients and matched control subjects. Sampling 
started at 1630 h and was continued at 20-min intervals 
for 24 h. 
Table 2. Deconvolution analysis of 24 h plasma leptin concentrations.
HD patients† Controls† p-value‡
Basal secretion rate 
[μg/L/24 h]
0.08 (0.03) 0.07 (0.03) 0.791
Pulsatile secretion 
rate [μg/L/24 h]
35 (12) 30 (13) 0.785
Total secretion rate  
[μg/L/24 h]
147 (55) 125 (54) 0.786
Percent pulsatile [%] 24.2 (2.0) 22.3 (2.8) 0.576
Pulse half-duration 
[min]
39.8 (8.4) 51.3 (5.8) 0.276
Pulse frequency 
[no./24 h]
6.4 (0.4) 5.6 (0.8) 0.889
Mean mass secreted 
per pulse [μg/L]
5.0 (1.6) 5.0 (2.1) 0.992
†) Values are indicated as mean  (SE).
‡) Differences between groups were assessed by unpaired t-tests.
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Diurnal rhythmicity analysis 
The results of the cosinor analysis of plasma leptin, adiponectin and resistin concentration series are listed in 
Supplementary Table 1. Leptin, adiponectin and resistin levels displayed significant diurnal variations, both 
in patients and controls. The acrophases of leptin, adiponectin and resistin concentration series occurred at 
similar time points in the patient and the control group and were not significantly different. Similarly, the 
amplitude and mesor of all three concentration series were not significantly different between the two groups 
(Supplementary Table 1). 
Leptin, adiponectin and resistin levels in relation to clinical phenotype
Comparison of the correlations between leptin production, and BMI and body fat stores in HD patients and 
control subjects revealed a number of differences between the two groups. Unlike in controls, mean 24 h leptin 
levels in HD patients did not significantly increase with higher BMI (r = +0.67 and p = 0.048 in controls vs. 
r = +0.43 and p = 0.25 in patients). Moreover, in controls basal, pulsatile and total leptin secretion rates per 
kilogram fat increased with higher fat mass, whereas in HD patients these associations were much weaker and 
not significant (Table 3). When adjusted for fat mass, mean 24 h resistin levels also significantly decreased with 
higher BMI in controls but not in HD patients (Table 3).
In the HD group, mean 24 h leptin as well as basal, pulsatile and total leptin secretion rates per kilogram fat all 
significantly increased with the size of the CAG repeat expansion in the mutant huntingtin gene (Table 3). Also 
mean 24 h adiponectin per kilogram fat increased with higher CAG repeat size, however, this relation failed 
to reach statistical significance. In addition, higher mean 24 h adiponectin as well as higher pulsatile leptin 
secretion rate per kilogram fat were significantly associated with a greater degree of motor and functional 
impairment as measured by scores on the UHDRS total motor, total functional capacity, functional assessment 
Figure 2.  Mean plasma adiponectin (A) and resistin (B) concentrations in HD patients and matched control 
subjects. Assessment of plasma adiponectin and resistin levels started at 1630 h and was continued at 60-min 
intervals for 24 h. 
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and independence scales (Table 3).
DISCUSSION
Here we present the first detailed description of leptin secretory dynamics and its diurnal variation in HD 
patients. In addition, we provide the first description of adiponectin and resistin levels in these patients. We 
found that there are no significant differences in the levels or diurnal rhythmicity of these adipokines between 
HD patients and controls. However, when corrected for fat mass, both mean plasma leptin concentration and 
secretion rate significantly increased with the size of the CAG repeat mutation in HD patients. Moreover, 
higher pulsatile leptin secretion and mean adiponectin levels were associated with a greater degree of clinical 
impairment. Interestingly, unlike in controls, neither BMI nor body fat mass was significantly related to leptin 
production in HD patients. These findings suggest that the HD mutation interferes with adipose tissue function 
and are important for understanding the cause of weight loss in HD.
The adipose-tissue derived hormone leptin is produced in proportion to body fat stores and its circulating 
levels serve to communicate body energy states to the central nervous system where it inhibits food intake and 
stimulates energy expenditure.14 Numerous studies have shown that circulating leptin levels as well as leptin 
gene expression per gram lipid weight increase with higher BMI and fat mass.24,25 However, here we demonstrate 
that in HD patients such a relation is not apparent. This is in line with findings from another study which did 
not find a correlation between the plasma leptin concentration in a single fasting blood sample and BMI in HD 
patients, while the correlation was highly significant in control subjects.17 Moreover, we found a significant 
association between leptin production rate and mutant CAG repeat size. As expression of an inducible mutant 
huntingtin transgene in an adipocyte cell line impaired gene expression and lipid accumulation6, it is likely 
that mutant huntingtin directly interferes with leptin production in a polyglutamine length-dependent manner, 
thereby confounding the relation between body fat content and leptin levels in HD patients.   
Recently, we demonstrated that the rate of weight loss in HD patients increases with a higher number of 
Table 3. Clinical correlates of adipokine levels in Huntington’s disease patients and controls
Leptin Mean 
adiponectin 
levels†
Mean 
resistin 
levels†
Mean levels† Basal 
secretion 
rate†
Pulsatile
secretion 
rate†
Total 
secretion 
rate†
HD C HD C HD C HD C HD C HD C
BMI -0.06 0.58 0.00 0.64 -0.31 0.38 -0.09 0.57 -0.47 -0.40 -0.48 -0.80*
Fat mass [kg] 0.37 0.82** 0.43 0.87** 0.08 0.68* 0.36 0.82** -0.19 0.00 -0.59 -0.64
Body fat [%] 0.72* 0.90** 0.76* 0.92** 0.48 0.82** 0.69* 0.90** -0.21 0.25 -0.64 -0.37
CAG repeat 
size
0.75* - 0.72* - 0.80** - 0.77* - 0.51 - 0.08 -
Motor score 0.55 - 0.49 - 0.75* - 0.57 - 0.73* - -0.13 -
TFC -0.46 - 0.38 - -0.72* - -0.49 - -0.79* - 0.18 -
FAS -0.46 - -0.51 - -0.80** - -0.60 - -0.80** - 0.23 -
IS -0.50 - -0.43 - -0.72* - -0.52 - -0.75* - 0.31 -
†) For each individual all parameters were divided by kilograms of body fat to correct for fat mass. Values are 
indicated as Pearson’s correlation coefficients: * p < 0.05, ** p < 0.01.
Abbreviations: BMI = Body Mass Index;  C = Control subjects; FAS = Functional Assessment; HD = 
Huntington disease patients; IS = Independence Score; TFC = Total Functional Capacity. 
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CAG repeats in the mutant huntingtin gene.3 Similarly, R6/2 mice with larger mutant CAG repeat lengths 
in the transgene had a lower body weight.3 Here we show that the production rate of leptin, an anorexigenic 
hormone that stimulates energy expenditure14, also increases with higher CAG repeat number. Therefore, 
enhanced leptin production rate in HD patients with higher CAG repeat lengths in the mutant allele could 
lead to decreased appetite and hypermetabolism, thereby contributing to the higher rate of weight loss in these 
subjects. In humans, leptin is encoded by the LEP gene, the promoter of which contains consensus sequence 
binding sites for the transcriptional activator specificity protein-1 (Sp1).26 In HD, gene microarray studies have 
indicated selective transcriptional alterations of many genes that contain binding sites for Sp127,28, which has 
been shown to interact with huntingtin in a polyglutamine length-dependent manner.29 Up-regulation of Sp1 
is thought to occur in response to mutant huntingtin, whereas down-regulation of Sp1 has been associated 
with neuroprotection in both in vitro and in vivo HD models.30 Therefore, the underlying mechanisms 
through which a higher CAG repeat number is related to increasing leptin levels in HD patients may involve 
polyglutamine length-dependent transcriptional dysregulation. Indeed, interrogation of a publicly available 
microarray database revealed that LEP gene expression is higher in HD brains compared with controls27, 
although the difference did not reach statistical significance likely because compared with adipose tissue LEP 
gene expression is much lower in the brain.  
Leptin is the only adipocyte the concentration of which has been reported previously in HD patients. However, 
while some investigators found decreased leptin levels 16,17, others reported no change.15,18,19  Differences in 
age, gender, BMI and circadian timing of the measurements  between patients and controls have likely been 
responsible for these contradictory results. Here we accounted for these differences by measuring plasma leptin 
levels throughout 24 h in a homogenous group of early-stage, medication-free HD patients and a group of age-
, gender- and BMI-matched controls. We demonstrate that although mean 24 h leptin levels and production 
rate in early-stage HD patients do not differ from those in controls, within the HD group there is substantial 
variability in leptin levels which is largely due to differences in mutant CAG repeat size.  Although age and 
gender are related to leptin levels, this association is assumed to be almost exclusively due to age- and gender-
specific changes in body fat content.24 Therefore, as we corrected leptin secretion for fat mass, age and gender 
heterogeneity within the HD group are unlikely to have influenced the association between leptin secretion and 
mutant CAG repeat size (Table 3). 
We also found that the levels of adiponectin and resistin, two other adipose tissue-specific hormones that are 
implicated in energy homeostasis and glucose and lipid metabolism14, are not significantly different between 
HD patients and controls. However, adiponectin levels corrected for fat mass did increase with disease severity 
in HD patients. Therefore, differences in adiponectin levels may become more marked in the later stages of the 
disease and, thus, might serve as a biomarker to tract disease progression in HD.
In conclusion, our findings suggest subtle abnormalities in adipose tissue function in early-stage HD patients 
that are possibly due to polyglutamine length-dependent interference of mutant huntingtin with transcriptional 
mechanisms. These abnormalities may aggravate with disease progression and could contribute to weight loss 
in HD patients.
ACKNOWLEDGMENTS 
We are greatly indebted to: E. J. M. Ladan-Eygenraam, E. C. Sierat-van der Steen, M. van Dijk-Besling and H. 
Chapter 10
170
G. Haasnoot-van der Bent for technical support during the study, and P. Kok, C.C. de Wit and S. Vidarsdottir 
for their invaluable suggestions and comments.
REFERENCES
 1.  The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat 
that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72(6):971-983.
 2.  Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic 
alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev 
Neurosci 2007; 18(3-4):223-251.
 3.  Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group et al. 
Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008; 
71(19):1506-1513.
 4.  Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. Assessment of the nutrition status of 
patients with Huntington’s disease. Nutrition 2004; 20(2):192-196.
 5.  Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of 
Huntington’s disease. Neurology 2002; 59(9):1325-1330.
 6.  Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K. Adipose tissue dysfunction tracks disease 
progression in two Huntington’s disease mouse models. Hum Mol Genet 2009; 18(6):1006-
1016.
 7.  van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B et al. Increased metabolism 
in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis 2008; 29(1):41-51.
 8.  Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov 
Disord 1996; 11(5):542-548.
 9.  Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK et al. Factors associated 
with slow progression in Huntington’s disease. Arch Neurol 1991; 48(8):800-804.
 10.  Farrer LA, Meaney FJ. An anthropometric assessment of Huntington’s disease patients and families. Am 
J Phys Anthropol 1985; 67(3):185-194.
 11.  Farrer LA, Yu PL. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in 
families with Huntington disease. Am J Med Genet 1985; 21(2):307-316.
 12.  Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D. Abnormalities in the functioning of adipocytes 
from R6/2 mice that are transgenic for the Huntington’s disease mutation. Hum Mol Genet 
2001; 10(2):145-152.
 13.  Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER et al. Thermoregulatory and 
metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s 
disease neurodegeneration. Cell Metab 2006; 4(5):349-362.
 14.  Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 
2006; 27(7):762-778.
 15.  Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage 
Huntington disease. Am J Clin Nutr 2005; 81(6):1335-1341.
Adipokines in Huntington’s disease patients 
171
 16.  Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L et al. Early energy deficit in Huntington 
disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 
2007; 2(7):e647.
 17.  Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S et al. Circulating and cerebrospinal 
fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J 
Endocrinol 2004; 151(4):451-455.
 18.  Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with 
Huntington’s disease. Ann Neurol 2000; 47(1):64-70.
 19.  Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ et al. The metabolic 
profile of early Huntington’s disease--a combined human and transgenic mouse study. Exp 
Neurol 2008; 210(2):691-698.
 20.  Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB et al. Human leptin levels are 
pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997; 3(5):575-579.
 21.  Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the 
sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci 2005; 25(1):157-163.
 22.  Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. 
Huntington Study Group. Mov Disord 1996; 11(2):136-142.
 23.  Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a deconvolution 
algorithm for identification and characterization of luteinizing hormone secretory bursts: 
description and validation using synthetic data. Anal Biochem 2008; 381(1):8-17.
 24.  Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum 
immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 
334(5):292-295.
 25.  Lonnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue 
of human obese subjects. Nat Med 1995; 1(9):950-953.
 26.  Gong DW, Bi S, Pratley RE, Weintraub BD. Genomic structure and promoter analysis of the human 
obese gene. J Biol Chem 1996; 271(8):3971-3974.
 27.  Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G et al. Regional and cellular gene 
expression changes in human Huntington’s disease brain. Hum Mol Genet 2006; 15(6):965-977.
 28.  Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL et al. Dysregulation of gene 
expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. 
Hum Mol Genet 2002; 11(17):1911-1926.
 29.  Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM et al. Sp1 and TAFII130 transcriptional 
activity disrupted in early Huntington’s disease. Science 2002; 296(5576):2238-2243. 
 30.  Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M et al. Sp1 is up-regulated in cellular 
and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 
2006; 281(24):16672-16680.
Chapter 10
172
Supplementary table 1. Cosinor analysis of diurnal leptin, adiponectin and resistin concentrations.
HD patients† Controls† p-value‡
Leptin Amplitude [μg/L] 1.2 (0.4) 1.6 (0.7) 0.617
Mesor [μg/L] 8.4 (3.1) 7.4 (3.2) 0.825
Acrophase [hh:mm] 02:22 (01:04) 03:35 (00:40) 0.355
Adiponectin Amplitude [mg/L] 0.6 (0.1) 0.6 (0.2) 0.982
Mesor [mg/L] 9.6 (1.9) 8.0 (1.6) 0.535
Acrophase [hh:mm] 05:07 (01:06) 06:13 (00:48) 0.428
Resistin Amplitude [μg/L] 0.6 (0.1) 1.1 (0.2) 0.087
Mesor [μg/L] 12.0 (1.7) 13.8 (1.6) 0.472
Acrophase [hh:mm] 04:56 (01:06) 03:27 (01:19) 0.401
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by unpaired t-tests.
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ABSTRACT
Sleep disturbances are very prevalent in Huntington’s disease (HD) patients and can substantially impair their 
quality of life. Accumulating evidence suggests considerable dysfunction of the hypothalamic suprachiasmatic 
nucleus (SCN), the biological clock, in both HD patients and transgenic mouse models of the disease. As 
melatonin has a major role in the regulation of sleep and other cyclical bodily activities and its synthesis is 
directly regulated by the SCN, we postulated that disturbed SCN function is likely to give rise to abnormal 
melatonin secretion in HD. Therefore, we compared 24h melatonin secretion profiles between early-stage 
HD patients and age-, sex- and body mass index-matched controls. Although mean diurnal melatonin levels 
were not different between the two groups (p=0.691), the timing of the evening rise in melatonin levels was 
significantly delayed by more than one and a half hours in HD patients (p=0.048). Moreover, diurnal melatonin 
levels strongly correlated with both motor (r=0.70, p =0.036) and functional impairment (r=0.78, p=0.013). 
These findings suggest a delayed sleep phase syndrome-like circadian rhythm disorder in early stage HD 
patients and suggest that melatonin levels may progressively decline with advancing disease. 
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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat size in the gene encoding the protein huntingtin.4 The disease is characterized by motor 
impairment, cognitive deterioration, behavioral problems and progressive weight loss.4 With an estimated 
prevalence of nearly 90% disturbed sleep is also a prominent feature of the disease, substantially impairing 
the quality of life of both patients and caregivers.20 Sleep disturbances in HD patients include an increased 
sleep onset latency, frequent nocturnal awakenings, reduced sleep efficiency, delayed and shortened rapid eye 
movement sleep, and increased periodic leg movements.1,8,22,24 Moreover, wrist actigraphy studies indicate 
circadian rhythm disturbances in HD patients, which are mirrored in the most widely used transgenic mouse 
model of the disease, the R6/2 mouse.10,14,15 The R6/2 mice show progressive disruption of the day-night 
activity patterns, with increased daytime activity and a concurrent decrease in nocturnal activity, eventually 
leading to a complete disintegration of the circadian behavior.14,15 Interestingly, disrupted circadian behavior 
in these mice is accompanied by marked dysregulation of expression of a number of circadian clock genes in 
the hypothalamic suprachiasmatic nucleus (SCN), the principal rhythm generating system in mammals.12,14,15 
Furthermore, we recently demonstrated an increased amplitude of the diurnal cortisol profile as well as an 
increased rate of early day cortisol production in HD patients, both of which are also consistent with SCN 
dysfunction in HD.3 
Melatonin is a hormone that is primarily secreted at night by the pineal gland and has a major role in the 
regulation of sleep and other cyclical bodily activities.5,16 Melatonin synthesis is directly regulated by the 
SCN via a multisynaptic pathway in response to the environmental light/dark cycle, and thus, melatonin is 
considered an endogenous humoral synchronizer that signals ‘time of day’ to all tissues throughout the body.5 
Conversely, the two major melatonin receptors, MT1 and MT2 receptors, are abundantly expressed in the SCN 
and are thought to mediate melatonin’s sleep-promoting and circadian phase-shifting effects.5 Therefore, we 
postulated that disturbed SCN function in HD is likely to give rise to abnormal melatonin secretion, which 
in turn could contribute to impaired sleep and circadian rhythm disturbances in HD patients. In addition, as 
apart from its timekeeping functions melatonin has also strong antioxidative properties, abnormal melatonin 
secretion may also influence the neurodegenerative process underlying HD. In order to test these hypotheses, 
we (1) compared 24 h plasma melatonin concentration profiles between early stage, medication-free HD 
patients and healthy matched controls, and (2) assessed the association between mean diurnal melatonin levels 
and clinical phenotype.
SUBJECTS AND METHODS
Subjects 
Nine early-stage HD patients and nine healthy control subjects, matched for age, sex, and body mass 
index (BMI), were enrolled in the study. Clinical details are summarized in Table 1.  The clinical 
diagnosis of HD was made by a neurologist specialized in movement disorders (R.A.C.R.). The 
Unified Huntington’s Disease Rating Scale (UHDRS) was used to assess HD symptoms and signs.9 
All subjects were free of medication, except one HD patient who discontinued paroxetine use 
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three weeks prior to 
study. Written informed 
consent was obtained 
from all subjects. The 
study was approved by 
the ethics committee of 
the Leiden University 
Medical Center. 
Clinical protocol 
Subjects were admitted 
to the Clinical Research 
Center for 24 h blood 
sampling. Two women 
(one patient and one control) were postmenopausal, the other women were studied in the early 
follicular phase of their menstrual cycle. A cannula was inserted into an antecubital vein 45 min before 
the start of blood sampling at 1630 h. Blood samples were collected with S-monovetten (Sarstedt, 
Etten-Leur, The Netherlands) from a three-way stopcock that was attached to a 0.9% NaCl and 
heparin (1 U/ml) infusion (500 ml/24 h) to keep the cannula from clotting. Sampling was performed 
through a long line to prevent sleep disruption by investigative manipulations. During 24 h, blood 
was collected in serum tubes every hour. Blood was allowed to clot and, within 60-min of sampling, 
centrifuged at 4000 rotations/min at 4 ºC for 20 min, and plasma was stored at -80 ºC until assay. 
Three standardized meals were served at 0900, 1300, and 1900 h (Nutridrink, 1.5 kcal/ml, 1500–
1800 kcal/d; macronutrient composition per 100 ml: protein, 5 g; fat, 6.5 g; carbohydrate, 17.9 g; 
Nutricia, Zoetermeer, The Netherlands). Twenty-four hour urine was collected for the determination 
of creatinine and catecholamine concentrations. Subjects remained sedentary except for bathroom 
visits. No daytime naps were allowed. Lights were switched off at 2300 h and back on at 0730 the 
next morning. 
Assays
Plasma melatonin was measured by radioimmunoassay (Labor Diagnostika Nord GmbH & Co. 
KG, Nordhorn, GER). The detection limit of the assay was 2 pg/mL. The intra-assay and interassay 
variations ranged from 9.8  to 12.3% and from 9.6 to 16.2%, respectively. Samples from each patient 
and matched control were handled in the same run. Urine creatinine was measured by a fully automated 
P 800 Modular system (Roche, Almere, the Netherlands). Urinary epinephrine, norepinephrine and 
dopamine concentrations were assessed by high performance liquid chromatography with electron 
capture detection (ESTA-Coulochem, Chelmsford, MA, USA).
Analysis of melatonin profiles 
Individual diurnal variations of plasma melatonin levels were quantified by a best-fit curve obtained 
Table 1. Characteristics of the study population
HD patients† Controls† p-value‡
Male/female 6/3 6/3 -
Age [y] 47.1 (3.4) 48.6 (3.3) 0.691
BMI 24.1 (1.0) 24.3 (0.6) 0.691
Mutant CAG repeat size 44.4 (1.0) - -
Disease duration [y] 5.7 (1.1) - -
UHDRS motor score 22.2 (6.0) - -
TFC score 11.7 (0.7) - -
Functional Assessment 23.3 (0.7) - -
Independence score 94.4 (2.8) - -
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by the Mann-Whitney U-test.
Abbreviations: BMI = Body Mass Index; FAS = Functional Assessment; TFC 
= Total Functional Capacity; UHDRS = Unified Huntington’s Disease Rating 
Scale. 
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using locally weighted linear regression with a Gaussian kernel and a regression window of four 
hours as previously described.11 For each melatonin profile the nadir and the acrophase were defined 
as the minimum and maximum of the best-fitting curve, while the amplitude was defined as half of the 
difference between the acrophase and nadir values. The onset of the melatonin rise was defined as the 
timing of the first plasma level exceeding the mean + 3 standard deviations (SDs) of baseline levels 
recorded over the 1030-1430 period, not followed to lower concentrations before the acrophase. 
The melatonin offset was defined as the timing of the last value occurring after the acrophase that 
exceeded +3 SDs of the baseline values.11    
Statistical analysis
Results are expressed as mean ± standard error (SE) unless otherwise specified. The non-parametric Mann-
Whitney U-test was used to assess group differences. Spearman’s correlation coefficient was applied to assess 
all correlations. All tests were two-tailed and significance level was set at p < 0.05. Statistical analyses were 
performed using SPSS for Windows (release 16.0, SPSS, Inc., Chicago, IL). 
RESULTS 
Subjects 
The HD and the control group did not differ with 
respect to age, sex, and BMI (all p ≥ 0.691, Table 
1). There were also no significant differences in 
urinary creatinine, epinephrine, norepinephrine 
and dopamine levels (all p ≥ 0.10).
Melatonin profiles 
Mean 24 h melatonin levels were not significantly 
different between HD patients and controls (24.8 
± 5.4 vs. 22.7 ± 2.8 pg/mL, p = 0.691; Figure 
1). Also the acrophase and nadir concentrations, 
as well as the amplitude of the diurnal melatonin 
profile were not significantly different between 
the two groups (p ≥ 0.857; Table 2). In one HD 
patient, however, the diurnal melatonin profile was 
extremely irregular and at no point did melatonin 
concentrations rise above three standard deviations of the mean baseline values (this subject also 
happened to be the most severely affected patient with scores of 63 and 7 on the UHDRS motor and 
total functional capacity subscales, respectively).  Consequently, melatonin onset, offset and duration 
could not be defined in this subject; therefore, for subsequent comparison of these parameter values 
between the two groups also the data of the matched control subject were excluded from the analyses. 
Figure 1. Mean 24 h melatonin levels in HD patients 
and matched controls. The diurnal melatonin rise 
was significantly delayed in HD patients by about 
one and a half hours (p=0.048). The black bar on the 
abscissa indicates the dark period (23:00-7:30 h).
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Melatonin onset time 
was significantly delayed 
in HD patients compared 
with controls (00:30 h 
± 22 min vs. 22:52 h 
± 37 min, p = 0.048). 
Melatonin offset time, 
however, was similar 
between the two groups 
(Table 2). Consequently, 
there was also a trend for 
a shorter duration of the 
nocturnal plasma melatonin plateau in HD patients (6.2 ± 1.2 vs. 9.1 ± 0.8 h, p = 0.063).    
Melatonin levels and clinical phenotype
In HD patients, mean 24 h melatonin levels significantly correlated with UHDRS motor score (r = -0.70, p = 
0.036), total functional capacity (r = + 0.78, p = 0.013), and independence score (r = + 0.88, p = 0.002), but not 
with mutant CAG repeat size (r = +0.18, p = 0.645).
DISCUSSION 
Here we present the first detailed description of diurnal melatonin profiles in HD patients. We show that the 
timing of the evening rise in melatonin levels is significantly delayed by more than one and a half hours in 
these patients compared with matched control subjects. Moreover, despite similar mean diurnal melatonin 
levels between our early stage HD patients and controls, we found strong inverse associations between mean 
diurnal melatonin levels and both motor and functional disability in these patients, suggesting that decreases in 
melatonin levels are likely to become more pronounced in the later stages of the disease. 
Delayed onset of melatonin secretion in HD patients is reminiscent of a delayed sleep phase syndrome (DSPS)-
like circadian rhythm disorder.25 The pathophysiological basis of DSPS is assumed to lie in a slower endogenous 
clock with an abnormally long intrinsic circadian periodicity,  resulting in a delayed phase position of the overt 
circadian rhythms, including those of melatonin, cortisol and core body temperature.25 Interestingly, recently we 
also found an increased rate of early day cortisol production in HD patients, which may also be a manifestation 
of delayed circadian rhythms in HD.3 Circadian rhythm disturbances in HD are likely to stem directly from 
pathology within the SCN molecular oscillation, caused either by the toxic effects of mutant huntingtin locally 
and/or arising from dysfunction of brain circuitry afferent to the SCN.14,15 In favour of local pathology is the 
detection of neuronal inclusions of mutant huntingtin in the SCN of HD patients2, as well as the finding of 
SCN dysfunction at both mRNA and protein level in R6/2 mice, with reduced levels of the positive regulator 
mBmal1 and truncated peak expression of its target genes mPer1, mPer2, and mProk2.14 However, intact 
oscillation of SCN neurons from R6/2 mice in vitro, when released from the pathological context, is consistent 
Table 2. Melatonin secretion characteristics in HD patients and controls.
HD patients† Controls† p-value‡
Mean 24 h levels (pg/mL) 24.8 (5.4) 22.7 (2.8) 0.601
Acrophase conc. (pg/mL) 76.6 (20.4) 60.1 (9.7) 0.860
Nadir conc. (pg/mL) 5.8 (0.9) 5.8 (0.7) 0.857
Amplitude (pg/mL) 35.4 (9.9) 27.2 (4.8) 0.895
Onset time (hh:mm) 00:30 (00:22) 22:52 (00:40) 0.048*
Offset time (hh:mm) 07:30 (00:48) 08:22 (00:21) 0.478
Nocturnal duration (h) 7.0 (1.0) 9.5 (0.8) 0.063
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by the Mann-Whitney U-test; * p 
< 0.05.
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with an afferent cause of SCN dysfunction in HD.15 Alternatively, impaired expression and/or function of the 
melatonin receptors in HD could play a role, particularly the MT2 receptor subtype which is enriched in the 
SCN and is known to be involved in phase-shifting of the biological clock.17 Regardless of the cause of diurnal 
rhythm disturbances in HD, however, restoration of circadian rhythms by pharmacological imposition of sleep 
has been shown to improve cognitive decline in R6/2 mice, suggesting that a similar strategy may be beneficial 
to HD patients. As our findings indicate a DSPS-like phenotype in early stage HD, another approach that may 
be evaluated in these patients is to treat them with melatonin and/or bright light at the appropriate times so as 
to phase advance the clock.13,25 The administration of melatonin at the subjective dusk, and the use of bright 
light at the subjective dawn and avoidance of light in the subjective evening, could be used to phase advance 
the clock.13,25 
Interestingly, we also found that mean diurnal melatonin levels in HD patients decreased with increasing 
severity of the clinical phenotype, suggesting that melatonin levels may decline substantially with advancing 
disease course. Progressive abnormalities in the metabolism of the melatonin precursor tryptophan may account 
for this association,7,19 although additional investigations are needed to pinpoint the exact underlying metabolic 
pathways. Numerous studies have shown the ability of melatonin and its kynuramine metabolites to increase the 
survival of neurons under conditions of enhanced oxidative stress.18 Therefore, declining melatonin levels may 
contribute to the progressive neurodegeneration in HD, and conversely, exogenous melatonin supplementation 
may be of benefit to HD patients. In fact, melatonin can antagonise the cytotoxic properties of both quinolinic 
acid and 3-nitropropionic acid, the administration of which is used to model HD induced pathology.6,21 
Moreover, recently it was demonstrated that melatonin can potently inhibit mitochondrial cytochrome  c 
release, which is known to activate downstream cell death pathways, resulting in neuroprotection in a mutant 
huntingtin expressing striatal cell line.23
In conclusion, our findings suggest a DSPS-like circadian rhythm disorder in early stage HD patients and 
indicate that melatonin levels may progressively decline with advancing disease. Therefore, strategies aimed 
at advancing the phase of the biological clock as well as melatonin supplementation might be of benefit to 
HD patients. However, first larger scale studies are needed to confirm our findings and to assess whether later 
stages of HD are also accompanied by a similar circadian rhythm disorder.
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“Diabetes. Ligate pancreatic ducts of dog. Keep dogs alive till acini degenerate 
leaving Islets. Try to isolate the internal secretion of these to releave glycosuria.”
Frederick Grant Banting Banting’s notebook, October 31, 1920, 2:00 AM. In: 
Bliss M. The Discovery of Insulin. Chicago: University of Chicago Press; 1982, 
p. 50. 
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ABSTRACT
Background. Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an increased 
number of CAG repeats in the HTT gene. Apart from neurological impairment, the disease is also accompanied 
by progressive weight loss, abnormalities in fat and glucose homeostasis and a higher prevalence of 
diabetes mellitus, the causes of which are unknown. Therefore, we aimed to perform a detailed analysis 
of systemic energy homeostasis in HD patients in relation to disease characteristics. Methods. Indirect 
calorimetry combined with a hyperinsulinemic-euglycemic clamp with stable isotopes ([6,6-2H2]-glucose 
and [2H5]- glycerol) was performed to assess energy expenditure, and glucose and fat metabolism in nine 
early-stage, medication-free HD patients and nine age-, sex- and body mass index-matched controls. Results. 
Compared with controls, fasting energy expenditure was higher in HD patients (1616±72 vs. 1883±93kCal/24 
h, p=0.037) and increased even further after insulin stimulation (1667±87 vs. 2068±122 kCal/24 h, p=0.016). 
During both basal and hyperinsulinemic conditions, glucose and glycerol disposal rates, endogenous glucose 
production and hepatic insulin sensitivity were similar between HD patients and controls. In HD patients, 
energy expenditure increased with disease duration, but not with a greater degree of motor or functional 
impairment. Moreover, a higher mutant CAG repeat size was associated with lower insulin sensitivity (r=-
0.84, p=0.018). Conclusion. These findings suggest sympathetic hyperactivity as an underlying mechanism 
of increased energy expenditure in HD, as well as peripheral polyglutamine-length dependent interference of 
mutant huntingtin with insulin signaling that may become clinically relevant in carriers of mutations with large 
CAG repeat sizes. 
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Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HTT gene, resulting in a long polyglutamine tract in the 
N-terminus of the encoded protein huntingtin.1 The disease is characterized by motor disturbances, cognitive 
deterioration, and psychiatric and behavioural problems.2 Progressive weight loss and muscle wasting, despite 
sustained or even increased caloric intake, are also hallmarks of the disease, both in HD patients3-5 and several 
transgenic mouse models of the disease.6-9 Moreover, abnormalities in glucose homeostasis as well as a higher 
prevalence of diabetes mellitus have been reported in HD patients, which are also evident in the transgenic 
models.7,10,11 These peripheral abnormalities may not only considerably impair the quality of life of HD patients 
but could also affect the neurodegenerative process.12,13 However, the cause of the peripheral signs in HD is 
largely unknown, although both hypothalamic dysfunction and peripheral defects in glucose and fat metabolism 
may be involved.3,13,14
 
Several studies have implicated transcriptional repression of  the peroxisome proliferator-activated 
receptor gamma coactivator-1α (PGC-1α) by mutant huntingtin in HD associated neurodegeneration.15-17 
The transcriptional coactivator PGC-1α is a potent regulator of mitochondrial biogenesis and respiration, 
and therefore, its downregulation by mutant huntingtin is thought to provide the long-sought link between 
transcriptional dysregulation and mitochondrial dysfunction in HD.18 Interestingly, recently it was shown that 
mutant huntingtin also inhibits transcriptional activity of PGC-1α and its target genes in peripheral tissues 
such as muscle and fat in both HD patients and animal models of the disease.19,20 As PGC-1α has emerged as 
a master regulator of systemic energy homeostasis involved in adaptive thermogenesis, β-oxidation of fatty 
acids, insulin sensitivity and carbohydrate metabolism in general,21 we hypothesized that impaired peripheral 
PGC-1α activity in HD patients is likely to give rise to disturbances of fat and glucose metabolism and diminish 
insulin sensitivity. 
Systemic substrate metabolism and its responsiveness to insulin stimulation has, however, not yet been 
rigorously assessed in HD patients. Hence, in order to elucidate the underlying mechanisms of weight loss and 
impaired glucose homeostasis in HD, in this study we aimed to accurately assess resting energy expenditure, 
as well as lipid and glucose metabolism during both basal and insulin stimulated conditions in early stage, 
medication-free HD patients in comparison with matched controls. 
SUBJECTS AND METHODS 
Subjects 
Nine early-stage HD patients (stages I and II)  and nine healthy control subjects  matched for age, sex, and body mass 
index (BMI), were enrolled in the study. Clinical details are summarized in Table 1. In the patient group, mutant 
CAG repeat size ranged between 41 and 50. The clinical diagnosis of HD was made by a neurologist specialized 
in movement disorders (R.A.C.R.). The Unified Huntington’s Disease Rating Scale (UHDRS) was used to assess 
HD symptoms and signs.22 None of the subjects used medication, except one HD patient who discontinued 
paroxetine (20 mg/day; t
1/2
 ≈ 21 h) use three weeks prior to study. Subjects were eligible for participation after 
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exclusion of hypertension, 
any known (history of) 
pituitary disease, recent 
intentional weight change 
(>3 kg weight gain or 
loss within the last 3 
months), and any other 
chronic condition except 
HD as assessed by clinical 
examination and routine 
laboratory tests. Written 
informed consent was 
obtained from all subjects. 
The study was approved 
by the Medical Ethics 
Committee of the Leiden 
University Medical Center.
Clinical protocol 
All studies started at 8:00 AM after an overnight fast. Height, weight, BMI and waist-to-hip ratio were measured 
according to the World Health Organization recommendations. Lean body mass and fat percentage were 
assessed by bioelectrical impedance analysis. Metabolic studies were performed as described previously.23 
In short, patients were requested to lie down on a bed in a semirecumbent position. A polyethylene catheter 
was inserted into an antecubital vein for infusion of test substances. Another catheter was inserted into a 
contralateral dorsal hand vein for blood sampling; this hand was kept in a heated box (60 ºC) throughout the 
test to obtain arterialized blood. Samples were taken for the measurement of basal levels of glucose, insulin, 
glucagon, cholesterol, triglycerides, nonesterified fatty acids (NEFAs), glycerol, and background enrichment 
of [6,6-2H2]-glucose and [
2H5]- glycerol. At 8:30 AM (t = 0 min), an adjusted primed (17.6 μmol/kg × actual 
plasma glucose concentration [mmol/L]) continuous (0.33 μmol/kg per minute) infusion of [6,6-2H2]-glucose 
(enrichment 99.9%; Cambridge Isotopes, Cambridge, Mass) was started and continued throughout the study. 
After 60 minutes, a primed (1.6 μmol/kg) continuous (0.11 μmol/kg) infusion of [2H5]-glycerol (Cambridge 
Isotopes) was started and continued throughout the study. During this period, indirect calorimetry with a 
ventilated hood (Oxycon Beta, Mijnhardt Jaegher, Breda, The Netherlands) was performed for 30-min for 
basal glucose and lipid oxidation rates.24 At the end of the basal period, four blood samples were taken at 
10-min intervals for the determination of plasma glucose, glycerol, insulin, and [6,6-2H2]-glucose – and [
2H5]-
glycerol –specific activities. Subsequently, a primed continuous infusion of insulin (Actrapid, Novo Nordisk 
Pharma BV, Alphen aan de Rijn, The Netherlands; 40 mU/m2/min) was started (t = 120 min). Exogenous 
glucose 20% enriched with 3% [6,6-2H2]-glucose was infused at a variable rate to maintain the plasma glucose 
level at 5.0 mmol/L. A second indirect calorimetry was performed at the end of the hyperinsulinemic clamp. 
From t = 210 to 240 min, blood was drawn every 10 min for the determination of [6,6-2H2]-glucose – and [
2H5]-
glycerol –specific activities, glucose, insulin, and glycerol. While blood in the serum samples was allowed to 
clot, plasma samples were immediately put on ice. Within 60 min of sampling, all samples were centrifuged at 
Table 1. Characteristics of the study population 
HD patients† Controls† p-value‡
Male/female 6/3 6/3 -
Age [y] 47.5 (3.4) 48.8 (3.3) 0.797
BMI 23.6 (0.8) 24.0 (0.6) 0.700
Fat [%] 24.5 (2.4) 24.6 (2.1) 0.972
Lean body mass [kg] 57.5 (3.6) 56.4 (3.0) 0.818
Waist-to-hip ratio 0.92 (0.02) 0.94 (0.02) 0.591
Mutant CAG repeat size 44.4 (1.0) - -
Disease duration [y] 6.1 (1.1) - -
UHDRS motor score 22.2 (6.0) - -
TFC score 11.7 (0.7) - -
†) Values are indicated as mean (SE).
‡) Differences between groups were assessed by unpaired t-tests.
Abbreviations: BMI = Body Mass Index; FAS = Functional Assessment; TFC 
= Total Functional Capacity; UHDRS = Unified Huntington’s Disease Rating 
Scale. 
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1610 g at 4 ºC for 20 min, and then stored at -80 ºC until assay.
Assays 
Serum insulin and glucagon were measured with an immunoradiometric assay (Biosource, Nivelles, Belgium) 
and a radioimmunoassay (Linco Research, St. Charles, MO, USA), respectively. Serum triacylglycerol was 
measured with a fully automated Modular P800 Hitachi system (Tokyo, Japan). Serum NEFAs were assessed 
by an enzymatic colorimetric acyl-CoA synthase/oxidase assay (Wako Chemicals, Neuss, Germany), while 
serum glucose, [6,6-2H2]-glucose, and [
2H5]-glycerol were determined in a single analytical run using gas 
chromatography-mass spectrometry as described previously.23 
Calculations
A physiological and isotopic steady-state was achieved during the last 30 min of both the basal as well as the 
hyperinsulinemic period; therefore, the rates of appearance and disappearance for glucose and glycerol were 
calculated as the tracer infusion rate divided by the tracer-to-tracee ratio.25 Glucose flux rates were expressed per 
kg fat free mass, whereas glycerol flux rates were normalized per kg fat mass. Endogenous glucose production 
(EGP) during the basal steady-state is equal to the rate of appearance of glucose, whereas EGP during the 
clamp was calculated as the difference between the rates of glucose appearance and infusion. Since the fasting 
plasma insulin concentration is a strong inhibitory stimulus for EGP, the basal hepatic insulin resistance 
index (μmol/min/kg
FFM
/pmol × L) was calculated as the product of fasting EGP and fasting plasma insulin 
concentration.26 The metabolic clearance rate of insulin was calculated as the constant infusion rate of insulin 
divided by the steady-state serum insulin concentration corrected for endogenous insulin secretion. Total lipid 
and carbohydrate oxidation rates were calculated as described by.24 Non-oxidative glucose metabolism was 
calculated by subtracting the glucose oxidation rate (determined by indirect calorimetry) from glucose rate of 
disappearance. 
Statistical analysis 
Results are expressed as mean ± standard error (SE) unless otherwise specified. Unpaired t tests were used 
to assess differences in means between the two groups, whereas paired t tests were applied to assess mean 
differences between basal and hyperinsulinemic conditions. Partial rank correlation coefficients were used to 
assess all correlations while adjusting for the effects of age and sex. All tests were two-tailed and significance 
level was set at p < 0.05. Statistical analyses were performed using SPSS for Windows (release 16.0, SPSS, 
Inc., Chicago, IL) and TANAGRA (release 1.4, Lyon, France).
RESULTS
Subjects 
The HD and the control group did not differ with respect to age, sex, BMI, body fat percentage, or lean body 
mass (all p ≥ 0.70, Table 1). Moreover, fasting levels of glucose, insulin, glycosylated hemoglobin (HbA1c), 
glucagon, triglycerides, cholesterol and NEFAs were similar between the two groups (all p ≥ 0.10, Table 2).
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Energy expenditure
Basal resting energy expenditure was significantly higher in HD patients compared with controls (1883 ± 
93 vs. 1616 ± 72 kCal/24 h, p = 0.037), which was mainly due to a higher rate of lipid oxidation (Table 2). 
Insulin stimulation caused a significant rise in the resting energy expenditure in HD patients, but not in controls 
(Figure 1, Table 2). Although insulin stimulation induced a significant rise in glucose oxidation rate in both 
groups, the magnitude of this rise was greater in HD patients (1130 ± 194 vs. 605 ± 110 μmol/min, p = 0.032). 
Glucose metabolism
Both during basal and hyperinsulinemic conditions whole body glucose disposal rate, as well as non-oxidative 
glucose disposal, endogenous glucose production and hepatic insulin resistance were similar between HD 
patients and controls (Table 2). Insulin stimulation significantly increased glucose disposal and suppressed 
glucose production, however, there were no significant differences between HD patients and controls (Table 2). 
Lipid metabolism
Plasma glycerol levels as well as the rate of appearance of glycerol, which is a measure of lipolysis, were 
similar between HD patients and controls. Moreover, hyperinsulinemia suppressed lipolysis to a similar degree 
in both groups (Table 2).  
Table 2. Metabolic parameters in patients with Huntington’s disease and matched controls during 
basal and hyperinsulinemic conditions 
Basal Conditions Hyperinsulinemia
HD 
patients
Controls p 
value
HD 
patients
Controls p 
value
Energy Expenditure (kCal/24 
h) 
1883 ± 93 1616 ± 72 0.037* 2068 ± 122 1667 ± 87 0.016*
Glucose Rd (μmol/kgFFM/min) 20.7 ± 0.8 21.2 ± 0.6 0.381 65.0 ± 7.2 68.6 ± 9.2 0.884
Glucose Oxidation (μmol/min) 653 ± 137 709 ± 102 0.748 1783 ± 227 1314 ± 68 0.065
NOGD (μmol/kg
FFM
/min) 12.7 ± 4.3 7.6 ± 1.7 0.290 33.6 ± 6.9 40.0 ± 7.8 0.543
EGP (μmol/kg
FFM
/min) 20.7 ± 0.8 21.2 ± 0.6 0.381 13.7 ± 1.0 15.0 ± 1.6 0.850
HIR (μmol kg
FFM
/min/
pmol × L) 
1176 ± 126 1232 ± 83 0.547 7841 ± 549 7891 ± 
595
0.558
Glycerol Ra (μmol/kgFM/min) 7.4 ± 0.9 6.4 ± 0.8 0.409 2.6 ± 0.4 2.3 ± 0.3 0.503
Lipid Oxidation (μmol/min) 340 ± 31 252 ± 26 0.045* 93 ± 47 107 ± 23 0.785
Plasma insulin (mU/l) 9.2 ± 0.9 8.8 ± 1.1 0.758 82.4 ± 3.1 76.0 ± 2.9 0.156
MCR
I
 (ml/m2/min) - - - 0.56 ± 0.02 0.60 ± 0.2 0.181
Glucose (mmol/l) 4.6 ± 0.2 4.6 ± 0.2 0.875 4.9 ± 0.1 4.8 ± 0.2 0.566
Glycerol (mmol/l) 50.0 ± 6.9 50.9 ± 8.4 0.938 21.8 ± 7.2 17.8 ± 2.9 0.618
HbA1c (%l) 4.8 ± 0.1 4.9 ± 0.1 0.579 - - -
Glucagon (ng/l) 39.8 ± 3.3 51.9 ± 6.1 0.103 - - -
NEFA (mmol/l) 0.51 ± 0.07 0.40 ± 0.04 0.200 - - -
Triacylglycerol (mmol/l) 1.0 ± 0.2 0.9 ± 0.1 0.662 - - -
Total cholesterol (mmol/l)  4.4 ± 0.2 4.0 ± 0.6 0.525 - - -
Data are means ± SEM. * p < 0.05 
Abbreviations: EGP = endogenous glucose production; FFM = fat free mass; FM = fat mass; HIR = hepatic 
insulin resistance; MCR
I
 = metabolic clearance rate of insulin; NEFA = non-esterified fatty acids; NOGD, non-
oxidative glucose disposal; Ra = rate of appearance; Rd = rate of disappearance 
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Metabolic parameters in relation to clinical 
phenotype
When corrected for age and sex, basal and insulin 
stimulated resting energy expenditure were 
significantly associated with disease duration 
(r = +0.80, p = 0.029, and r = +0.83, p = 0.020, 
respectively), but not with total motor score, 
chorea, dystonia, rigidity, bradykinesia, total 
functional capacity or CAG repeat size (all p 
≥ 0.32). However, there was a strong negative 
association between insulin sensitivity, defined as 
the glucose disposal rate per kilogram fat free mass 
during the hyperinsulinemic clamp, and the length 
of the mutant CAG repeat stretch (r = -0.84, p = 
0.018), while total motor score and total functional 
capacity were not associated with insulin sensitivity 
(both p ≥ 0.83). Although in controls there was a 
significant association between BMI and insulin 
sensitivity (r = -0.87, p = 0.012), this association 
was reversed and not significant in HD patients (r 
= +0.42, p =0.345). 
DISCUSSION
We present a detailed description of the resting energy expenditure, as well as lipid and glucose metabolism 
in early stage, medication-free HD patients during both basal and hyperinsulinemic conditions. Compared 
with matched controls, we found a significantly higher basal resting energy expenditure in HD patients which 
was primarily due to an increased fat oxidation rate. Moreover, unlike in controls, hyperinsulinemia induced 
a further increase in energy expenditure in HD patients which was now primarily due to an elevated rate 
of glucose oxidation. Although we did not find any evidence for insulin resistance in HD patients, higher 
CAG repeat size was associated with lower insulin sensitivity. These findings point towards defective energy 
homeostatic mechanisms even in early stage HD patients that could account for the progressive weight loss 
and muscle wasting in this disorder.
Our finding of a higher resting energy expenditure during basal conditions is in line with a number of previous 
reports.27-29 Here we expand on these findings by showing that resting energy expenditure in HD patients 
increases even further after insulin stimulation, which contrasts with what was found in our controls and what 
has been reported in other healthy subjects.30 Insulin is known to stimulate sympathetic nervous system outflow 
through the ventromedial nucleus of the hypothalamus.31 Moreover, pathology of this hypothalamic structure 
is known to impair suppression of sympathetic activity during fasting.32 Indeed, recently it was shown that HD 
transgenic mice fail to reduce brown adipose tissue uncoupling protein-1 levels and paradoxically upregulate 
Figure 1. Energy expenditure in Huntington’s disease 
patients and controls. Compared with matched controls 
resting energy expenditure is significantly higher in 
Huntington’s disease (HD) patients during both basal 
and insulin stimulated conditions. Bars represent 
standard errors of the mean. * p < 0.05.
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PGC-1α levels during fasting, indicating persistent sympathetic activation.17 Sympathetic hyperactivity has 
also been demonstrated in mildly disabled HD patients as well as in otherwise asymptomatic HD mutation 
carriers.33 Hence, as sympathetic nervous activity is an important determinant of resting metabolic rate,31 
dysfunction of the ventromedial hypothalamic nucleus in HD may lead to sympathetic hyperactivity and could 
thereby account for the elevated rate of energy expenditure during both the basal and insulin stimulated state. 
Paradoxical upregulation of PGC-1α as a consequence of unabated sympathetic activity  may also account for 
the predominant oxidation of fat during the basal state in HD patients,17 whereas the relative inability to induce 
PGC-1α expression beyond a certain level, as well as enhanced ability of insulin to induce leptin secretion 
from HD adipocytes may be involved in the increased rate of glucose oxidation during hyperinsulinemic 
conditions.15-17,34
Using the hyperinsulinemic-euglycemic clamp technique, the most accurate method available to assess insulin 
sensitivity, we could not find any evidence for insulin resistance in early stage HD patients. This result extends 
findings from recent studies in HD transgenic mouse models and provides conclusive support for the notion 
that impaired glucose homeostasis in HD is likely due to disturbances of pancreatic insulin release rather than 
peripheral resistance to insulin.6-8,35,36 In particular, glucose disposal rate, endogenous glucose production and 
hepatic insulin sensitivity were all similar between HD patients and controls, both during the basal state and 
insulin challenge. Although a recent study suggested that insulin resistance may also be involved in HD, this 
study applied the homeostatic model assessment (HOMA) index for the determination of insulin sensitivity.10 
However, the HOMA index is based on a number of assumptions, such as an intact negative feedback loop 
between plasma glucose and insulin levels,37 which may not hold in HD subjects due to, for example, distinct 
pancreatic islets defects.6-8 Moreover, the authors did not report on the stage of the illness or medication use in 
their subjects rendering direct comparisons difficult.10   
Assessment of the relation between metabolic parameters and clinical characteristics in HD patients revealed 
a number of interesting associations. Resting energy expenditure during both basal and insulin stimulated 
states was strongly associated with disease duration, but not with total motor score, chorea, dystonia or 
functional capacity suggesting a progressive hypermetabolic state in HD patients that is not secondary to 
increased motor activity or functional impairment. Moreover, higher mutant CAG repeat size was associated 
with lower insulin sensitivity which could be accounted for by polyglutamine-length dependent interference of 
mutant huntingtin with both mitochondrial function and transcription of genes that are involved in the insulin 
signaling pathway.38,39 However, as our HD cohort as a whole was as sensitive to insulin as the controls, the 
effect of mutant huntingtin on insulin signaling is either modest or only likely to become appreciable past a 
certain polyglutamine-tract size; therefore, it would be interesting to evaluate insulin sensitivity in juvenile 
HD patients who invariably carry very large mutant CAG repeat sizes. The inverse relation between mutant 
CAG repeat size and insulin sensitivity could also account for the absence of the well-established association 
between BMI and insulin sensitivity in our HD patients.40 
In conclusion, we found a higher rate of resting energy expenditure in early stage HD patients that increased 
further in response to insulin. However, although there was an inverse association between mutant CAG 
repeat size and insulin sensitivity, HD patients were not insulin resistant. These findings suggest sympathetic 
hyperactivity as an underlying mechanism of increased energy expenditure in HD, as well as peripheral 
polyglutamine-length dependent interference of mutant huntingtin with insulin signaling that may become 
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clinically relevant in carriers of mutations with large CAG repeat sizes. 
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With them the seed of Wisdom did I sow,  
And with mine own hand wrought to make it grow;  
And this was all the Harvest that I reap’d,  
“I came like Water, and like Wind I go.”
Omar Khayyam (1048-1131 CE) 
(Translation from Persian by Edward FitzGerald in 1859)
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SYNOPSIS & CONCLUSIONS
The nuclear symptoms and signs of Huntington’s disease (HD) consist of motor, cognitive and behavioural disturbances. Other less well-known, but prevalent and debilitating features of HD include unintended 
weight loss, sleep and circadian rhythm disturbances, as well as autonomic nervous system dysfunction. 
However, the pathogenesis of these less well-known features of HD is poorly understood and currently no 
effective treatment options are available. It is thus of paramount importance to elucidate the pathological 
basis of these symptoms and signs in order to design and apply more effective therapeutic interventions. 
Recently, substantial dysfunction of the hypothalamus was reported in both human studies and various knock-
in and transgenic animal models of HD. The hypothalamus consists of groups of interconnected neuronal 
nuclei located at the base of the brain that regulate a broad array of physiologic, homeostatic and behavioural 
activities. Therefore, in this thesis we attempt to substantiate the premise that hypothalamic dysfunction per 
se, as well as secondary (neuro)endocrine and metabolic alterations could contribute to the pathogenesis of 
several non-motor symptoms and signs of HD (Chapter 1). 
Part I: Secondary signs of HD
The first part of the thesis is largely devoted to the exploration of the nature and extent of weight loss, sleep 
and circadian rhythm disturbances, and autonomic complaints in HD patients. In addition, an effort is made to 
identify the clinical predictors associated with these secondary signs. 
A significant decrease in body weight was found over the course of three years in a large group of early 
stage HD patients (Chapter 2). However, no single motor, cognitive or behavioural score was independently 
associated with weight loss, suggesting that loss of body weight in HD is not secondary to hyperactivity or 
other symptoms, but likely results from a metabolic defect. As both HD patients and transgenic mice showed a 
higher rate of weight loss with greater CAG repeat number, this metabolic defect possibly stems directly from 
polyglutamine length dependent interference of the mutant protein with cellular homeostasis in central (e.g. 
hypothalamus) or peripheral (e.g. muscle, fat) tissues that are involved in body weight regulation. Moreover, 
these findings indicate that patients with a higher number of CAG repeats are at an increased risk of unintended 
weight loss. 
The effects of the interaction between mutant and normal HTT on clinical phenotype are presented in Chapter 
3. We found that normal and mutant CAG repeat sizes interact to influence age of onset, and the severity or 
progression of motor, cognitive and functional symptoms in HD patients, but not body weight.  As the effect of 
the interaction on basal ganglia volume could already be detected in premanifest subjects, these data suggest 
that the interplay between normal and mutant huntingtin (fragments) directly influences neuronal atrophy or 
loss and is thus an integral feature of HD pathogenesis. The underlying mechanism may involve interaction of 
the polyglutamine domains of normal and mutant huntingtin (fragments) and needs further elucidation. These 
findings may have predictive value and are essential for the design and interpretation of future therapeutic 
trials. 
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Data from a systematic evaluation of  subjective sleep quality and daytime somnolence in a large cohort of HD 
patients and premanifest mutation carriers are reported in Chapter 4. The findings indicate that while night-
time sleep impairment is more prevalent in HD patients, daytime sleepiness appears unlikely to be a major 
issue in HD. We also show that depression is the most important clinical predictor of sleep impairment in HD 
patients. Moreover, our findings suggest a delayed sleep phase syndrome-like circadian rhythm disorder in HD 
patients which appears to be associated with lower cognitive performance. 
Findings from a questionnaire study indicated that HD patients experience various symptoms suggestive of 
autonomic nervous system dysfunction (Chapter 5). The complaints particularly concerned the gastrointestinal, 
urinary, cardiovascular and male sexual domains, and some of them were also present in premanifest mutation 
carriers. These findings indicate that, contrary to common belief, autonomic symptoms are highly prevalent 
in HD patients and may even precede the onset of motor signs. Moreover, we found that a greater degree 
of autonomic dysfunction in HD patients was associated with more functional disability as well as more 
depressive symptoms, suggesting that adequate management of autonomic symptoms in HD patients could be 
evaluated as a potential strategy to improve their quality of life.
Part II: Hypothalamic pathology in HD
In this section (Chapter 6) we report a significant reduction by about 30% in the total number of hypocretin-1 
immunoreactive neurons in the lateral hypothalamus of HD patients. This decrease appears to be relatively 
specific as the total number of melanin-concentrating hormone (MCH) immunoreactive neurons was 
not significantly altered. Hypocretin-1 levels in the prefrontal cortex were reduced to the same extent, but 
ventricular cerebrospinal fluid levels were unchanged. It remains to be shown whether this moderate decrease 
in hypocretin signalling could contribute to clinical symptoms. As MCH cell number was not clearly affected 
in HD patients, alterations in MCH neurotransmission are unlikely to have clinical effects in HD. Interestingly, 
neuronal intranuclear and cytoplasmic inclusions were not uniformly present in various hypothalamic and 
adjacent structures in HD patients. This finding may indicate that various hypothalamic nuclei are differentially 
affected by inclusion formation despite their close anatomical juxtaposition in the hypothalamus.
Part III: Endocrine studies in HD
A detailed description of cortisol secretory dynamics in patients with HD is presented in Chapter 7. We 
found that the total 24 h cortisol production rates were significantly elevated in HD patients. The increase in 
cortisol production was primarily confined to the morning and early afternoon period. In addition, circadian 
rhythmicity analysis revealed a significantly higher amplitude of the diurnal cortisol concentration profile 
in HD patients. These findings point towards a disturbed central glucocorticoid feedback regulation in HD 
patients and indicate that hypothalamic-pituitary-adrenal axis dysfunction is an early feature of the disease.
We found no significant differences in growth hormone and ghrelin secretion characteristics between HD 
patients and controls (Chapter 8). However, in HD patients, both growth hormone secretion and its irregularity 
as well as the degree of postprandial ghrelin suppression significantly increased with worsening motor and 
functional impairment. Moreover, postprandial ghrelin suppression also increased with decreasing body 
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weight and higher CAG repeat number. These findings suggest subtle changes in the regulation of growth 
hormone and ghrelin secretion dynamics in early stage HD patients that may become more pronounced in the 
later stages of the disease.
Investigation of the thyrotropic and lactotropic axes function (Chapter 9) revealed a mild hyperactivity of the 
hypothalamic-pituitary-thyroid axis, as well as a more irregular pattern of prolactin secretion in HD patients 
compared with matched controls. These findings are consistent with disrupted hypothalamic-pituitary dopamine 
signaling in HD. Interestingly, higher free T4 levels were associated with larger mutant CAG repeat sizes. In 
addition, there was an inverse trend for the relation between total T4 levels and body mass index (BMI) in HD 
patients. As thyroid hormones are known to increase energy expenditure, elevated thyroid hormone levels in 
early stage HD patients that seem to increase with mutant CAG repeat size, may contribute to the lower BMI 
in HD mutation carriers,1,2 and possibly account for the association between mutant HTT CAG repeat size and 
weight loss in HD.3
The plasma levels and diurnal rhythmicity of the adipokines leptin, adiponectin and resistin did not significantly 
differ between HD patients and controls (Chapter 10). However, when corrected for fat mass, both mean plasma 
leptin concentration and secretion rate significantly increased with the size of the CAG repeat mutation in HD 
patients. As leptin is an anorexigenic hormone that stimulates energy expenditure,4 enhanced leptin production 
rate in HD patients with higher CAG repeat lengths in the mutant allele could lead to decreased appetite and 
hypermetabolism, thereby contributing to the higher rate of weight loss in these subjects.3 Interestingly, unlike 
in controls, neither BMI nor body fat mass was significantly related to leptin production in HD patients. These 
findings suggest that the HD mutation interferes with adipose tissue function, which may contribute to weight 
loss in HD patients.
The timing of the evening rise in melatonin levels was significantly delayed by more than one and a half hours 
in early stage HD patients compared with control subjects (Chapter 11). Moreover, despite similar mean 
diurnal melatonin levels between HD patients and controls, we found strong negative associations between 
mean diurnal melatonin levels and both motor and functional disability in these patients. These findings suggest 
a delayed sleep phase syndrome-like circadian rhythm disorder in early stage HD patients and suggest that 
melatonin levels may progressively decline with advancing disease. 
Part IV: Metabolic studies in HD
Compared with controls, we found a significantly higher basal resting energy expenditure in HD patients 
which was primarily due to an increased fat oxidation rate (Chapter 12). Moreover, unlike in controls, 
hyperinsulinemia induced a further increase in energy expenditure in HD patients which was now primarily 
due to an elevated rate of glucose oxidation. Although we did not find any evidence for insulin resistance in 
HD patients, higher CAG repeat size was associated with lower insulin sensitivity. These findings suggest 
sympathetic hyperactivity, possibly due to dysfunction of the hypothalamic ventromedial nucleus, as well as 
peripheral polyglutamine length dependent interference of mutant huntingtin with insulin signaling that may 
become clinically relevant in carriers of mutations with large CAG repeat sizes. 
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FUTURE PERSPECTIVES
The studies described in this thesis provide fertile ground for further basic as well as clinical research into 
several facets of HD.  First, however, alike every other claim of scientific advance, our assertions should be 
subjected to scrutiny and attempts should be undertaken to replicate the findings in other, preferably larger, 
cohorts of HD patients. Moreover, it would be interesting to assess patients in various stages of the disease, 
although medication use as well as functional and mental disabilities in more advanced stage patients posit 
major feasibility challenges. In this regard, it is particularly encouraging to note that several of our results, 
such as the inverse association between body weight and mutant CAG repeat size and increased cortisol 
levels, have already been replicated in independent investigations implicating relatively large numbers of 
HD patients, 5,6 while confirmational studies are underway for several other of our findings, including the 
effect of normal and mutant HTT interaction on disease severity that will be assessed in the TRACK-HD 
cohort.7 With this conditional stipulation in mind, in the remaining part of this section we will put forth a few 
lines of thought that may serve to direct future research endeavours in this field. The mechanism underlying 
the negative association between body weight and mutant CAG repeat length needs further elucidation, as 
this may facilitate the generation of therapeutics aiming to restore cellular energy homeostasis in HD. In 
particular, it remains to be shown to what extent the relation between body weight and mutant CAG repeat size 
is due to polyglutamine length dependent pathology of brain structures involved in energy homeostasis (e.g. 
the hypothalamus),8,9 or due to pathology of peripheral tissues such as muscle, fat and pancreatic tissue.10-12 
Evaluation of the association between CAG repeat size and the functional integrity of the  hypothalamus, for 
instance as assessed by various imaging techniques, combined with hormone challenge tests and muscle/fat 
biopsies may greatly advance our understanding of this issue. Likewise, the pathways mediating the effect of 
the interaction between normal and mutant HTT CAG repeat sizes on disease severity await further clarification. 
Several models could account for this phenomenon, including competitive polyglutamine length dependent 
interaction of normal and mutant huntingtin with numerous protein binding partners,13,14 mitochondrial energy 
production15 or transcriptional mechanisms.16 Regardless of the responsible mechanisms, however, an important 
corollary of this study is that future clinical trials aiming to assess the efficacy of a particular therapy in HD 
patients should consider adjusting the outcome for the CAG repeat sizes in both HTT alleles. Findings from 
our inventory of sleep disturbances, as well as cortisol and melatonin rhythms in HD indicate a delayed sleep-
phase syndrome-like circadian rhythm disturbance that requires further scrutiny by means of other measures 
of circadian rhythm such as 24 h body temperature recordings and actigraphy. This is important as HD patients 
may benefit from similar strategies applied for the re-entrainment of the circadian rhythms in subjects suffering 
from a delayed-sleep phase syndrome. We also found that HD patients experience a large number of symptoms 
that, at least partly, could be manifestations of autonomic nervous system dysfunction. Application of more 
extensive, standardized questionnaires in combination with objective measures of autonomic nervous system 
function may help to elucidate to what degree putative symptoms of autonomic origin actually stem from 
autonomic failure in HD, rather than being expressions of pathognomonic debilities such as motor impairment. 
Neuropathological assessment of the hypothalamus revealed that neuronal intranuclear and cytoplasmic 
inclusions are not uniformly present in various hypothalamic and adjacent structures in HD. Characterization 
of the processes mediating this heterogeneity may illuminate why certain neuronal populations are more 
susceptible to HD pathology than others. In this respect, it would be interesting to assess whether Rhes (Ras 
homologue enriched in striatum), a protein that is thought to mediate the relative selectivity of striatal pathology 
in HD,17 is present in the hypothalamus, whether its distribution differs between various hypothalamic nuclei, 
and whether its expression is altered in HD hypothalami. The findings from our endocrine and metabolic 
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studies in early stage HD patients are consistent with hypothalamic pathology, and especially implicate the 
suprachiasmatic nucleus in the disease process. Employing immunocytochemical and in situ hybridization 
techniques, systematic neuropathological evaluation of the suprachiasmatic and other hypothalamic nuclei 
in HD are currently underway in close collaboration with the Netherlands Institute for Neurosciences. In 
addition, regarding the progressive nature of HD, longitudinal studies of endocrine (particularly cortisol and 
growth hormone secretion) and metabolic (especially energy expenditure and response to insulin challenge) 
parameters in conjunction with clinical assessments may provide more insight into potential dynamic alterations 
which might prove useful as biomarkers of disease progression. Last but not least, it should be noted that 
certain of our findings, such as the association between the secretion of the adipocyte specific hormone leptin 
and mutant CAG repeat size, are better explained by peripheral, rather than central, pathology in HD. Hence, 
dictated by the expression of mutant huntingtin throughout the body, a holistic approach with the evaluation 
of both central as well as peripheral tissues appears a prudent strategy for the identification of the pathological 
basis of secondary signs in HD.10    
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Appendix A
SAMENVATTING & CONCLUSIES
De ziekte van Huntington (ZvH) is een erfelijke neurodegeneratieve aandoening die wordt gekenmerkt door progressieve motorische, psychiatrische en cognitieve stoornissen.1 Andere minder bekende symptomen 
van de ZvH, die niettemin frequent voorkomen en de levenskwaliteit nadelig kunnen beïnvloeden, zijn 
ongewenst gewichtsverlies en stoornissen van de slaap en het autonome zenuwstelsel. Echter, de pathogenese 
van deze laatstgenoemde symptomen bij de ZvH is grotendeels onopgehelderd en thans zijn bijgevolg geen 
effectieve therapeutische opties voorhanden. Teneinde het ontwerpen en toepassen van effectieve therapeutische 
interventies te bespoedigen, is het van groot belang om de pathologische basis van deze ziekteverschijnselen te 
achterhalen. Recent werden aanwijzingen gevonden voor een aanzienlijke mate van hypothalame pathologie 
bij zowel patiënten met de ZvH als muismodellen van de ziekte. De hypothalamus is gelokaliseerd aan de basis 
van het brein en bestaat uit groepen van onderling verbonden neuronale kernen die tezamen zorgdragen voor 
de regulatie van een groot aantal fysiologische, homeostatische en adaptieve functies. Ergo, in dit proefschrift 
hebben wij gepoogd om de premisse te substantiëren dat zowel hypothalame disfunctie op zich, alsmede 
secundaire (neuro)endocriene en metabole veranderingen zouden kunnen bijdragen aan de pathogenese van 
diverse niet-motorische symptomen van de ZvH (Hoofdstuk 1).
Deel I: Secundaire symptomen van de ZvH
Het eerste gedeelte van dit proefschrift is grotendeels gewijd aan het verkennen van de aard en de mate van 
gewichtsverlies en stoornissen in het slaappatroon, het circadiaanse ritme en de functie van het autonome 
zenuwstelsel bij patiënten met de ZvH. Tevens is getracht om de klinische correlaten van deze secundaire 
symptomen te identificeren.
In de loop van een drie jaar durend vervolgonderzoek werd een significante afname van het lichaamsgewicht 
gevonden in een omvangrijke groep patiënten met de ZvH die in een relatief vroeg stadium van de ziekte 
verkeerden (Hoofdstuk 2). Evenwel, geen enkele motorische, cognitieve of gedragsscore was onafhankelijk 
geassocieerd met de mate van gewichtsverlies, hetgeen erop kan duiden dat gewichtsverlies bij de ZvH niet 
secundair is aan hyperactiviteit of andere ziekteverschijnselen, maar waarschijnlijk zijn oorsprong vindt 
in een metabool defect. Aangezien bij zowel patiënten met de ZvH als transgene muizen de snelheid van 
het gewichtsverlies bleek samen te hangen met het aantal CAG repeatherhalingen, zou het metabole defect 
rechtstreeks kunnen voortvloeien uit een polyglutamine-lengte afhankelijke interferentie tussen het mutante 
huntingtine eiwit en cellulaire homeostase in hetzij centrale (bijv. hypothalamus) of perifere (bijv. spier, vet) 
weefsels die nauw zijn betrokken bij gewichtsregulatie. Bovendien wijzen deze bevindingen erop dat patiënten 
met een groter aantal CAG repeatherhalingen een verhoogd risico hebben op ongewenst gewichtsverlies.
De klinische effecten van de interactie tussen het normale en het mutante HTT allel worden gepresenteerd in 
Hoofdstuk 3. De interactie tussen normale en mutante CAG repeatlengtes bleek invloed te hebben op zowel de 
aanvangsleeftijd van de ZvH als de ernst of progressie van de motorische, cognitieve en functionele symptomen. 
Echter, psychiatrische symptomen en lichaamsgewicht bleken niet te worden beïnvloed. Aangezien het effect 
van de interactie op het volume van de basale ganglia tevens reeds in premanifeste mutatiedragers kon worden 
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gedetecteerd, suggereren deze data dat het samenspel tussen normale en mutante huntingtine (fragmenten) 
rechtstreeks neuronale atrofie of verlies kan beïnvloeden en dientengevolge een integraal kenmerk van de 
pathogenese van de ZvH zou kunnen vormen. Het onderliggende mechanisme zou een interactie tussen de 
polyglutamine domeinen van normale en mutante huntingtine eiwitten kunnen behelzen en behoeft nadere 
opheldering. Deze bevindingen hebben enige voorspellende waarde en zijn cruciaal voor het ontwerpen en 
interpreteren van de uitkomsten van toekomstige interventieonderzoeken. 
In Hoofdstuk 4 wordt een systematische evaluatie van de subjectieve slaapkwaliteit alsmede mogelijke klachten 
van slaperigheid overdag gepresenteerd bij zowel patiënten met de ZvH als premanifeste mutatiedragers. De 
bevindingen duiden erop dat de slaapkwaliteit vooral ’s nachts is verminderd bij de ZvH, terwijl slaperigheid 
overdag waarschijnlijk weinig voorkomt. Depressie bleek de belangrijkste klinische voorspeller van 
slaapproblemen te zijn. Bovendien suggereren de resultaten dat de slaapfase bij patiënten met de ZvH naar 
later op de dag is verschoven en dat deze faseverschuiving samenhangt met een lager niveau van cognitief 
functioneren.
Bevindingen uit een vragenlijstonderzoek wezen erop dat patiënten met de ZvH last hebben van verschillende 
symptomen die suggestief zijn voor een stoornis van het autonome zenuwstelsel (Hoofdstuk 5). De klachten 
betroffen voornamelijk de gastro-intestinale, urogenitale en cardiovasculaire domeinen bij patiënten met de 
ZvH, terwijl enkele klachten tevens aanwezig waren in premanifeste mutatiedragers. De strekking van deze 
bevindingen is dat, in tegenstelling tot de gangbare notie, autonome klachten vaak voorkomen bij patiënten met 
de ZvH en zelfs vooraf kunnen gaan aan de motorische manifestatie. Voorts bleek dat de mate van autonome 
klachten bij patiënten met de ZvH samenhangt met de graad van functionele beperking en depressie, hetgeen 
erop kan duiden dat adequate behandeling van autonome klachten bij patiënten met de ZvH zou kunnen worden 
geëvalueerd als een strategie om de levenskwaliteit te verbeteren.
Deel II: Hypothalame pathologie bij de ZvH
In deze sectie (Hoofdstuk 6) rapporteren we een significante reductie van ongeveer 30% in het totale aantal 
hypocretine-1 immunoreactieve neuronen in de laterale hypothalamus in post mortem materiaal van patiënten 
met de ZvH. Deze afname bleek betrekkelijk specifiek aangezien het totale aantal melanine-concentrerend-
hormoon (MCH) immunoreactieve neuronen niet significant was veranderd. Hypocretine-1 niveaus in 
de prefrontale cortex waren eveneens in dezelfde mate afgenomen, maar ventriculaire cerebrospinale 
vloeistof concentraties waren onveranderd. Het valt te bezien of deze relatief matige afname in hypocretine 
signaaltransductie klinische consequenties zou kunnen hebben. Aangezien MCH celaantallen niet duidelijk 
waren aangetast, is het onwaarschijnlijk dat veranderingen in MCH neurotransmissie klinische repercussies 
zouden hebben bij de ZvH. Neuronale intranucleaire en cytoplasmatische inclusielichaampjes van mutant 
huntingtine waren niet uniform aanwezig in de verschillende hypothalame en belendende structuren, hetgeen 
zou kunnen inhouden dat de mate van inclusievorming verschilt tussen de verscheidene hypothalame kernen 
ondanks hun nauwe anatomische juxtapositie.  
Deel III: Endocriene studies bij de ZvH
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Een gedetailleerde beschrijving van de diurnale en secretoire kenmerken van cortisolafgifte is te vinden in 
Hoofdstuk 7. De totale 24-uurs cortisolsecretiesnelheid bleek significant hoger te liggen bij patiënten met de 
ZvH vergeleken met controlepersonen. De toename in cortisolproductie was primair beperkt tot de ochtend 
en vroege namiddag. Voorts toonde circadiaanse ritmiciteitsanalyse aan dat de amplitude van het diurnale 
cortisolprofiel bij patiënten met de ZvH significant hoger was. Deze bevindingen duiden op een ontregelde 
centrale glucocorticoïd-terugkoppelingsmechanisme en suggereren dat disfunctie van de hypothalamus-
hypofyse-bijnieras als een vroeg kenmerk van de ZvH kan worden beschouwd.
De secretiekarakteristieken van groeihormoon en ghreline bleken niet te verschillen tussen patiënten met de ZvH 
en controlepersonen (Hoofdstuk 8). Evenwel, bij patiënten met de ZvH, bleken zowel de groeihormoonsecretie 
als diens irregulariteit van afgifte, evenals de postprandiale suppressie van ghrelinesecretie significant toe te 
nemen met de ziekteprogressie. Daarnaast bleek de postprandiale suppressie van ghrelinesecretie eveneens 
toe te nemen met een afnemend lichaamsgewicht of een toenemend aantal CAG repeatherhalingen. Deze 
observaties suggereren subtiele veranderingen in de regulatie van groeihormoon- en ghrelineafgifte in een 
vroeg stadium van de ZvH die wellicht geprononceerder zouden kunnen worden in de latere stadia van deze 
aandoening.
Evaluatie van de thyreotrope en lactotrope assen bij patiënten met de ZvH (Hoofdstuk 9) liet een milde 
hyperactiviteit van de hypothalamus-hypofyse-schildklieras zien, evenals een meer irregulair patroon van 
prolactinesecretie vergeleken met controlepersonen. Deze bevindingen zijn consistent met de notie van een 
ontregelde hypothalamus/hypofyse dopaminesignaaltransductie bij de ZvH. Hogere vrije T4 niveaus waren 
geassocieerd met een groter aantal CAG repeatherhalingen. Voorts waren de totale T4 niveaus negatief 
geassocieerd met de ‘body-mass-index’ (BMI). Aangezien schildklierhormonen het energieverbruik kunnen 
stimuleren, zouden de verhoogde schildklierhormoonconcentraties bij de ZvH die samenhangen met het aantal 
CAG repeatherhalingen bij kunnen dragen aan de lagere BMI bij de mutatiedragers,2,3 en mogelijkerwijs 
tevens ten dele de relatie tussen het aantal mutante HTT CAG repeatherhalingen en gewichtsverlies kunnen 
verklaren.4
De plasmaconcentraties en de diurnale ritmiciteit van de adipokinen leptine, adiponectine en resistine 
verschillenden niet significant tussen patiënten met de ZvH en controlepersonen (Hoofdstuk 10). Na correctie 
voor vetmassa bleken nochtans zowel de gemiddelde plasmaconcentratie als de secretiesnelheid van leptine 
significant toe te nemen met een groter aantal CAG repeatherhalingen bij patiënten met de ZvH. Daar leptine 
als een anorexinogeen hormoon wordt beschouwd dat het energieverbruik stimuleert,5 zou toegenomen 
leptinesecretiesnelheid bij patiënten met een groter aantal CAG repeatherhalingen in het mutante allel tot 
een verminderde eetlust en hypermetabolisme kunnen leiden en daarmee bijdragen aan de hogere mate van 
gewichtsverlies bij deze individuen.4 Het was tevens frappant dat bij patiënten met de ZvH noch de BMI, 
noch de vetmassa significant waren geassocieerd met de leptineproductie. Deze observaties suggereren dat de 
mutatie bij de ZvH op enigerlei wijze interfereert met de functie van het vetweefsel.
Ten opzichte van de controlepersonen was het tijdstip van de avondelijke toename van de melatonineconcentratie 
met ongeveer anderhalf uur verlaat bij patiënten met de ZvH (Hoofdstuk 11). Tevens bleek dat, ondanks 
gelijke diurnale melatonineniveaus tussen patiënten en controles, er sterke negatieve associaties bestonden 
tussen de gemiddelde diurnale melatonineniveaus en zowel de motorische als de functionele beperkingen bij 
de patiënten. Deze bevindingen duiden op een ’delayed sleep-phase syndrome’-achtige verstoring van het 
circadiaanse ritme in de vroege stadia van de ZvH en suggereren dat de melatonineconcentraties mogelijkerwijs 
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progressief zouden kunnen afnemen met het voortschrijden van de ziekte.
Deel IV: Metabole studies bij de ZvH
Vergeleken met de controlepersonen was het energieverbruik in rust significant hoger bij patiënten met de 
ZvH, hetgeen primair werd veroorzaakt door een hogere oxidatie van vet (Hoofdstuk 12). Anders dan bij 
de controlepersonen bleek hyperinsulinemie daarenboven een verdere toename van het energieverbruik te 
induceren, hetgeen in dit geval voornamelijk door een hogere oxidatie van glucose werd teweeggebracht. 
Ofschoon er geen aanwijzingen werden gevonden voor insulineresistentie bij patiënten met de ZvH, hing 
een groter aantal CAG repeatherhalingen in het mutante allel samen met een lagere insulinegevoeligheid. 
Deze bevindingen wijzen op sympathische hyperactiviteit, mogelijkerwijs ten gevolge van disfunctie van de 
ventromediale kern van de hypothalamus, alsmede perifere polyglutamine-lengte afhankelijke interferentie 
van mutant huntingtine met insulinesignaaltransductie die eventueel klinisch relevant zou kunnen zijn in 
dragers van mutaties met een groot aantal CAG repeatherhalingen. 
TOEKOMSTPERSPECTIEVEN
De studies beschreven in dit proefschrift vormen een vruchtbare grond voor zowel verder basaal als klinisch 
onderzoek naar verscheidene facetten van de ZvH. Echter, ten eerste behoeven onze beweringen nadere staving 
middels pogingen om de beschreven bevindingen te repliceren in andere, en bij voorkeur grotere, cohorten 
patiënten. Voorts zou het interessant zijn om patiënten in verschillende stadia van de ziekte te beoordelen, 
alhoewel medicatiegebruik evenals functionele en mentale beperkingen in de latere stadia van de ziekte niet 
gering te schatten obstakels zouden kunnen vormen voor de haalbaarheid van zulk onderzoek. In dit opzicht 
is het inzonderheid bemoedigend om op te merken dat meerdere van onze bevindingen, zoals de omgekeerde 
associatie tussen het lichaamsgewicht en de grootte van de mutante CAG repeatsequentie alsmede verhoogde 
cortisolconcentraties,6,7 reeds zijn gerepliceerd in onafhankelijke studies met betrekkelijk grote aantallen 
patiënten, terwijl confirmerende studies onderweg zijn voor andere bevindingen zoals het klinische effect 
van de interactie tussen het normale en het mutante HTT die nader zal worden beoordeeld in de TRACK-HD 
cohort.8 Met deze voorwaardelijke stipulatie in het achterhoofd, zullen wij in het resterende deel van deze 
sectie een klein aantal gedachtegangen entameren die mogelijk richting zouden kunnen geven aan verdere 
onderzoeksinspanningen in dit veld. Het verantwoordelijke mechanisme voor de negatieve associatie tussen 
het lichaamsgewicht en de mutante CAG repeatlengte behoeft nadere opheldering aangezien zodoende het 
ontwikkelen van nieuwe behandelingen die herstel van de cellulaire energiehomeostase bij de ZvH beogen, 
zou kunnen worden gefaciliteerd. In het bijzonder dient te worden beoordeeld in hoeverre de associatie tussen 
het lichaansgewicht en het aantal CAG repeatherhalingen het gevolg is van polyglutamine-lengte afhankelijke 
pathologie van hersencentra betrokken bij de energiehomeostase (bijv. de hypothalamus),9,10 of toe te schrijven 
is aan defecten in perifere weesfels zoals spier- en vetweefsel.11-13 Evaluatie van de associatie tussen CAG 
repeatlengte en de functionele integriteit van de hypothalamus, bijvoorbeeld zoals beoordeeld middels 
verschillende beeldvormende technieken in combinatie met hormonale functietesten en spier-/vetbiopsieën, 
zou ons begrip inzake aanzienlijk kunnen verbeteren. Evenzo behoeven de mechanismen die het effect 
van de interactie tussen normale en mutante CAG repeatlengtes mediëren nadere verduidelijking. Diverse 
modellen zouden dit fenomeen kunnen verklaren, zoals een polyglutamine-lengte afhankelijke interactie 
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tussen het normale en het mutante huntingtine eiwit met onder meer een groot scala aan bindingspartners,14,15 
mitochondriale energieproductie16 of transcriptieregulatie.17 Niettemin, ongeacht het verantwoordelijke 
mechanisme, is een belangrijk uitvloeisel van onze bevindingen dat in toekomstige klinische experimentele 
onderzoekingen met het oogmerk om de potentiële merites van een specifieke behandeling bij de ZvH te 
beoordelen de uitkomsten dienen te worden gecorrigeerd voor de CAG repeatlengtes in beide HTT allelen. De 
resultaten van de inventarisatie van de slaapproblemen, evenals de analyses van de diurnale secretiepatronen 
van cortisol en melatonine wijzen op een ‘delayed sleep-phase syndrome’-achtige circadiaanse ritmestoornis 
die nader zou kunnen worden gekarakteriseerd middels andere maten voor het beoordelen van het circadiaanse 
ritme zoals 24-uurs lichaamstemperatuurmetingen en actigrafie. Dit is belangrijk omdat patiënten met de ZvH 
eventueel zouden kunnen profiteren van maatregelen bedoeld voor het herinstellen van het circadiaanse ritme. 
Patiënten met de ZvH bleken tevens last te hebben van een groot aantal klachten die, tenminste gedeeltelijk, 
manifestaties zouden kunnen zijn van disfunctie van het autonome zenuwstelsel. Het aanwenden van 
extensievere standaardvragenlijsten in combinatie met objectieve maten voor het functioneren van het autonome 
zenuwstelsel zouden kunnen helpen om te verhelderen in hoeverre vermeende symptomen van autonome origine 
daadwerkelijk ontspruiten aan autonoom falen, ofwel manifestaties zijn van pathognomonische verschijnselen 
zoals motorische stoornissen. Neuropathologische evaluatie van de hypothalamus wees uit dat neuronale 
intranucleaire en cytoplasmatische inclusielichaampjes van mutant huntingtine niet uniform aanwezig zijn 
in de verschillende hypothalame en belendende structuren bij de ZvH. Karakterisatie van de processen die 
deze heterogeniteit teweegbrengen, zou kunnen verhelderen waarom bepaalde neuronale populaties gevoeliger 
zijn dan andere voor de pathologie van de ZvH. In dit opzicht zou het interessant zijn om te beoordelen of 
Rhes (‘Ras homologue enriched in striatum’), een eiwit waarvan wordt vermoed dat het de relatief selectieve 
striatale pathologie van de ZvH medieert,18 eveneens aanwezig is in de hypothalamus, of de distributie ervan 
verschilt tussen de diverse hypothalame kernen, en of de expressie ervan is veranderd in de hypothalami van 
patiënten met de ZvH. De uitkomsten van de endocriene en metabole experimenten bij patiënten met de ZvH 
in een vroeg stadium van de aandoening zijn consistent met de notie van hypothalame pathologie en wijzen 
inzonderheid op de betrokkenheid van de suprachiasmatische kern bij het ziekteproces. Gebruikmakend van 
immunocytochemische en in situ hybridizatie technieken zijn thans systematische neuropathologische studies 
van de suprachiasmatische en andere hypothalame kernen onderweg in nauwe samenwerking met het Nederlands 
Instituut voor Neurowetenschappen. Gezien het progressieve karakter van de ZvH zouden voorts longitudinale 
studies van endocriene (in het bijzonder de cortisol- en groeihormoonsecretie) en metabole (met name het 
energieverbruik en de respons op insulinestimulatie) parameters in samenhang met klinische evaluaties meer 
inzicht kunnen verschaffen in potentiële dynamische veranderingen die eventueel bruikbaar zouden kunnen 
zijn als biomarkers voor de ziekteprogressie. En ten slotte zij opgemerkt dat enkele van onze bevindingen, 
zoals de associatie tussen de secretie van het adipocytenhormoon leptine en mutante CAG repeatlengte, veeleer 
kunnen worden begrepen in het licht van perifere dan centrale pathologie bij de ZvH. Ergo, gedicteerd door 
het feit dat mutant huntingtine bijna overal in het lichaam tot expressie wordt gebracht, schijnt een holistische 
benadering met zowel oog voor de centrale als de perifere weefsels een prudente strategie voor het achterhalen 
van het pathologische substraat van de secundaire symptomen bij de ZvH.13
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P×DhÞ DFéÆ PvC íÇësßÎÞoßÛ  í¬D®eÛC Þ íRoC  êoDØìF Èë ÚßOËÜìOÛDç êoDØìF
.lzDGì×  æCpØç íÛCÞo Þ êpÇ¾ , íOÆpd MÓÔOhC  ÚßZ íØñÔµ êlµD¥N
ÝëC krÛ HNp× éÆ ÚßOËÜìOÛDçêoDØìF  pËëk ôlz éOh DÜz pOØÆ  ÙñÔµ
:qC lÜNoDGµ ,lÛoCnËì×  DèÛA íÊlÛq  Pì¿ìÆ  pF í¿Ü× pìR DNÞ   ælz ælëkÚCoDØìF
.íNDGÛ íG¥µ ÙOwìv Þ ECßh MÓÔOhC , éOvCßh DÛ Moß¤ éF ÚqÞ ÚkCkPvk qC
ÚßOËÜìOÛDç ÚCoDØìF krÛ Áß¾ ôlz éOh DÜz pOØÆ ÙñÔµ ÝëC íëCrëoDØìF PÃìÃd ok
 DèÛA êCpF êpRß× ÚD×ok  Ùç ÚßÜÆ DN  ÐìÎk ÝìØèF Þ æl¡Û ÝzÞo "D×DØN qßÜç
pRß× êDèzÞo ÍDØµC Þ cp¬ éF Úlì¡iF ¸ëpwN êCpF ÝëCpFDÜF  .PvC ælëkpËÛ À¡Æ
.lzDGì×oCkphpF êkDëq oDìwF PìØçC qC ÙñÔµÝëC rÛsßNDJ Úlz ÝzÞo , íÛD×ok
ÚCoDØìF uß×ÓDN ßKìç ok ¦i¡×  êDèGìvA pF íÜG× êlçCßz  "CpìhC
. PvC ælzClìJ êoDØìF  ÝëC éFÔOG× íÛCßìd êDç éÛßØÛÞ  ÚßOËÜìOÛDç
íÛÞoßÛ êDçÞpÊ qC ælz ÐÇ¡O× Þ éO¾pÊ oCpÂ r»×  ælµDÂ ok kßh uß×ÓDNßKìç
êDè×rìÛDÇ×qC êkDëq kCl·N  Ùì²ÜN Íßòw× pËëlØç DF éÆ  æk ßF éOvßìJ ÙèF
.lÜzDGì× ÚlF íÃ¾Þ  Þ íÇësßÎßërì¾
HìvA éÆ ÙìÜÆ MDGRC Åol× Þ  ÐìÎk DF éÆ ÙìÜÇì× ¢zßÆ êpOÆk éÎDvo ÝëC ok
ÚlF ÙwìÎßFDO×Þrëo ÚÞok klº oDÆok êßÛDR MCpì»N  ÚDÜaØçÞ uß×Ó DN ßKìç
.kÛßzÚßOËÜìOÜç êoDØìF íÆpdpìº ÙñÔµqC êkCl·N  íëCrëoDØìF TµDF lÜÛCßOì×
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